<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59067</article-id><article-id pub-id-type="doi">10.7554/eLife.59067</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Pancreatic progenitor epigenome maps prioritize type 2 diabetes risk genes with roles in development</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-195510"><name><surname>Geusz</surname><given-names>Ryan J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4897-9305</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-195511"><name><surname>Wang</surname><given-names>Allen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9870-7888</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-35953"><name><surname>Chiou</surname><given-names>Joshua</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4618-0647</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-69071"><name><surname>Lancman</surname><given-names>Joseph J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1238-4446</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195513"><name><surname>Wetton</surname><given-names>Nichole</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195514"><name><surname>Kefalopoulou</surname><given-names>Samy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195515"><name><surname>Wang</surname><given-names>Jinzhao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195516"><name><surname>Qiu</surname><given-names>Yunjiang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0539-9714</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195517"><name><surname>Yan</surname><given-names>Jian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1267-2870</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195518"><name><surname>Aylward</surname><given-names>Anthony</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3524-856X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195519"><name><surname>Ren</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-69072"><name><surname>Dong</surname><given-names>P Duc Si</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-195520"><name><surname>Gaulton</surname><given-names>Kyle J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1318-7161</contrib-id><email>kgaulton@health.ucsd.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-30316"><name><surname>Sander</surname><given-names>Maike</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5308-7785</contrib-id><email>masander@ucsd.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pediatrics, Pediatric Diabetes Research Center, University of California, San Diego</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Cellular &amp; Molecular Medicine, University of California, San Diego</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Sanford Consortium for Regenerative Medicine</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Biomedical Graduate Studies Program, University of California, San Diego</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Graduate School of Biomedical Sciences, Sanford Burnham Prebys Medical Discovery Institute</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Ludwig Institute for Cancer Research</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>05</day><month>02</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e59067</elocation-id><history><date date-type="received" iso-8601-date="2020-07-01"><day>01</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-01-18"><day>18</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Geusz et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Geusz et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-59067-v2.pdf"/><abstract><p>Genetic variants associated with type 2 diabetes (T2D) risk affect gene regulation in metabolically relevant tissues, such as pancreatic islets. Here, we investigated contributions of regulatory programs active during pancreatic development to T2D risk. Generation of chromatin maps from developmental precursors throughout pancreatic differentiation of human embryonic stem cells (hESCs) identifies enrichment of T2D variants in pancreatic progenitor-specific stretch enhancers that are not active in islets. Genes associated with progenitor-specific stretch enhancers are predicted to regulate developmental processes, most notably tissue morphogenesis. Through gene editing in hESCs, we demonstrate that progenitor-specific enhancers harboring T2D-associated variants regulate cell polarity genes <italic>LAMA1</italic> and <italic>CRB2</italic>. Knockdown of <italic>lama1</italic> or <italic>crb2</italic> in zebrafish embryos causes a defect in pancreas morphogenesis and impairs islet cell development. Together, our findings reveal that a subset of T2D risk variants specifically affects pancreatic developmental programs, suggesting that dysregulation of developmental processes can predispose to T2D.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Zebrafish</kwd><kwd>pancreas</kwd><kwd>hESC</kwd><kwd>chromatin</kwd><kwd>Type 2 diabetes</kwd><kwd>GWAS</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32 GM008666</award-id><principal-award-recipient><name><surname>Geusz</surname><given-names>Ryan J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30 DK064391</award-id><principal-award-recipient><name><surname>Gaulton</surname><given-names>Kyle J</given-names></name><name><surname>Sander</surname><given-names>Maike</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 DK068471</award-id><principal-award-recipient><name><surname>Sander</surname><given-names>Maike</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U01 DK105541</award-id><principal-award-recipient><name><surname>Ren</surname><given-names>Bing</given-names></name><name><surname>Dong</surname><given-names>P Duc Si</given-names></name><name><surname>Sander</surname><given-names>Maike</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1DP2DK098092</award-id><principal-award-recipient><name><surname>Dong</surname><given-names>P Duc Si</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000888</institution-id><institution>W.M. Keck Foundation</institution></institution-wrap></funding-source><award-id>2017-01</award-id><principal-award-recipient><name><surname>Dong</surname><given-names>P Duc Si</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Diabetes Research Connection</institution></institution-wrap></funding-source><award-id>Project #08</award-id><principal-award-recipient><name><surname>Lancman</surname><given-names>Joseph J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Analysis of epigenome maps from human pancreatic progenitors and functional validation in zebrafish identify <italic>LAMA1</italic> and <italic>CRB2</italic> as type 2 diabetes risk-associated genes with roles in pancreatic development.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Type 2 diabetes (T2D) is a multifactorial metabolic disorder characterized by insulin insensitivity and insufficient insulin secretion by pancreatic beta cells (<xref ref-type="bibr" rid="bib31">Halban et al., 2014</xref>). Genetic association studies have identified hundreds of loci influencing risk of T2D (<xref ref-type="bibr" rid="bib48">Mahajan et al., 2018</xref>). However, disease-relevant target genes of T2D risk variants, the mechanisms by which these genes cause disease, and the tissues in which the genes mediate their effects remain poorly understood.</p><p>The majority of T2D risk variants map to non-coding sequence, suggesting that genetic risk of T2D is largely mediated through variants affecting transcriptional regulatory activity. Intersection of T2D risk variants with epigenomic data has uncovered enrichment of T2D risk variants in regulatory sites active in specific cell types, predominantly in pancreatic beta cells, including risk variants that affect regulatory activity directly (<xref ref-type="bibr" rid="bib9">Chiou et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Fuchsberger et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Gaulton et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Gaulton et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Greenwald et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Mahajan et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Pasquali et al., 2014</xref>; <xref ref-type="bibr" rid="bib80">Thurner et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Varshney et al., 2017</xref>). T2D risk-associated variants are further enriched within large, contiguous regions of islet active chromatin, referred to as stretch or super-enhancers (<xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>). These regions of active chromatin preferentially bind islet-cell-restricted transcription factors and drive islet-specific gene expression (<xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Pasquali et al., 2014</xref>).</p><p>Many genes associated with T2D risk in islets are not uniquely expressed in differentiated islet endocrine cells, but also in pancreatic progenitor cells during embryonic development. For example, T2D risk variants map to <italic>HNF1A, HNF1B, HNF4A, MNX1, NEUROG3, PAX4,</italic> and <italic>PDX1</italic> (<xref ref-type="bibr" rid="bib23">Flannick et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Mahajan et al., 2018</xref>; <xref ref-type="bibr" rid="bib76">Steinthorsdottir et al., 2014</xref>), which are all transcription factors also expressed in pancreatic developmental precursors. Studies in model organisms and hESC-based models of pancreatic endocrine cell differentiation have shown that inactivation of these transcription factors causes defects in endocrine cell development, resulting in reduced beta cell numbers (<xref ref-type="bibr" rid="bib25">Gaertner et al., 2019</xref>). Furthermore, heterozygous mutations for <italic>HNF1A, HNF1B, HNF4A, PAX4,</italic> and <italic>PDX1</italic> are associated with maturity onset diabetes of the young (MODY), which is an autosomal dominant form of diabetes with features similar to T2D (<xref ref-type="bibr" rid="bib83">Urakami, 2019</xref>). Thus, there is evidence that reduced activity of developmentally expressed transcription factors can cause diabetes later in life.</p><p>The role of these transcription factors in T2D and MODY could be explained by their functions in regulating gene expression in mature islet cells. However, it is also possible that their function during endocrine cell development could predispose to diabetes instead of, or in addition to, endocrine cell gene regulation. One conceivable mechanism is that individuals with reduced activity of these transcription factors are born with either fewer beta cells or beta cells more prone to fail under conditions of increased insulin demand. Observations showing that disturbed intrauterine metabolic conditions, such as maternal malnutrition, can lead to reduced beta cell mass and T2D predisposition in the offspring (<xref ref-type="bibr" rid="bib47">Lumey et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Nielsen et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Portha et al., 2011</xref>) support the concept that compromised beta cell development could predispose to T2D. However, whether there is T2D genetic risk relevant to the regulation of endocrine cell development independent of gene regulation in mature islet cells has not been explored.</p><p>In this study, we investigated the contribution of gene regulatory programs specifically active during pancreatic development to T2D risk. First, we employed a hESC-based differentiation system to generate chromatin maps of hESCs during their stepwise differentiation into pancreatic progenitor cells. We then identified T2D-associated variants localized in active enhancers in developmental precursors but not in mature islets, used genome editing in hESCs to define target genes of pancreatic progenitor-specific enhancers harboring T2D variants, and employed zebrafish genetic models to study the role of two target genes in pancreatic and endocrine cell development.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Pancreatic progenitor stretch enhancers are enriched for T2D risk variants</title><p>To determine whether there is a development-specific genetic contribution to T2D risk, we generated genome-wide chromatin maps of hESCs during their stepwise differentiation into pancreatic progenitors through four distinct developmental stages: definitive endoderm (DE), gut tube (GT), early pancreatic progenitors (PP1), and late pancreatic progenitors (PP2) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We then used ChromHMM (<xref ref-type="bibr" rid="bib20">Ernst and Kellis, 2012</xref>) to annotate chromatin states, such as active promoters and enhancers, at all stages of hESC differentiation as well as in primary islets (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>T2D-associated risk variants are enriched in stretch enhancers of pancreatic progenitors independent of islet stretch enhancers.</title><p>(<bold>A</bold>) Schematic illustrating the stepwise differentiation of human embryonic stem cells (hES) into pancreatic progenitors (solid arrows) and lineage relationship to islets (dotted arrow). Developmental intermediates include definitive endoderm (DE), gut tube (GT), early pancreatic progenitor (PP1), and late pancreatic progenitor (PP2) cells. (<bold>B</bold>) Box plots depicting length of typical enhancers (TE) and stretch enhancers (SE) at each developmental stage and in primary human islets. Plots are centered on median, with box encompassing 25–75th percentile and whiskers extending up to 1.5 interquartile range. Total numbers of enhancers are shown above each box plot. (<bold>C</bold>) Examples of stretch enhancers (denoted with red boxes) near the genes encoding the pancreatic lineage-determining transcription factors NKX6.1 and PDX1, respectively. Chromatin states are based on ChromHMM classifications: TssA, active promoter; TssFlnk, flanking transcription start site; TssBiv, bivalent promoter; Repr, repressed; EnhA, active enhancer; EnhP, poised enhancer. (<bold>D</bold>) Percentage of TE and SE overlapping with at least one ATAC-seq peak at PP2 or in islets. Enrichment analysis comparing observed and expected overlap based on random genomic regions of the same size and located on the same chromosome averaged over 10,000 iterations (***p&lt;1 × 10<sup>−4</sup>; permutation test). ATAC-seq peaks were merged from two independent differentiations for PP2 stage cells and four donors for primary islets. (<bold>E</bold>) Genome-wide enrichment of T2D-associated variants (minor allele frequency &gt;0.0025) in stretch enhancers, ATAC-seq peaks, and ATAC-seq peaks within stretch enhancers for all developmental stages when modeling each annotation separately. Points and lines represent log-scaled enrichment estimates and 95% confidence intervals from functional genome wide association analysis (fgwas), respectively. ATAC-seq peaks were merged from two independent differentiations for ES, DE, GT, PP1, and PP2 stage cells and from four donors for primary islets. (<bold>F</bold>) Genome-wide enrichment of T2D-associated variants (minor allele frequency &gt;0.0025) in ATAC-seq peaks within stretch enhancers for all developmental stages and coding exons when considering all annotations in a joint model. Points and lines represent log-scaled enrichment estimates and 95% confidence intervals from fgwas, respectively. ATAC-seq peaks were merged from two independent differentiations for ES, DE, GT, PP1, and PP2 stage cells and from four donors for primary islets. See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Characterization of typical and stretch enhancers in pancreatic developmental intermediates and islets.</title><p>(<bold>A</bold>) Diagram illustrating incorporation of histone modification and CTCF ChIP-seq data to generate chromatin state calls via ChromHMM. (<bold>B</bold>) Percentage of the genome covered by defined chromatin states at each developmental stage and in primary human islets. Chromatin states are based on ChromHMM classifications: TssA, active promoter; TssFlnk, flanking transcription start site; TssBiv, bivalent promoter; Repr, repressed; EnhA, active enhancer; EnhP, poised enhancer. (<bold>C</bold>) Percentage of typical (TE) and stretch enhancers (SE) relative to all enhancers at each developmental stage and in islets. (<bold>D</bold>) Box plots showing mRNA levels based on RNA-seq of nearest expressed genes (fragments per kilobase per million fragments mapped (FPKM) ≥1) for TE and SE at each developmental stage and in islets (***p=4.68 × 10<sup>−7</sup>, 4.64 × 10<sup>−11</sup>, 1.31 × 10<sup>−5</sup>, 8.85 × 10<sup>−9</sup>, 5.34 × 10<sup>−6</sup>, and &lt;2.2 × 10<sup>−16</sup> for TE vs SE comparisons in ES, DE, GT, PP1, PP2, and islets, respectively; Wilcoxon rank sum test, two sided). Plots are centered on median, with box encompassing 25-75th percentile and whiskers extending up to 1.5 interquartile range. n = 3 replicates from independent differentiations at ES, DE, GT, PP1, and PP2, respectively; n = 3 islet replicates. (<bold>E</bold>) Percentage of TE and SE overlapping with at least one ATAC-seq peak in ES, DE, GT, or PP1. Enrichment analysis comparing observed and expected overlap based on random genomic regions of the same size and located on the same chromosome averaged over 10,000 iterations (***p&lt;1 × 10<sup>−4</sup>; permutation test). ATAC-seq peaks were merged from two independent differentiations. (<bold>F</bold>) Percentage of TE and SE overlapping 0, 1, 2, 3, or 4+ ATAC-seq peaks at each developmental stage and in islets. ATAC-seq peaks were merged from two independent differentiations for ES, DE, GT, PP1, and PP2 stage cells and from four donors for primary islets.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Large and contiguous regions of active enhancer chromatin, which have been termed stretch- or super-enhancers (<xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>; <xref ref-type="bibr" rid="bib91">Whyte et al., 2013</xref>), are highly enriched for T2D risk variants in islets (<xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Pasquali et al., 2014</xref>). We therefore partitioned active enhancers from each hESC developmental stage and islets into stretch enhancers (SE) and traditional (non-stretch) enhancers (TE) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Consistent with prior observations of SE features (<xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>; <xref ref-type="bibr" rid="bib91">Whyte et al., 2013</xref>), SE comprised a small subset of all active enhancers (7.7%, 7.8%, 8.8%, 8.1%, 8.1%, and 10.4% of active enhancers in ES, DE, GT, PP1, PP2, and islets, respectively; <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>) and genes proximal to SE were more highly expressed than genes proximal to TE (p=4.68 × 10<sup>−7</sup>, 4.64 × 10<sup>−11</sup>, 1.31 × 10<sup>−5</sup>, 8.85 × 10<sup>−9</sup>, 5.34 × 10<sup>−6</sup>, and &lt;2.2 × 10<sup>−16</sup> for expression of genes near TE vs SE in ES, DE, GT, PP1, PP2, and islets, respectively; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Genes near SE in pancreatic progenitors included transcription factors involved in the regulation of pancreatic cell identity, such as <italic>NKX6.1</italic> and <italic>PDX1</italic> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Since disease-associated variants are preferentially enriched in narrow peaks of accessible chromatin within broader regions of active chromatin (<xref ref-type="bibr" rid="bib30">Greenwald et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Thurner et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Varshney et al., 2017</xref>), we next used ATAC-seq to generate genome-wide maps of chromatin accessibility across all time points of differentiation. Nearly all identified SE contained at least one ATAC-seq peak (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E,F</xref>). At the PP2 stage, 62.3% of SE harbored one, 32.2% two or three, and 0.7% four or more ATAC-seq peaks (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). Similar percentages were observed in earlier developmental precursors and islets.</p><p>Having annotated accessible chromatin sites within SE, we next tested for enrichment of T2D-associated variants in SE active in mature islets and in pancreatic developmental stages. We observed strongest enrichment of T2D-associated variants in islet SE (log enrichment = 2.18, 95% CI = 1.80, 2.54) and late pancreatic progenitor SE (log enrichment = 2.17, 95% CI = 1.40, 2.74), which was more pronounced when only considering variants in accessible chromatin sites within these elements (islet log enrichment = 3.20, 95% CI = 2.74, 3.60; PP2 log enrichment = 3.18, 95% CI = 2.35, 3.79; <xref ref-type="fig" rid="fig1">Figure 1E</xref>). Given that a subset of pancreatic progenitor SE is also active in islets, we next determined whether pancreatic progenitor SE contribute to T2D risk independently of islet SE. Variants in accessible chromatin sites of late pancreatic progenitor SE were enriched for T2D association in a joint model including islet SE (islet log enrichment = 2.94, 95% CI = 2.47, 3.35; PP2 log enrichment = 1.27, 95% CI = 0.24, 2.00; <xref ref-type="fig" rid="fig1">Figure 1F</xref>). We also observed enrichment of variants in accessible chromatin sites of pancreatic progenitor SE after conditioning on islet SE (log enrichment = 0.60, 95% CI = −0.87, 1.48), as well as when excluding pancreatic progenitor SE active in islets (log enrichment = 1.62, 95% CI = &lt;-20, 3.14). Examples of known T2D loci with T2D-associated variants in SE active in pancreatic progenitors but not in islets included <italic>LAMA1</italic> and <italic>PROX1</italic>. These results suggest that a subset of T2D variants may affect disease risk by altering regulatory programs specifically active in pancreatic progenitors.</p></sec><sec id="s2-2"><title>Pancreatic progenitor-specific stretch enhancers are near genes that regulate tissue morphogenesis</title><p>Having observed enrichment of T2D risk variants in pancreatic progenitor SE independent of islet SE, we next sought to further characterize the regulatory programs of SE with specific function in pancreatic progenitors. We therefore defined a set of pancreatic progenitor-specific stretch enhancers (PSSE) based on the following criteria: (i) annotation as a SE at the PP2 stage, (ii) no classification as a SE at the ES, DE, and GT stages, and (iii) no classification as a TE or SE in islets. Applying these criteria, we identified a total of 492 PSSE genome-wide (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Candidate target genes of pancreatic progenitor-specific stretch enhancers regulate developmental processes.</title><p>(<bold>A</bold>) Schematic illustrating identification of pancreatic progenitor-specific stretch enhancers (PSSE). (<bold>B</bold>) Heatmap showing density of H3K27ac ChIP-seq and ATAC-seq reads at PSSE, centered on overlapping H3K27ac and ATAC-seq peaks, respectively, and spanning 5 kb in ES, DE, GT, PP1, PP2, and islets. PSSE coordinates in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. (<bold>C</bold>) Percentage of PSSE exhibiting indicated chromatin states at defined developmental stages and in islets. (<bold>D</bold>) Percentage of PSSE overlapping with at least one ChIP-seq peak at PP2 for the indicated transcription factors. Enrichment analysis comparing observed and expected overlap based on random genomic regions of the same size and located on the same chromosome averaged over 10,000 iterations (***p&lt;1×10<sup>−4</sup>; permutation test). (<bold>E</bold>) Gene ontology analysis for nearest expressed genes (fragments per kilobase per million fragments mapped (FPKM) ≥1 at PP2) to the 492 PSSE. See also <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>. (<bold>F</bold>) Enrichment (LD score regression coefficient z-scores) of T2D, developmental, and metabolic GWAS trait-associated variants at accessible chromatin sites in PSSE as compared with PP2 and islet stretch enhancers. Significant enrichment was identified within accessible chromatin at PP2 stretch enhancers for lean type 2 diabetes (Z = 2.06, *p=3.94 × 10<sup>−2</sup>), at PP2 stretch enhancers for type 2 diabetes (Z = 3.57, ***p=3.52 × 10<sup>−4</sup>), at islet stretch enhancers for type 2 diabetes (Z = 2.78, **p=5.46 × 10<sup>−3</sup>), at islet stretch enhancers for fasting proinsulin levels (Z = 2.83, **p=4.61 × 10<sup>−3</sup>), at islet stretch enhancers for HOMA-B (Z = 2.58, **p=9.85 × 10<sup>−3</sup>), at PP2 stretch enhancers for disposition index (Z = 2.18, *p=2.94 × 10<sup>−2</sup>), at islet stretch enhancers for acute insulin response (Z = 2.24, *p=2.51 × 10<sup>−2</sup>), at islet stretch enhancers for HbA1c (Z = 1.98, *p=4.72 × 10<sup>−2</sup>), and at islet stretch enhancers for fasting glucose levels (Z = 2.64, **p=8.31 × 10<sup>−3</sup>). See also <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Chromosomal coordinates of pancreatic progenitor-specific stretch enhancers (PSSE).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59067-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Enriched gene ontology terms for PSSE-associated genes.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59067-fig2-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Proportion of variants nominally associated with beta cell functional traits.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59067-fig2-data3-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Tissue identity of downloaded data from ROADMAP consortium.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59067-fig2-data4-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Characterization of pancreatic progenitor-specific stretch enhancers.</title><p>(<bold>A</bold>) Percentage of PSSE overlapping with at least one ATAC-seq peak at PP2. Enrichment analysis comparing observed and expected overlap based on random genomic regions of the same size and located on the same chromosome averaged over 10,000 iterations (***p&lt;1 × 10<sup>−4</sup>; permutation test). (<bold>B</bold>) Percentage of PSSE overlapping 0, 1, 2, 3, or 4+ ATAC-seq peaks at PP2. (<bold>C</bold>) Enriched transcription factor (TF) binding motifs with associated p-values at ATAC-seq peaks at PP2 intersecting PSSE. Fisher’s exact test, two sided, corrected for multiple comparisons. (<bold>D</bold>) Box plots showing mRNA levels based on RNA-seq of nearest expressed genes (fragments per kilobase per million fragments mapped (FPKM) ≥1 at PP2) for PSSE at each developmental stage and in islets (*p=1.10 × 10<sup>−2</sup> for GT vs PP1; ***p=1.80 × 10<sup>−8</sup> for GT vs PP2, p&lt;2.2 × 10<sup>−16</sup> for PP2 vs islet; Wilcoxon rank sum test, two sided). Plots are centered on median, with box encompassing 25-75th percentile and whiskers extending up to 1.5 interquartile range. n = 3 replicates from independent differentiations at ES, DE, GT, PP1, and PP2, respectively; n = 3 islet replicates. (<bold>E</bold>) Box plots showing H3K27ac signal at PSSE in tissues and cell lines from the ENCODE and Epigenome Roadmap projects as well as in developmental intermediates and islets (ISL). Plots are centered on median, with box encompassing 25-75th percentile and whiskers extending up to 1.5 interquartile range. See also <xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>. (<bold>F</bold>) Number of PSSE overlapping defined chromatin states in human adipose stromal cells from preadipose (hASC1) to mature adipose state (hASC4) (from <xref ref-type="bibr" rid="bib86">Varshney et al., 2017</xref>). ChromHMM classifications: Quiescent; ReprPCWk, Weak Repressed PolyComb; TxWk, Weak Transcription; Tx, Strong Transcription; EnhWk, Weak Enhancer; ReprPC, Repressed Polycomb; EnhA1, Active Enhancer 1; EnhG, Genic Enhancer; EnhA2, Active Enhancer 2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig2-figsupp1-v2.tif"/></fig></fig-group><p>As expected based on their chromatin state classification, PSSE acquired broad deposition of the active enhancer mark H3K27ac at the PP1 and PP2 stages (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). Coincident with an increase in H3K27ac signal, chromatin accessibility at PSSE also increased (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and 93.5% of PSSE contained at least one accessible chromatin site at the PP2 stage (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>). Further investigation of PSSE chromatin state dynamics at earlier stages of pancreatic differentiation revealed that PSSE were often poised (defined by H3K4me1 in the absence of H3K27ac) prior to activation (42%, 48%, 63%, and 17% of PSSE in ES, DE, GT, and PP1, respectively; <xref ref-type="fig" rid="fig2">Figure 2C</xref>), consistent with earlier observations that a poised enhancer state frequently precedes enhancer activation during development (<xref ref-type="bibr" rid="bib66">Rada-Iglesias et al., 2011</xref>; <xref ref-type="bibr" rid="bib88">Wang et al., 2015</xref>). Intriguingly, a subset of PSSE was classified as TE earlier in development (13%, 23%, 29%, and 46% of PSSE in ES, DE, GT, and PP1, respectively; <xref ref-type="fig" rid="fig2">Figure 2C</xref>), suggesting that SE emerge from smaller regions of active chromatin seeded at prior stages of development. During differentiation into mature islet cells, PSSE lost H3K27ac but largely retained H3K4me1 signal (62% of PSSE) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), persisting in a poised state in terminally differentiated islet cells.</p><p>To gain insight into the transcription factors that regulate PSSE, we conducted motif enrichment analysis of accessible chromatin sites within PSSE (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Consistent with the activation of PSSE upon pancreas induction, motifs associated with transcription factors known to regulate pancreatic development (<xref ref-type="bibr" rid="bib11">Conrad et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Masui et al., 2007</xref>) were enriched, including FOXA (p=1 × 10<sup>−34</sup>), PDX1 (p=1 × 10<sup>−30</sup>), GATA (p=1 × 10<sup>−25</sup>), ONECUT (p=1 × 10<sup>−17</sup>), and RBPJ (p=1 × 10<sup>−14</sup>), suggesting that pancreatic lineage-determining transcription factors activate PSSE. Analysis of the extent of PSSE overlap with ChIP-seq binding sites for FOXA1, FOXA2, GATA4, GATA6, PDX1, HNF6, and SOX9 at the PP2 stage substantiated this prediction (p&lt;1 × 10<sup>−4</sup> for all transcription factors; permutation test; <xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>Annotation of biological functions of predicted target genes for PSSE (nearest gene with FPKM ≥1 at PP2 stage) revealed gene ontology terms related to developmental processes, such as tissue morphogenesis (p=1 × 10<sup>−7</sup>) and vascular development (p=1 × 10<sup>−8</sup>), as well as developmental signaling pathways, including BMP (p=1 × 10<sup>−5</sup>), NOTCH (p=1 × 10<sup>−4</sup>), and canonical Wnt signaling (p=1 × 10<sup>−4</sup>; <xref ref-type="fig" rid="fig2">Figure 2E</xref> and <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>), which have demonstrated roles in pancreas morphogenesis and cell lineage allocation (<xref ref-type="bibr" rid="bib1">Ahnfelt-Rønne et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Li et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Murtaugh, 2008</xref>; <xref ref-type="bibr" rid="bib73">Sharon et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">Sui et al., 2013</xref>). Consistent with the temporal pattern of H3K27ac deposition at PSSE, transcript levels of PSSE-associated genes increased upon pancreatic lineage induction and peaked at the PP2 stage (p=1.8 × 10<sup>−8</sup>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Notably, expression of these genes sharply decreased in islets (p&lt;2.2 × 10<sup>−16</sup>), underscoring the likely role of these genes in regulating pancreatic development but not mature islet function.</p></sec><sec id="s2-3"><title>Pancreatic progenitor-specific stretch enhancers are highly specific across T2D-relevant tissues and cell types</title><p>We next sought to understand the phenotypic consequences of PSSE activity in the context of T2D pathophysiology. Variants in accessible chromatin sites of PSSE genome-wide were enriched for T2D association (log enrichment = 2.85, 95% CI = &lt;-20, 4.09). We determined enrichment of genetic variants for T2D-related quantitative endophenotypes within accessible chromatin sites of PSSE, as well as all pancreatic progenitor SE (not just progenitor-specific) and islet SE, using LD score regression (<xref ref-type="bibr" rid="bib7">Bulik-Sullivan et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Finucane et al., 2015</xref>). As expected based on prior observations (<xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Pasquali et al., 2014</xref>), we observed enrichment (Z &gt; 1.96) of variants associated with quantitative traits related to insulin secretion and beta cell function within islet SE, exemplified by fasting proinsulin levels, HOMA-B, and acute insulin response (Z = 2.8, Z = 2.6, and Z = 2.2, respectively; <xref ref-type="fig" rid="fig2">Figure 2F</xref>). Conversely, PSSE showed a trend toward depletion for these traits, although the estimates were not significant. We further tested for enrichment in the proportion of variants in PSSE and islet SE nominally associated (p&lt;0.05) with beta cell function traits compared to background variants. There was significant enrichment of beta cell trait association among islet SE variants (χ<sup>2</sup> test; p&lt;0.05 for all beta cell functional traits except for insulin secretion rate), but no corresponding enrichment for PSSE (<xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>).</p><p>A prior study found that variants at the <italic>LAMA1</italic> locus had stronger effects on T2D risk among lean relative to obese cases (<xref ref-type="bibr" rid="bib60">Perry et al., 2012</xref>). Since we identified a PSSE at the <italic>LAMA1</italic> locus, we postulated that variants in PSSE collectively might have differing impact on T2D risk in cases segregated by BMI. We therefore tested PSSE, as well as pancreatic progenitor SE and islet SE, for enrichment of T2D association using GWAS of lean and obese T2D (<xref ref-type="bibr" rid="bib60">Perry et al., 2012</xref>), using LD score regression (<xref ref-type="bibr" rid="bib7">Bulik-Sullivan et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Finucane et al., 2015</xref>). We observed nominally significant enrichment of variants in pancreatic progenitor SE for T2D among lean cases (Z = 2.1). Variants in PSSE were mildly enriched for T2D among lean (Z = 1.1) and depleted among obese (Z = −0.70) cases, although neither estimate was significant. By comparison, islet SE showed positive enrichment for T2D among both lean (Z = 1.9) and obese cases (Z = 1.3; <xref ref-type="fig" rid="fig2">Figure 2F</xref>). Together, these results suggest that PSSE may affect T2D risk in a manner distinct from islet SE function.</p><p>Having observed little evidence for enrichment of PSSE variants for traits related to beta cell function, we asked whether the enrichment of PSSE for T2D-associated variants could be explained by PSSE activity in T2D-relevant tissues and cell types outside the pancreas. We assessed PSSE activity by measuring H3K27ac signal in 95 representative tissues and cell lines from the ENCODE and Epigenome Roadmap projects (<xref ref-type="bibr" rid="bib41">Kundaje et al., 2015</xref>). Interestingly, there was group-wide specificity of PSSE to pancreatic progenitors relative to other cells and tissues including those relevant to T2D, such as adipose tissue, skeletal muscle, and liver (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref> and <xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>). Since gene regulation in adipocyte precursors also contributes to T2D risk (<xref ref-type="bibr" rid="bib10">Claussnitzer et al., 2014</xref>), we further examined PSSE specificity with respect to chromatin states during adipogenesis, using data from human adipose stromal cell differentiation stages (hASC1-4) (<xref ref-type="bibr" rid="bib53">Mikkelsen et al., 2010</xref>; <xref ref-type="bibr" rid="bib86">Varshney et al., 2017</xref>). PSSE exhibited virtually no active chromatin during adipogenesis (9, 8, 6, and 8 out of the 492 PSSE were active enhancers in hACS-1, hASC-2, hASC-3, and hASC-4, respectively; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). These findings identify PSSE as highly pancreatic progenitor-specific across T2D-relevant tissues and cell types.</p></sec><sec id="s2-4"><title>Identification of pancreatic progenitor-specific stretch enhancers harboring T2D-associated variants</title><p>Given the relative specificity of PSSE to pancreatic progenitors, we next sought to identify T2D-associated variants in PSSE at specific loci which may affect pancreatic development. We therefore identified variants in PSSE with evidence of T2D association (at p=4.7 × 10<sup>−6</sup>) after correcting for the total number of variants in PSSE genome-wide (n = 10,738). In total there were 49 variants in PSSE with T2D association exceeding this threshold mapping to 11 loci (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). This included variants at nine loci with known genome-wide significant T2D association (<italic>PROX1</italic>, <italic>ST6GAL1</italic>, <italic>SMARCAD1</italic>, <italic>XKR6</italic>, <italic>INS-IGF2</italic>, <italic>HMGA2</italic>, <italic>SMEK1</italic>, <italic>HMG20A</italic>, and <italic>LAMA1</italic>), as well as at two previously unreported loci with sub-genome-wide significant association, <italic>CRB2</italic> and <italic>PGM1</italic>. To identify candidate target genes of the T2D-associated PSSE in pancreatic progenitors, we analyzed the expression of all genes within the same topologically associated domain (TAD) as the PSSE in PP2 cells and in primary human embryonic pancreas tissue (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). These expressed genes are candidate effector transcripts of T2D-associated variants in pancreatic progenitors.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Identification of T2D risk variants associated with pancreatic progenitor-specific stretch enhancers.</title><p>(<bold>A</bold>) Manhattan plot showing T2D association p-values (from <xref ref-type="bibr" rid="bib48">Mahajan et al., 2018</xref>) for 10,738 variants mapping within PSSE. The dotted line shows the threshold for Bonferroni correction (p=4.66 × 10<sup>−6</sup>). Novel loci identified with this threshold and mapping at least 500 kb away from a known locus are highlighted in blue. Chromosomal coordinates of T2D-associated PSSE are indicated. (<bold>B</bold>) mRNA levels (measured in fragments per kilobase per million fragments mapped [FPKM]) at PP2 (blue) and in human embryonic pancreas (54 and 58 days gestation, gold) of nearest expressed (FPMK ≥1) gene at PP2 for PSSE harboring T2D variants identified in A. (<bold>C</bold>) PP2 specificity of H3K27ac signal at PSSE harboring T2D variants identified in A. Z-score comparing H3K27ac signal at PP2 to H3K27ac signal in tissues and cell lines from the ENCODE and Epigenome Roadmap projects. See also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Activity of T2D risk-associated pancreatic progenitor-specific stretch enhancers across human tissues.</title><p>(<bold>A</bold>) mRNA levels (measured in fragments per kilobase per million fragments mapped [FPKM]) at PP2 and in human embryonic pancreas (54 and 58 days gestation, Emb Pan) of all genes expressed (FPKM ≥1) at PP2 and located within topologically associated domains (TADs) containing indicated PSSE harboring T2D variants identified in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. (<bold>B</bold>) Heatmap showing H3K27ac signal at PSSE harboring T2D variants identified in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. Quantification in tissues and cell lines from the ENCODE and Epigenome Roadmap projects (tissues) as well as in developmental intermediates and islets (ISL) is shown. (<bold>C</bold>) H3K27ac signal at <italic>LAMA1</italic>-associated PSSE in tissues and cell lines from the ENCODE and Epigenome Roadmap projects as well as in developmental intermediates and islets.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig3-figsupp1-v2.tif"/></fig></fig-group><p>As many pancreatic progenitor SE remain poised in mature islets (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), we considered whether T2D-associated variants in PSSE could have gene regulatory function in islets that is re-activated in the disease state. We therefore assessed overlap of PSSE variants with accessible chromatin of islets from T2D donors (<xref ref-type="bibr" rid="bib39">Khetan et al., 2018</xref>). None of the strongly T2D-associated variants in PSSE (p=4.7 × 10<sup>−6</sup>) overlapped an islet accessible chromatin site in T2D islets, arguing against the relevance of PSSE in broadly regulating islet gene activity during T2D.</p></sec><sec id="s2-5"><title>A pancreatic progenitor-specific stretch enhancer at <italic>LAMA1</italic> harbors T2D risk variants and regulates <italic>LAMA1</italic> expression selectively in pancreatic progenitors</title><p>Variants in a PSSE at the <italic>LAMA1</italic> locus were associated with T2D at genome-wide significance (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), and <italic>LAMA1</italic> was highly expressed in the human embryonic pancreas (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Furthermore, the activity of the PSSE at the <italic>LAMA1</italic> locus was almost exclusively restricted to pancreatic progenitors (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B,C</xref>), and was further among the most progenitor-specific across all PSSE harboring T2D risk variants (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In addition, reporter gene assays in zebrafish embryos have shown that this enhancer drives gene expression specific to pancreatic progenitors in vivo (<xref ref-type="bibr" rid="bib8">Cebola et al., 2015</xref>). We therefore postulated that the activity of T2D-associated variants within the <italic>LAMA1</italic> PSSE is relevant for gene regulation in pancreatic progenitors, and we sought to characterize the <italic>LAMA1</italic> PSSE in greater depth.</p><p>Multiple T2D-associated variants mapped within the <italic>LAMA1</italic> PSSE, and these variants were further in the 99% credible set in fine-mapping data from the DIAMANTE consortium (<xref ref-type="bibr" rid="bib48">Mahajan et al., 2018</xref>; <xref ref-type="fig" rid="fig4">Figure 4A</xref>). No other variants in the 99% credible set mapped in an accessible chromatin site active in islets from either non-diabetic or T2D samples. The PSSE is intronic to the <italic>LAMA1</italic> gene and contains regions of poised chromatin and TE at prior developmental stages (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Consistent with its stepwise genesis as a SE throughout development, regions of open chromatin within the <italic>LAMA1</italic> PSSE were already present at the DE and GT stages. Furthermore, pancreatic lineage-determining transcription factors, such as FOXA1, FOXA2, GATA4, GATA6, HNF6, SOX9, and PDX1, were all bound to the PSSE at the PP2 stage (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Among credible set variants in the <italic>LAMA1</italic> PSSE, rs10502347 overlapped an ATAC-seq peak as well as ChIP-seq sites for multiple pancreatic lineage-determining transcription factors. Additionally, rs10502347 directly coincided with a SOX9 footprint identified in ATAC-seq data from PP2 cells, and the T2D risk allele C is predicted to disrupt SOX9 binding (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Consistent with the collective endophenotype association patterns of PSSE (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), rs10502347 showed no association with beta cell function (p=0.81, 0.23, 0.46 for fasting proinsulin levels, HOMA-B, and acute insulin response, respectively; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Thus, T2D variant rs10502347 is predicted to affect the binding of pancreatic transcription factors and does not appear to affect beta cell function.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A T2D risk-associated <italic>LAMA1</italic> pancreatic progenitor-specific stretch enhancer regulates <italic>LAMA1</italic> expression specifically in pancreatic progenitors.</title><p>(<bold>A</bold>) (Top) Locus plots showing T2D association p-values for variants in a 35 kb window (hg19 chr18:7,050,000–7,085,000) at the <italic>LAMA1</italic> locus and <italic>LAMA1</italic> PSSE (red box). Fine mapped variants within the 99% credible set for the <italic>LAMA1</italic> locus are colored black. All other variants are colored light gray. (Bottom) Chromatin states and ATAC-seq signal in ES, DE, GT, PP1, and PP2. TssA, active promoter; TssFlnk, flanking transcription start site; TssBiv, bivalent promoter; Repr, repressed; EnhA, active enhancer; EnhP, poised enhancer. (<bold>B</bold>) FOXA1, FOXA2, GATA4, GATA6, HNF6, SOX9, and PDX1 ChIP-seq profiles at the <italic>LAMA1</italic> PSSE in PP2. The variant rs10502347 (red) overlaps transcription factor binding sites and a predicted ATAC-seq footprint for the SOX9 sequence motif. Purple dotted lines indicate the core binding profile of the average SOX9 footprint genome-wide and the blue dotted line indicates the position of rs10502347 within the SOX9 motif. (<bold>C</bold>) <italic>LAMA1</italic> mRNA expression at each developmental stage determined by RNA-seq, measured in fragments per kilobase per million fragments mapped (FPKM). Data shown as mean ± S.E.M. (n = 3 replicates from independent differentiations). Light blue and purple indicate classification of the <italic>LAMA1</italic> PSSE as typical enhancer (TE) and stretch enhancer (SE), respectively. (<bold>D</bold>) <italic>LAMA1</italic> mRNA expression at each developmental stage determined by qPCR in control and ∆<italic>LAMA1</italic>Enh cells. Data are shown as mean ± S.E.M. (n = 3 replicates from independent differentiations for control cells. ∆<italic>LAMA1</italic>Enh cells represent combined data from two clonal lines with three replicates for each line from independent differentiations. n = 3 technical replicates for each sample; p=0.319, 0.594, 0.945, 0.290, and &lt;1 × 10<sup>−6</sup> for comparisons in ES, DE, GT, PP1, and PP2, respectively; student’s t-test, two sided; ***p&lt;0.001, n.s., not significant). Light blue and purple indicate classification of the <italic>LAMA1</italic> PSSE as TE and SE, respectively. Each plotted point represents the average of technical replicates for each differentiation. (<bold>E</bold>) mRNA expression determined by RNA-seq at PP2 of genes expressed in either control or ∆<italic>LAMA1</italic>Enh cells (FPKM ≥ 1 at PP2) and located within the same topologically associated domain as <italic>LAMA1</italic>. Data are shown as mean FPKM ± S.E.M. (n = 2 replicates from independent differentiations for control cells. ∆<italic>LAMA1</italic>Enh cells represent combined data from two clonal lines with two replicates for each line from independent differentiations. p adj. = 0.389 and 8.11 × 10<sup>−3</sup> for <italic>ARHGAP28</italic> and <italic>LAMA1</italic>, respectively; DESeq2). See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Genes downregulated in ∆<italic>LAMA1</italic>Enh PP2 stage cells compared to control cells (p adj. &lt;0.05).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59067-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Genes upregulated in ∆<italic>LAMA1</italic>Enh PP2 stage cells compared to control cells (p adj. &lt;0.05).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59067-fig4-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Deletion of the <italic>LAMA1</italic>-associated pancreatic progenitor-specific enhancer does not affect pancreatic lineage specification.</title><p>(<bold>A</bold>) Odds ratio estimates (points) and 95% CIs (lines) for rs10502347 association with T2D and metabolic GWAS traits. Significant associations are colored black, non-significant are colored light grey. (<bold>B</bold>) Schematic illustrating CRISPR-Cas9-mediated deletion strategy of <italic>LAMA1</italic>-associated PSSE to generate independent ∆<italic>LAMA1</italic>Enh hESC clones with different DNA cleavage products. (<bold>C</bold>) Flow cytometry analysis for NKX6.1 and PDX1 comparing control and ∆<italic>LAMA1</italic>Enh PP2 cells. Isotype control (ISO) for each antibody is shown in red and target protein staining in green. Percentage of cells expressing each protein is indicated (representative experiment, n = 3 independent differentiations). (<bold>D</bold>) Immunofluorescent staining for NKX6.1 and PDX1 in control and ∆<italic>LAMA1</italic>Enh PP2 cells (representative images, n = 2 slides). Scale bar, 50 μm. (<bold>E</bold>) mRNA expression of pancreatic transcription factors determined by RNA-seq in control and ∆<italic>LAMA1</italic>Enh PP2 cells. Data are shown as mean of fragments per kilobase per million fragments mapped (FPKM) ± S.E.M. (n = 2 replicates from independent differentiations for control cells. ∆<italic>LAMA1</italic>Enh cells represent combined data from two clonal lines with two replicates for each line from independent differentiations. p adj. = 3.56 × 10<sup>−2</sup>, 0.224, 0.829, 8.14 × 10<sup>−2</sup>, and 0.142, for comparisons of <italic>PDX1</italic>, <italic>NKX6.1</italic>, <italic>PROX1</italic>, <italic>PTF1A</italic>, and <italic>SOX9</italic>, respectively; DESeq2; * p adj. &lt;0.05, n.s., not significant). (<bold>F</bold>) Similarity matrix showing Pearson correlations for normalized transcriptomes (log transformed expression for genes with FPKM ≥1 in ≥1 replicates) in control and ∆<italic>LAMA1</italic>Enh PP2 cells (n = 2 independent differentiations for control cells and for each ∆<italic>LAMA1</italic>Enh clone). See also <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source datas 1</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Deletion of <italic>LAMA1</italic> does not affect pancreatic lineage specification.</title><p>(<bold>A</bold>) Schematic illustrating CRISPR-Cas9-mediated deletion strategy of <italic>LAMA1</italic> to generate ∆<italic>LAMA1</italic> hESC clonal line. (<bold>B</bold>) Immunofluorescent staining for Laminin in control and ∆<italic>LAMA1</italic> PP2 cells (representative images, n = 2 independent slides). Scale bar, 50 μm. (<bold>C</bold>) Flow cytometry analysis for NKX6.1 and PDX1 comparing control and ∆<italic>LAMA1</italic> PP2 cells. Isotype control (ISO) for each antibody is shown in red and target protein staining in green. Percentage of cells expressing each protein is indicated. (<bold>D</bold>) Immunofluorescent staining for NKX6.1 and PDX1 in control and ∆<italic>LAMA1</italic> PP2 cells (representative images, n = 2 independent slides). Scale bar, 50 μm. (<bold>E</bold>) mRNA expression of pancreatic transcription factors determined by qPCR in control and ∆<italic>LAMA1</italic> PP2 cells. Data are shown as mean ± S.E.M. (n = 3 replicates from independent differentiations. n = 3 technical replicates for each sample; p=2.19 × 10<sup>−2</sup>, 0.360, 6.25 × 10<sup>−2</sup>, 0.710, and 0.122 for comparisons of <italic>PDX1</italic>, <italic>NKX6.1</italic>, <italic>PROX1</italic>, <italic>PTF1A</italic>, and <italic>SOX9</italic> expression in control compared to ∆<italic>LAMA1</italic> PP2 cells, respectively; student’s t-test, two sided; n.s., not significant, *p&lt;0.01). Each plotted point represents the average of technical replicates for each differentiation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Enhancers can control gene expression over large genomic distances, and therefore their target genes cannot be predicted based on proximity alone. To directly assess the function of the <italic>LAMA1</italic> PSSE in regulating gene activity, we utilized CRIPSR-Cas9-mediated genome editing to generate two independent clonal human hESC lines harboring homozygous deletions of the <italic>LAMA1</italic> PSSE (hereafter referred to as ∆<italic>LAMA1</italic>Enh; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). We examined <italic>LAMA1</italic> expression in ∆<italic>LAMA1</italic>Enh compared to control cells throughout stages of pancreatic differentiation. Consistent with the broad expression of <italic>LAMA1</italic> across developmental and mature tissues, control cells expressed <italic>LAMA1</italic> at all stages (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). <italic>LAMA1</italic> was expressed at similar levels in ∆<italic>LAMA1</italic>Enh and control cells at early developmental stages, but was significantly reduced in PP2 cells derived from ∆<italic>LAMA1</italic>Enh clones (p=0.319, 0.594, 0.945, 0.290, and &lt;1 × 10<sup>−6</sup> for comparisons in ES, DE, GT, PP1, and PP2, respectively; <xref ref-type="fig" rid="fig4">Figure 4D</xref>). To next investigate whether the <italic>LAMA1</italic> PSSE regulates other genes at this locus, we utilized Hi-C datasets from PP2 cells to identify topologically associated domains (TADs). We then examined expression of genes mapping in the same TAD as the <italic>LAMA1</italic> PSSE. <italic>ARHGAP28</italic> was the only other expressed gene within the TAD, and albeit not significantly different from controls (p.adj &gt;0.05), showed a trend toward lower expression in ∆<italic>LAMA1</italic>Enh PP2 cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), raising the possibility that <italic>ARHGAP28</italic> is an additional target gene of the <italic>LAMA1</italic> PSSE. Together, these results demonstrate that while <italic>LAMA1</italic> itself is broadly expressed across developmental stages, the T2D-associated PSSE regulates <italic>LAMA1</italic> expression specifically in pancreatic progenitors.</p><p>To determine whether deletion of the <italic>LAMA1</italic> PSSE affects pancreatic development, we generated PP2 stage cells from ∆<italic>LAMA1</italic>Enh and control hESC lines and analyzed pancreatic cell fate commitment by flow cytometry and immunofluorescence staining for PDX1 and NKX6.1 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C,D</xref>). At the PP2 stage, ∆<italic>LAMA1</italic>Enh and control cultures contained similar percentages of PDX1- and NKX6.1-positive cells. Furthermore, mRNA expression of <italic>PDX1</italic>, <italic>NKX6.1</italic>, <italic>PROX1</italic>, <italic>PTF1A</italic>, and <italic>SOX9</italic> was either unaffected or only minimally reduced (p adj. = 3.56 × 10<sup>−2</sup>, 0.224, 0.829, 8.14 × 10<sup>−2</sup>, and 0.142, for comparisons of <italic>PDX1</italic>, <italic>NKX6.1</italic>, <italic>PROX1</italic>, <italic>PTF1A</italic>, and <italic>SOX9</italic> expression, respectively; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>), and the overall gene expression profiles as determined by RNA-seq were similar in ∆<italic>LAMA1</italic>Enh and control PP2 cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref> and <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source datas 1</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">2</xref>). To examine effects of complete <italic>LAMA1</italic> loss-of-function, we additionally generated a hESC line harboring a deletion of the <italic>LAMA1</italic> coding sequences (hereafter referred to as ∆<italic>LAMA1;</italic> <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A,B</xref>), and produced PP2 stage cells. Similar to ∆<italic>LAMA1</italic>Enh cultures, ∆<italic>LAMA1</italic> and control PP2 stage cultures contained similar numbers of PDX1- and NKX6.1-positive cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C,D</xref>). Likewise, mRNA expression of <italic>PDX1, NKX6.1, PROX1, PTF1A,</italic> and <italic>SOX9</italic> was similar in ∆<italic>LAMA1</italic> and control PP2 cells (p=4.3 × 10<sup>−2</sup>, 0.19, 0.16, 0.17, and 8.7 × 10<sup>−2</sup>, respectively; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2E</xref>). These findings indicate that in vitro pancreatic lineage induction is unperturbed in both ∆<italic>LAMA1</italic>Enh cells exhibiting reduced <italic>LAMA1</italic> expression, as well as ∆<italic>LAMA1</italic> cells where <italic>LAMA1</italic> coding sequences are disrupted.</p></sec><sec id="s2-6"><title>Pancreatic progenitor-specific stretch enhancers at the <italic>CRB2</italic> and <italic>PGM1</italic> loci harbor T2D-associated variants</title><p>Multiple variants with evidence for T2D association in PSSE mapped outside of known risk loci, such as those mapping to <italic>CRB2</italic> and <italic>PGM1</italic> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). As with the <italic>LAMA1</italic> PSSE, PSSE harboring variants at <italic>CRB2</italic> and <italic>PGM1</italic> were intronic to their respective genes, contained ATAC-seq peaks, and bound pancreatic lineage-determining transcription factors FOXA1, FOXA2, GATA4, GATA6, HNF6, SOX9, and PDX1 (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A,B</xref>). Compared to the <italic>LAMA1</italic> PSSE, <italic>CRB2</italic> and <italic>PGM1</italic> PSSE were less specific to pancreatic progenitors and exhibited significant H3K27ac signal in several other tissues and cell types, most notably brain, liver, and the digestive tract (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C,D</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>A T2D risk-associated <italic>CRB2</italic> pancreatic progenitor-specific stretch enhancer regulates <italic>CRB2</italic> expression specifically in pancreatic progenitors.</title><p>(<bold>A</bold>) (Top) Locus plots showing T2D association p-values for variants in a 35 kb window (hg19 chr9:126,112,000–126,147,000) at the <italic>CRB2</italic> locus and <italic>CRB2</italic> PSSE (red box). Fine mapped variants within the 99% credible set for the novel <italic>CRB2</italic> locus are colored black. All other variants are colored light gray. (Bottom) Chromatin states and ATAC-seq signal in ES, DE, GT, PP1, and PP2. TssA, active promoter; TssFlnk, flanking transcription start site; TssBiv, bivalent promoter; Repr, repressed; EnhA, active enhancer; EnhP, poised enhancer. (<bold>B</bold>) FOXA1, FOXA2, GATA4, GATA6, HNF6, SOX9, and PDX1 ChIP-seq profiles at the <italic>CRB2</italic> PSSE in PP2. The variant rs2491353 (black) overlaps with transcription factor binding sites. (<bold>C</bold>) <italic>CRB2</italic> mRNA expression at each developmental stage determined by RNA-seq, measured in fragments per kilobase per million fragments mapped (FPKM). Data shown as mean ± S.E.M. (n = 3 replicates from independent differentiations). Light blue and purple indicate classification of the <italic>CRB2</italic> PSSE as typical enhancer (TE) and stretch enhancer (SE), respectively. Plotted points represent average of technical replicates for each differentiation. (<bold>D</bold>) <italic>CRB2</italic> mRNA expression at each developmental stage determined by qPCR in control and ∆<italic>CRB2</italic>Enh cells. Data are shown as mean ± S.E.M. (n = 3 replicates from independent differentiations for control cells. ∆<italic>CRB2</italic>Enh cells represent combined data from two clonal lines with three replicates for each line from independent differentiations. n = 3 technical replicates for each sample; p=7.03 × 10<sup>−4</sup>,&lt;1 × 10<sup>−6</sup>,&lt;1 × 10<sup>−6</sup>, 1.46 × 10<sup>−2</sup>, and &lt;1 × 10<sup>−6</sup> for comparisons in ES, DE, GT, PP1, and PP2, respectively; student’s t-test, two sided; ***p&lt;0.001 **p&lt;0.01). Light blue and purple indicate classification of the <italic>CRB2</italic> PSSE as TE and SE, respectively. Each plotted point represents the average of technical replicates for each differentiation. (<bold>E</bold>) mRNA expression determined by RNA-seq at PP2 of genes expressed in either control or ∆<italic>CRB2</italic>Enh cells (FPKM ≥ 1 at PP2) and located within the same topologically associated domain as <italic>CRB2</italic>. Data are shown as mean FPKM ± S.E.M. (n = 2 replicates from independent differentiations for control cells. ∆<italic>CRB2</italic>Enh cells represent combined data from two clonal lines with two replicates for each line from independent differentiations. p adj. = 0.158, 1.00, and 3.51 × 10<sup>−3</sup>, for <italic>MIR600HG</italic>, <italic>STRBP</italic>, and <italic>CRB2</italic>, respectively; DESeq2; **p&lt;0.01, n.s., not significant). See also <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s3">3</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Genes downregulated in ∆<italic>CRB2</italic>Enh PP2 stage cells compared to control cells (p adj. &lt;0.05).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59067-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Activity of <italic>CRB2-</italic> and <italic>PGM1-</italic>associated pancreatic progenitor-specific stretch enhancers across human tissues.</title><p>(<bold>A</bold>) (Top) Locus plots showing T2D association p-values for variants in a 43 kb window (hg19 chr1:64,084,000–64,127,000) at the <italic>PGM1</italic> locus and <italic>PGM1</italic> PSSE (red box). Fine mapped variants within the 99% credible set for the novel <italic>PGM1</italic> locus are colored black. All other variants are colored light gray. (Bottom) Chromatin states and ATAC-seq signal in ES, DE, GT, PP1, and PP2. TssA, active promoter; TssFlnk, flanking transcription start site; TssBiv, bivalent promoter; Repr, repressed; EnhA, active enhancer; EnhP, poised enhancer. (<bold>B</bold>) FOXA1, FOXA2, GATA4, GATA6, HNF6, SOX9, and PDX1 ChIP-seq profiles at the <italic>PGM1</italic> PSSE in PP2 cells. The variants rs2269247, rs2301055, rs2301054, and rs2269246 (black) overlap with transcription factor binding sites. (<bold>C</bold>) H3K27ac signal at <italic>CRB2-</italic>associated PSSE in tissues and cell lines from the ENCODE and Epigenome Roadmap projects as well as in developmental intermediates and islets (ISL). (<bold>D</bold>) H3K27ac signal at <italic>PGM1-</italic>associated PSSE in tissues and cell lines from the ENCODE and Epigenome Roadmap projects as well as in developmental intermediates and islets.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Deletion of the <italic>CRB2</italic>-associated pancreatic progenitor-specific enhancer does not affect pancreatic lineage specification.</title><p>(<bold>A</bold>) Schematic illustrating CRISPR-Cas9-mediated deletion strategy of <italic>CRB2</italic>-associated PSSE to generate independent ∆<italic>CRB2</italic>Enh hESC clones with different DNA cleavage products. (<bold>B</bold>) Flow cytometry analysis for NKX6.1 and PDX1 comparing control and ∆<italic>CRB2</italic>Enh PP2 cells. Isotype control (ISO) for each antibody is shown in red and target protein staining in green. Percentage of cells expressing each protein is indicated (representative experiment, n = 3 independent differentiations). (<bold>C</bold>) Immunofluorescent staining for NKX6.1 and PDX1 in control and ∆<italic>CRB2</italic>Enh PP2 cells (representative images, n = 2 independent slides). Scale bar, 50 μm. (<bold>D</bold>) mRNA expression of pancreatic transcription factors determined by RNA-seq in control and ∆<italic>CRB2</italic>Enh PP2 cells. Data are shown as mean of fragments per kilobase per million fragments mapped (FPKM) ± S.E.M. (n = 2 replicates from independent differentiations for control cells ∆<italic>CRB2</italic>Enh cells represent combined data from two clonal lines with two replicates for each line from independent differentiations. p adj. = 1.00, 1.00, 1.00, 1.00, and 1.00, for comparisons of <italic>PDX1</italic>, <italic>NKX6.1</italic>, <italic>PROX1</italic>, <italic>PTF1A</italic>, and <italic>SOX9</italic>, respectively; DESeq2; n.s., not significant). (<bold>E</bold>) Similarity matrix showing Pearson correlations for normalized transcriptomes (log transformed expression for genes with FPKM ≥1 in ≥1 replicates) in control and ∆<italic>CRB2</italic>Enh PP2 cells (n = 2 independent differentiations for control cells and for each ∆<italic>CRB2</italic>Enh clone). See also <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Deletion of <italic>CRB2</italic> does not affect pancreatic lineage specification.</title><p>(<bold>A</bold>) Schematic illustrating CRISPR-Cas9-mediated deletion strategy of <italic>CRB2</italic> to generate ∆<italic>CRB2</italic> hESC clonal line. (<bold>B</bold>) Immunofluorescent staining for CRB2 in control and ∆<italic>CRB2</italic> PP2 cells (representative images, n = 2 independent slides). Scale bar, 50 μm. (<bold>C</bold>) Flow cytometry analysis for NKX6.1 and PDX1 comparing control and ∆<italic>CRB2</italic> PP2 cells. Isotype control (ISO) for each antibody is shown in red and target protein staining in green. Percentage of cells expressing each protein is indicated. (<bold>D</bold>) Immunofluorescent staining for NKX6.1 and PDX1 in control and ∆<italic>CRB2</italic> PP2 cells (representative images, n = 2 independent slides). Scale bar, 50 μm. (<bold>E</bold>) mRNA expression of pancreatic transcription factors determined by qPCR in control and ∆<italic>CRB2</italic> PP2 cells. Data are shown as mean ± S.E.M. (n = 3 replicates from independent differentiations. n = 3 technical replicates for each sample; p=0.241, 0.971, 0.397, 0.374, and 0.311 for comparisons of <italic>PDX1</italic>, <italic>NKX6.1</italic>, <italic>PROX1</italic>, <italic>PTF1A</italic>, and <italic>SOX9</italic> expression in control compared to ∆<italic>CRB2</italic> PP2 cells, respectively; student’s t-test, two sided; n.s., not significant). Each plotted point represents the average of technical replicates for each differentiation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig5-figsupp3-v2.tif"/></fig></fig-group><p>CRB2 is a component of the Crumbs protein complex involved in the regulation of cell polarity and neuronal, heart, retinal, and kidney development (<xref ref-type="bibr" rid="bib2">Alves et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Bulgakova and Knust, 2009</xref>; <xref ref-type="bibr" rid="bib16">Dudok et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Jiménez-Amilburu and Stainier, 2019</xref>; <xref ref-type="bibr" rid="bib75">Slavotinek et al., 2015</xref>). However, its role in pancreatic development is unknown. To determine whether the <italic>CRB2</italic> PSSE regulates <italic>CRB2</italic> expression in pancreatic progenitors, we generated two independent hESC clones with homozygous deletions of the <italic>CRB2</italic> PSSE (hereafter referred to as ∆<italic>CRB2</italic>Enh; <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>) and performed pancreatic differentiation of ∆<italic>CRB2</italic>Enh and control hESC lines. In control cells, <italic>CRB2</italic> was first expressed at the GT stage and increased markedly at the PP1 stage (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). This pattern of <italic>CRB2</italic> expression is consistent with H3K27ac deposition at the <italic>CRB2</italic> PSSE in GT stage cells and classification as a SE at the PP1 and PP2 stages (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). In ∆<italic>CRB2</italic>Enh cells, we observed upregulation of <italic>CRB2</italic> expression at earlier developmental stages, in particular at the DE and GT stages (p&lt;1 × 10<sup>−6</sup> at both stages; <xref ref-type="fig" rid="fig5">Figure 5D</xref>), suggesting that the <italic>CRB2</italic> PSSE may be associated with repressive transcriptional complexes prior to pancreas induction. At the PP2 stage, <italic>CRB2</italic> expression was significantly reduced in ∆<italic>CRB2</italic>Enh cells (p adj. = 3.51 × 10<sup>−3</sup>; <xref ref-type="fig" rid="fig5">Figure 5D</xref>), whereas the expression of other genes in the same TAD was not affected (p adj. ≥0.05; <xref ref-type="fig" rid="fig5">Figure 5E</xref>). Thus, the <italic>CRB2</italic> PSSE specifically regulates <italic>CRB2</italic> and is required for <italic>CRB2</italic> expression in pancreatic progenitors.</p><p>Phenotypic characterization of PP2 stage ∆<italic>CRB2</italic>Enh cultures revealed similar percentages of PDX1- and NKX6.1-positive cells as in control cultures (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B,C</xref>). The expression of pancreatic transcription factors and global gene expression profiles were also similar in ∆<italic>CRB2</italic>Enh and control PP2 cells (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D,E</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). Likewise, <italic>CRB2</italic> deletion hESCs (∆<italic>CRB2</italic>) differentiated to the PP2 stage (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A,B</xref>) produced similar numbers of PDX1- and NKX6.1-positive cells and expressed pancreatic transcription factors at levels similar to control cells (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3C–E</xref>). Thus, neither deletion of the <italic>CRB2</italic> PSSE nor the <italic>CRB2</italic> gene overtly impairs pancreatic lineage induction in the in vitro hESC differentiation system.</p></sec><sec id="s2-7"><title><italic>lama1</italic> and <italic>crb2</italic> zebrafish morphants display annular pancreas and decreased beta cell mass</title><p>Based on their classification as extracellular matrix and cell polarity proteins, respectively, Laminin (encoded by <italic>LAMA1</italic>) and CRB2 are predicted to regulate processes related to tissue morphogenesis, such as cell migration, tissue growth, and cell allocation within the developing organ. Furthermore, PSSE in general were enriched for proximity to genes involved in tissue morphogenesis (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), suggesting that T2D risk variants acting within PSSE could have roles in pancreas morphogenesis. Since cell migratory processes and niche-specific signaling events are not fully modeled during hESC differentiation, we reasoned that the in vitro pancreatic differentiation system might not be suitable for studying Laminin and CRB2 function in pancreatic development.</p><p>To circumvent these limitations, we employed zebrafish as an in vivo vertebrate model to study the effects of reduced <italic>lama1</italic> and <italic>crb2</italic> levels on pancreatic development. The basic organization and cell types in the pancreas as well as the genes regulating endocrine and exocrine pancreas development are highly conserved between zebrafish and mammals (<xref ref-type="bibr" rid="bib15">Dong et al., 2008</xref>; <xref ref-type="bibr" rid="bib21">Field et al., 2003</xref>; <xref ref-type="bibr" rid="bib40">Kimmel et al., 2015</xref>). To analyze pancreatic expression of Laminin and Crb proteins, we used <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> embryos to visualize pancreatic progenitor cells and the acinar pancreas by eGFP expression. At 48 hr post-fertilization (hpf), both Laminin and Crb proteins were detected in the eGFP and Nkx6.1 co-positive pancreatic progenitor cell domain (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A,B</xref>).</p><p>To determine the respective functions of <italic>lama1</italic> and <italic>crb2</italic> in pancreatic development, we performed knockdown experiments using anti-sense morpholinos directed against <italic>lama1</italic> and the two zebrafish <italic>crb2</italic> genes, <italic>crb2a</italic> and <italic>crb2b</italic> (<xref ref-type="bibr" rid="bib57">Omori and Malicki, 2006</xref>; <xref ref-type="bibr" rid="bib62">Pollard et al., 2006</xref>). Knockdown efficiency of each morpholino was validated using whole-mount immunohistochemistry. We observed significant reduction of Laminin staining throughout the pancreatic progenitor cell domain in embryos treated with morpholinos targeting <italic>lama1</italic> (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–D</xref>). In embryos treated with morpholinos targeting <italic>crb2a</italic> or <italic>crb2a</italic> and <italic>crb2b</italic>, we observed loss of staining in the pancreatic progenitor cell domain using antibodies specific to Crb2a or antibodies detecting all Crb proteins, respectively (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A–H</xref>) Residual panCrb protein signal was observed in the dorsal pancreas, which may be the result of expression of Crb proteins other than Crb2a and Crb2b in this region.</p><p>Consistent with prior studies (<xref ref-type="bibr" rid="bib62">Pollard et al., 2006</xref>), <italic>lama1</italic> morphants exhibited reduced body size and other gross anatomical defects at 78 hpf, whereas <italic>crb2a/b</italic> morphants appeared grossly normal. Both <italic>lama1</italic> and <italic>crb2a/b</italic> morphants displayed an annular pancreas (15 out of 34 <italic>lama1</italic> and 27 out of 69 <italic>crb2a/b</italic> morphants) characterized by pancreatic tissue partially or completely encircling the duodenum (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>), a phenotype indicative of impaired migration of pancreatic progenitors during pancreas formation. These findings suggest that both <italic>lama1</italic> and <italic>crb2a/b</italic> control cell migratory processes during early pancreatic development and that reduced levels of <italic>lama1</italic> or <italic>crb2a/b</italic> impair pancreas morphogenesis.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>lama1</italic> and <italic>crb2</italic> regulate pancreas morphogenesis and beta cell differentiation.</title><p>(<bold>A,B</bold>) Representative 3D renderings of <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> control zebrafish embryos (<bold>A,A’</bold>) and <italic>lama1</italic> morphants (<bold>B,B’</bold>) stained with DAPI (nuclei, blue) and antibody against insulin (red); n ≥ 15 embryos per condition. To account for reduced acinar pancreas size in <italic>lama1</italic> morphants, control embryos were imaged at 50 hr post fertilization (hpf) and <italic>lama1</italic> morphants at 78 hpf. 15 out of 34 <italic>lama1</italic> morphants displayed an annular pancreas with two acinar pancreas domains (green) connected behind the presumptive intestine (<bold>B’</bold>, white arrow). Scale bar, 40 µM. (<bold>C,D</bold>) Representative 3D renderings of 78 hpf <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> control zebrafish embryos (<bold>C,C’</bold>) and <italic>crb2a/b</italic> morphants (<bold>D,D’</bold>) stained with DAPI (nuclei, blue) and antibodies against insulin (red); n ≥ 15 embryos per condition. Twenty-seven out of 69 <italic>crb2a/b</italic> morphants displayed an annular pancreas with the acinar pancreas (green) completely surrounding the presumptive intestine. Scale bar, 40 µM. (<bold>E</bold>) Representative 3D renderings of <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> control zebrafish embryos and <italic>crb2a/b, lama1</italic>, or <italic>crb2a/b + lama1</italic> morphants stained with DAPI (nuclei, blue) and antibody against insulin (red). All embryos were imaged at 78 hpf except for controls to <italic>lama1</italic> and <italic>crb2a/b + lama1</italic> morphants, which were imaged at 50 hpf to account for reduced acinar pancreas size of <italic>lama1</italic> morphants. Scale bar, 20 µM. (<bold>F</bold>) Quantification of beta (insulin<sup>+</sup>) cell nuclei per embryo from experiment in (<bold>E</bold>). p adj. = 4.0 × 10<sup>−3</sup>, 8.0 × 10<sup>−3</sup>, and 2.0 × 10<sup>−4</sup> for comparison of hfp 78 control (n = 7 embryos) to hfp 78 <italic>crb2a/b</italic> (n = 8), hpf 50 control (n = 12) to hpf 78 <italic>lama1</italic> (n = 10), or <italic>crb2a/b + lama1</italic> (n = 12) morphants, respectively; ANOVA-Dunnett’s multiple comparison test; ***p&lt;0.001 **p&lt;0.01. 5 out of 8 <italic>crb2a/b</italic>, 3 out of 10 <italic>lama1</italic>, and 9 out of 12 <italic>crb2a/b + lama1</italic> morphants displayed an annular pancreas. MO, morpholino; Control, standard control morpholino. See also <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplements 1</xref>–<xref ref-type="fig" rid="fig6s4">4</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Laminin and Crb are expressed in zebrafish pancreas progenitors.</title><p>(<bold>A,B</bold>) Confocal images of 36 hr post fertilization (hpf) <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> zebrafish foregut endoderm labeled with DAPI (nuclei, grey) and antibodies against Nkx6.1 (blue; pancreatic progenitors) and Laminin (<bold>A</bold>, red) or panCrb (<bold>B</bold>, red); n = 10 embryos stained. (<bold>A–A”’’</bold>) Z-focal plane image showing pancreatic progenitor cells marked by Nkx6.1 (blue) and low level ptf1a:eGFP, labeled with anti-Laminin antibodies (red). (<bold>B–B”’’</bold>) Pancreatic progenitors labeled with anti-panCrb antibodies (red). Scale bar, 20 µM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Validation of morpholinos targeting <italic>lama1</italic>.</title><p>Confocal images (3D rendered) of 32–34 hpf <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> zebrafish foregut endoderm labeled with DAPI (nuclei, grey) and anti-Laminin antibodies (red). (<bold>A–A’’</bold>) Z-focal plane image of pancreatic progenitors marked by ptf1a:eGFP (green) and labeled with anti-Laminin antibodies (red) from embryos injected with non-targeting standard control morpholinos (n = 6). (<bold>B–B’’</bold>) Z-focal plane image showing loss of Laminin staining (red) in pancreatic progenitors marked by ptf1a:eGFP (green) from embryos injected with morpholinos targeting <italic>lama1</italic> (n = 5/6). (<bold>C,D</bold>) 3D renderings of 45 hpf <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> zebrafish foregut endoderm labeled with antibodies against Nkx6.1 (blue) and Laminin (red). (<bold>C–C’’</bold>) Z-focal plane image of pancreatic progenitors marked by ptf1a:eGFP (green) and labeled with anti-Nkx6.1 (blue) and anti-Laminin (red) antibodies from embryos injected with standard control morpholinos (n = 4/4). (<bold>D–D’’</bold>) Z-focal plane image showing loss of Laminin staining (red) in pancreatic progenitors marked by ptf1:eGFP and labeled with anti-Nkx6.1 antibodies (blue) from embryos injected with morpholinos targeting <italic>lama1</italic> (n = 3/4). Scale bar, 20 µM. Arrows highlight pancreatic progenitors marked by Laminin (red), Nkx6.1 (blue) and ptf1a:eGFP. MO, morpholino.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Validation of morpholinos targeting <italic>crb2a</italic> and <italic>crb2b</italic>.</title><p>(<bold>A,B</bold>) 3D renderings of 32–34 hpf <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> zebrafish foregut endoderm labeled with DAPI (nuclei, grey) and anti-Crb2a antibodies (red). (<bold>A–A’’</bold>) Z-focal plane image showing Crb2a labeled (red) foregut endoderm from embryos injected with standard control morpholinos (n = 6). (<bold>B–B’’</bold>) Z-focal plane image showing loss of Crb2a staining (red) in the foregut endoderm from embryos injected with morpholinos targeting <italic>crb2a</italic> (n = 6/6). (<bold>C,D</bold>) 3D renderings of 45 hpf <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> zebrafish foregut endoderm labeled with DAPI (nuclei, grey) and anti-Crb2a antibodies (red). (<bold>C–C’</bold>) Z-focal plane image showing Crb2a-labeled (red) embryos injected with standard control morpholinos (n = 3). (<bold>D–D’</bold>) Z-focal plane image showing loss of Crb2a staining (red) in embryos injected with morpholinos targeting <italic>crb2a</italic> (n = 3/3).(<bold>E,F</bold>) 3D renderings of 32–34 hpf <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> zebrafish foregut endoderm labeled with DAPI (nuclei, grey) and anti-panCrb antibodies (red). (<bold>E–E’’</bold>) Z-focal plane image showing pancreatic progenitors marked by ptf1a:eGFP (green) and labeled with anti-panCrb antibodies (red; white arrows) from embryos injected with standard control morpholinos (n = 8). (<bold>F–F’’</bold>) Z-focal plane image showing reduced panCrb (red) staining in pancreatic progenitors marked by ptf1a:eGFP (green) from embryos injected with morpholinos targeting both <italic>crb2a</italic> and <italic>crb2b</italic> (n = 4/5). (<bold>G,H</bold>) 3D renderings of 45 hpf <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> zebrafish foregut endoderm labeled with anti-Nkx6.1 (blue) and anti-panCrb (red) antibodies. (<bold>G–G’’</bold>) Z-focal plane image showing pancreatic progenitors marked by ptf1a:eGFP (green) and labeled with anti-Nkx6.1 (blue) and anti-panCrb (red; white arrows) antibodies from embryos injected with standard control morpholinos (n = 4). (<bold>H–H’’</bold>) Z-focal plane image showing reduced panCrb (red) staining in pancreatic progenitors marked by ptf1a:eGFP and labeled with anti-Nkx6.1 antibodies (blue) from embryos injected with morpholinos targeting both <italic>crb2a</italic> and <italic>crb2b</italic> (n = 3/4). Yellow arrows denote dorsal pancreas where panCrb labeling remains in control injected embryos, possibly due to expression of alternate Crb proteins present within the dorsal pancreas. Scale bar, 20 µM. MO, morpholino.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig6-figsupp3-v2.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title><italic>crb2b</italic> but not <italic>crb2a</italic> regulates pancreatic beta cell differentiation.</title><p>Quantification of beta (insulin<sup>+</sup>) cell nuclei per embryo in <italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic> control zebrafish embryos and <italic>crb2a</italic> or <italic>crb2b</italic> morphants at 78 hr post fertilization (hpf). p adj. = 0.91 and 4.4 × 10<sup>−2</sup> for comparison of control (n = 7 embryos) to <italic>crb2a</italic> (n = 8) or <italic>crb2b</italic> (n = 8) morphants, respectively; ANOVA-Dunnett’s multiple comparison test; **p&lt;0.01, n.s., not significant. 0 out of 8 <italic>crb2a</italic>, 0 out of 8 <italic>crb2b</italic> morphants displayed an annular pancreas. MO, morpholino; Control, standard control morpholino.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59067-fig6-figsupp4-v2.tif"/></fig></fig-group><p>To gain insight into the effects of <italic>lama1</italic> and <italic>crb2a/b</italic> knockdown on pancreatic endocrine cell development, we examined beta cell numbers (insulin<sup>+</sup> cells) at 78 hpf. We also evaluated potential synergistic effects of combined <italic>lama1</italic> and <italic>crb2a/b</italic> knockdown. To account for the reduction in body and pancreas size in <italic>lama1</italic> morphants, we compared cell numbers in 78 hpf <italic>lama1</italic> morphants with 50 hpf control embryos, which have a similarly sized acinar compartment as 78 hpf <italic>lama1</italic> morphants. Beta cell numbers were significantly reduced in both <italic>lama1</italic> and <italic>crb2a/b</italic> morphants (p=8.0 × 10<sup>−3</sup> and 4.0 × 10<sup>−3</sup> for comparisons of <italic>lama1</italic> and <italic>crb2a/b</italic> morphants, respectively; <xref ref-type="fig" rid="fig6">Figure 6E,F</xref>), as well as in morphants with a combined knockdown of <italic>lama1</italic> and <italic>crb2a/b</italic> (p=2.0 × 10<sup>−4</sup>; <xref ref-type="fig" rid="fig6">Figure 6F</xref>), showing that reduced <italic>lama1</italic> and <italic>crb2a/b</italic> levels, both individually and in combination, impair beta cell development. Furthermore, we found that nearly all <italic>lama1</italic>, <italic>crb2a/b,</italic> and combined <italic>lama1</italic> and <italic>crb2a/b</italic> morphants without an annular pancreas had reduced beta cell numbers, indicating independent roles of <italic>lama1</italic> and <italic>crb2</italic> in pancreas morphogenesis and beta cell differentiation. Finally, to investigate the contributions of individual <italic>crb2</italic> genes to the observed phenotype, we performed knockdown experiments using morpholinos against <italic>crb2a</italic> and <italic>crb2b</italic> alone. Only <italic>crb2b</italic> morphants showed a significant reduction in beta cell numbers (p=4.4 × 10<sup>−2</sup>; <xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4</xref>), suggesting that <italic>crb2b</italic> is the predominant <italic>crb2</italic> gene required for beta cell development. Combined, these findings demonstrate that <italic>lama1</italic> and <italic>crb2</italic> are regulators of pancreas morphogenesis and beta cell development in vivo.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we identify T2D-associated variants localized within chromatin active in pancreatic progenitors but not islets or other T2D-relevant tissues, suggesting a novel mechanism whereby a subset of T2D risk variants specifically alters pancreatic developmental processes. We link T2D-associated enhancers active in pancreatic progenitors to the regulation of <italic>LAMA1</italic> and <italic>CRB2</italic> and demonstrate a functional requirement in zebrafish for <italic>lama1</italic> and <italic>crb2</italic> in pancreas morphogenesis and endocrine cell formation. Furthermore, we provide a curated list of T2D risk-associated enhancers and candidate effector genes for further exploration of how the regulation of developmental processes in the pancreas can predispose to T2D.</p><p>Our analysis identified 11 loci where T2D-associated variants mapped in SE specifically active in pancreatic progenitors. Among these loci was <italic>LAMA1</italic>, which has stronger effects on T2D risk in lean compared to obese individuals (<xref ref-type="bibr" rid="bib60">Perry et al., 2012</xref>). We also found evidence that variants in PSSE collectively have stronger enrichment for T2D in lean individuals, although the small number of PSSE and limited sample size of the BMI-stratified T2D genetic data prohibits a more robust comparison. There was also a notable lack of enrichment among PSSE variants for association with traits related to insulin secretion and beta cell function. If T2D-associated variants in PSSE indeed confer diabetes susceptibility by affecting beta cell development, the question arises as to why variants associated with traits related to beta cell function are not enriched within PSSE. As genetic association studies of endophenotypes are based on data from non-diabetic subjects, a possible explanation is that variants affecting beta cell developmental processes have no overt phenotypic effect under physiological conditions and contribute to T2D pathogenesis only during the disease process.</p><p>Since the genomic position of enhancers and transcription factor binding sites is not well conserved between species (<xref ref-type="bibr" rid="bib87">Villar et al., 2015</xref>), a human cell model is necessary to identify target genes of enhancers associated with disease risk. By employing enhancer deletion in hESCs, we demonstrate that T2D-associated PSSE at the <italic>LAMA1</italic> and <italic>CRB2</italic> loci regulate <italic>LAMA1</italic> and <italic>CRB2</italic>, respectively, and establish <italic>LAMA1</italic> and <italic>CRB2</italic> as the predominant target gene of their corresponding PSSE within TAD boundaries. By analyzing <italic>LAMA1</italic> and <italic>CRB2</italic> expression throughout the pancreatic differentiation time course, we show that the identified PSSE control <italic>LAMA1</italic> and <italic>CRB2</italic> expression in a temporal manner consistent with the activation pattern of their associated PSSE. While the specific T2D-relevant target genes of the majority of T2D-associated PSSE remain to be identified, it is notable that several are localized within TADs containing genes encoding transcriptional regulators. These include <italic>PROX1</italic> and <italic>GATA4</italic>, which are known to regulate pancreatic development (<xref ref-type="bibr" rid="bib74">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib81">Tiyaboonchai et al., 2017</xref>; <xref ref-type="bibr" rid="bib90">Westmoreland et al., 2012</xref>), as well as <italic>HMGA2</italic> and <italic>BCL6</italic> with unknown functions in the pancreas. Our catalogue of T2D-associated PSSE provides a resource to fully characterize the gene regulatory program associated with developmentally mediated T2D risk in the pancreas. Our finding that predicted target genes of PSSE are similarly expressed in hESC-derived pancreatic progenitors and primary human embryonic pancreas (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>) further underscores the utility of the hESC-based system for these studies.</p><p>In the embryo, endocrine cells differentiate by delaminating from a polarized epithelium of progenitors governed by local cell-cell and cell-matrix signaling events (<xref ref-type="bibr" rid="bib49">Mamidi et al., 2018</xref>). These processes are not well-recapitulated in the hESC-based pancreatic differentiation system, highlighting a limitation of this system for studying the function of Laminin and CRB2, which are mediators of mechanical signals within an epithelium. Therefore, we analyzed their function in zebrafish as an in vivo model. We show that <italic>lama1</italic> or <italic>crb2</italic> knockdown leads to an annular pancreas and reduced beta cell numbers. The beta cell differentiation defect was also evident in embryos not displaying an annular pancreas, suggesting independent mechanisms.</p><p>Consistent with our findings in <italic>lama1</italic> morphants, culture of pancreatic progenitors on Laminin-based substrates promotes endocrine cell differentiation (<xref ref-type="bibr" rid="bib49">Mamidi et al., 2018</xref>). During in vivo pancreatic development, endothelial cells are an important albeit not the only source of Laminin in the pancreas (<xref ref-type="bibr" rid="bib33">Heymans et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Mamidi et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Nikolova et al., 2006</xref>). While we do not know the respective contributions of endothelial cell- and pancreatic progenitor cell-derived Laminin to the phenotype of <italic>lama1</italic> morphants, the T2D-associated <italic>LAMA1</italic> PSSE is not active in endothelial cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Furthermore, we found no other T2D-associated variants at the <italic>LAMA1</italic> locus mapping in endothelial cell enhancers or accessible chromatin sites in islets, suggesting that T2D risk is linked to <italic>LAMA1</italic> regulation in pancreatic progenitors.</p><p>Similar to Laminin, CRB2 has been shown to regulate mechanosignaling (<xref ref-type="bibr" rid="bib85">Varelas et al., 2010</xref>). Our observation that pancreatic progenitor cells express Crb proteins is consistent with the phenotype of <italic>crb2</italic> morphants reflecting a progenitor-autonomous role of Crb2. Furthermore, the similarity in pancreatic phenotype between <italic>lama1</italic> or <italic>crb2</italic> morphants raises the possibility that signals from Laminin and Crb2 could converge on the same intracellular pathways in pancreatic progenitors.</p><p>Our findings suggest that variation in gene regulation during pancreatic development can predispose to T2D later in life. Several lines of evidence support the concept of a developmental impact on T2D risk. First, human genetic studies have shown a strong correlation between birth weight and adult cardiometabolic traits and disease (<xref ref-type="bibr" rid="bib34">Horikoshi et al., 2016</xref>). Second, epidemiological studies provide evidence that offspring of mothers who were pregnant during a famine have a higher prevalence of T2D (<xref ref-type="bibr" rid="bib47">Lumey et al., 2015</xref>). This phenomenon has been experimentally reproduced in rodents, where maternal malnutrition has been shown to cause reduced beta cell mass at birth and to render beta cells more prone to failure under stress (<xref ref-type="bibr" rid="bib55">Nielsen et al., 2014</xref>). Together, our results provide a strong rationale for further exploration of how genetic variants affecting developmental gene regulation in the pancreas contribute to T2D risk.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) <break/>or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Antibody</td><td valign="top">APC Mouse monoclonal IgG1, κ Isotype Control</td><td valign="top">BD Pharmingen</td><td valign="top">Cat# 555751, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_398613">AB_398613</ext-link></td><td valign="top">Flow cytometry (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Chicken polyclonal anti-GFP</td><td valign="top">Aves Labs</td><td valign="top">Cat# GFP-1020, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10000240">AB_10000240</ext-link></td><td valign="top">Immunohistochemistry (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Cy3-conjugated donkey polyclonal anti-mouse</td><td valign="top">Jackson ImmunoResearch Labs</td><td valign="top">Cat# 715-165-150, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340813">AB_2340813</ext-link></td><td valign="top">Immunofluorescence (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">DyLight 488-conjugated donkey polyconal anti-goat</td><td valign="top">Jackson ImmunoResearch Labs</td><td valign="top">Cat# 705-545-003, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340428">AB_2340428</ext-link></td><td valign="top">Immunofluorescence (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-CTCF</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# SC-15914X, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2086899">AB_2086899</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-FOXA1</td><td valign="top">Abcam</td><td valign="top">Cat# ab5089, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_304744">AB_304744</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-FOXA2</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc-6554, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2262810">AB_2262810</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-GATA4</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc-1237, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2108747">AB_2108747</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-PDX1</td><td valign="top">Abcam</td><td valign="top">Cat# ab47383, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2162359">AB_2162359</ext-link></td><td valign="top">Immunofluorescence (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Guinea pig polyclonal anti-Insulin</td><td valign="top">Biomeda</td><td valign="top">Cat# v2024</td><td valign="top">Immunohistochemistry (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-Crb2a</td><td valign="top">ZIRC</td><td valign="top">Cat# Zs-4</td><td valign="top">Immunohistochemistry (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse polyclonal anti-GATA6</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc-9055, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2108768">AB_2108768</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-NKX6.1</td><td valign="top">Developmental Studies Hybridoma Bank</td><td valign="top">Cat# F64A6B4, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_532380">AB_532380</ext-link></td><td valign="top">Immunofluorescence (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-NKX6.1-Alexa Fluor 647</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 563338, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2738144">AB_2738144</ext-link></td><td valign="top">Flow cytometry (1:5)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-NKX6.1</td><td valign="top">Developmental Studies Hybridoma Bank</td><td valign="top">Cat# F55A10, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_532378">AB_532378</ext-link></td><td valign="top">Immunohistochemistry (1:10)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-PDX1-PE</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 562161, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10893589">AB_10893589</ext-link></td><td valign="top">Flow cytometry (1:10)</td></tr><tr><td valign="top">Antibody</td><td valign="top">PE Mouse monoclonal IgG1, κ Isotype Control</td><td valign="top">BD Pharmingen</td><td valign="top">Cat# 555749, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396091">AB_396091</ext-link></td><td valign="top">Flow cytometry (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-CRB2</td><td valign="top">Sigma</td><td valign="top">Cat # SAB1301340</td><td valign="top">Immunofluorescence (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-H3K27ac</td><td valign="top">Active Motif</td><td valign="top">Cat# 39133, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2561016">AB_2561016</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-H3K4me1</td><td valign="top">Abcam</td><td valign="top">Cat# ab8895, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_306847">AB_306847</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-HNF6</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc-13050, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2251852">AB_2251852</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-laminin</td><td valign="top">Sigma</td><td valign="top">Cat# L9393, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477163">AB_477163</ext-link></td><td valign="top">Immunohistochemistry (1:100) <break/>Immunofluorescence (1:30)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal anti-panCrb</td><td valign="top">Jensen Laboratory, University of Massachusetts, Amherst</td><td valign="top">N/A</td><td valign="top">Immunohistochemistry (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-PDX1</td><td valign="top">Beta Cell Biology Consortium</td><td valign="top">AB1068</td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-SOX9</td><td valign="top">Chemicon</td><td valign="top">Cat# 5535, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2239761">AB_2239761</ext-link></td><td valign="top">ChIP-seq (4 ug)</td></tr><tr><td valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">CyT49</td><td valign="top">ViaCyte, Inc</td><td valign="top">NIHhESC-10–0041, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_B850">CVCL_B850</ext-link></td><td valign="top">Male</td></tr><tr><td valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">H1</td><td valign="top">WiCell Research <break/>Institute</td><td valign="top">NIHhESC-10–0043, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_9771">CVCL_9771</ext-link></td><td valign="top">Male</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">2-Mercaptoethanol</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 21985023</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Accutase</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 00-4555-56</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">B-27 supplement</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 17504044</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Bovine Albumin Fraction V</td><td valign="top">Life Technologies</td><td valign="top">Cat# 15260037</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">D-(+)-Glucose Solution, 45%</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# G8769</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DAPI</td><td valign="top">Invitrogen</td><td valign="top">Cat# D1306</td><td valign="top">Immunohistochemistry (1:200)</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DMEM High Glucose</td><td valign="top">VWR</td><td valign="top">Cat# 16750–082</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DMEM/F12 [-] L-glutamine</td><td valign="top">VWR</td><td valign="top">Cat# 15–090-CV</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DMEM/F12 with L-Glutamine, HEPES</td><td valign="top">Corning</td><td valign="top">Cat# 45000–350</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DMF</td><td valign="top">EMD Millipore</td><td valign="top">Cat# DX1730</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DPBS</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 21–031-CV</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DTT</td><td valign="top">Sigma</td><td valign="top">Cat# D9779</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Fetal Bovine Serum</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# MT35011CV</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Glutamax</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 35050–079</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">GlutaMAX</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 35050061</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Hoechst 33342</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# H3570</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">HyClone Dulbecco’s Modified Eagles Medium</td><td valign="top">Thermo Fisher <break/>Scientific</td><td valign="top">Cat# SH30081.FS</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">IGEPAL-CA630</td><td valign="top">Sigma</td><td valign="top">Cat# I8896</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Illumina tagmentation enzyme</td><td valign="top">Illumina</td><td valign="top">Cat# FC-121–1030</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Insulin-Transferrin-Selenium (ITS)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 41400045</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Insulin-Transferrin-Selenium-Ethanolamine (ITS-X)</td><td valign="top">Thermo Fisher <break/>Scientific</td><td valign="top">Cat# 51500–056</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">KAAD-Cyclopamine</td><td valign="top">Toronto Research Chemicals</td><td valign="top">Cat# K171000</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">K-acetate</td><td valign="top">Sigma</td><td valign="top">Cat# P5708</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">KnockOut SR XenoFree</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# A1099202</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">LDN-193189</td><td valign="top">Stemgent</td><td valign="top">Cat# 04–0074</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Matrigel</td><td valign="top">Corning</td><td valign="top">Cat# 356231</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">MCDB 131</td><td valign="top">Thermo Fisher <break/>Scientific</td><td valign="top">Cat# 10372–019</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Mg-acetate</td><td valign="top">Sigma</td><td valign="top">Cat# M2545</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">mTeSR1 Complete Kit - GMP</td><td valign="top">STEMCELL <break/>Technologies</td><td valign="top">Cat# 85850</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">NEBNext High-Fidelity 2X PCR Master Mix</td><td valign="top">NEB</td><td valign="top">Cat# M0541</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Non-Essential Amino Acids</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 11140050</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">O.C.T. Compound</td><td valign="top">Sakura Finetek USA</td><td valign="top">Cat# 25608–930</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Penicillin-Streptomycin</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 15140122</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Polyethylenimine (PEI)</td><td valign="top">Polysciences</td><td valign="top">Cat# 23966–1</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Protease inhibitor</td><td valign="top">Roche</td><td valign="top">Cat# 05056489001</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Retinoic acid</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# R2625</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">RNA ScreenTape Sample Buffer</td><td valign="top">Agilent Technologies</td><td valign="top">Cat# 5067–5577</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">ROCK Inhibitor Y-27632</td><td valign="top">STEMCELL <break/>Technologies</td><td valign="top">Cat# 72305</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">RPMI 1640 [-] L-glutamine</td><td valign="top">VWR</td><td valign="top">Cat# 15–040-CV</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">SANT-1</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# S4572</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sodium Bicarbonate</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# NC0564699</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tamoxifen</td><td valign="top">Sigma</td><td valign="top">Cat# T5648</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TGF-β RI Kinase Inhibitor IV</td><td valign="top">Calbiochem</td><td valign="top">Cat# 616454</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TPB</td><td valign="top">Calbiochem</td><td valign="top">Cat# 565740</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tranylcypromine</td><td valign="top">Cayman Chemical</td><td valign="top">Cat# 10010494</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tris-acetate</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# BP-152</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TTNPB</td><td valign="top">Enzo Life Sciences</td><td valign="top">Cat# BML-GR105</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Vectashield Antifade Mounting Medium</td><td valign="top">Vector Laboratories</td><td valign="top">Cat# H-1000</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">XtremeGene 9</td><td valign="top">Roche</td><td valign="top">Cat# 6365787001</td><td valign="top"/></tr><tr><td valign="top">Commercial assay</td><td valign="top">High Sensitivity D1000 ScreenTape</td><td valign="top">Agilent Technologies</td><td valign="top">Cat# 5067–5584</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">RNA ScreenTape</td><td valign="top">Agilent Technologies</td><td valign="top">Cat# 5067–5576</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">RNA ScreenTape Ladder</td><td valign="top">Agilent Technologies</td><td valign="top">Cat# 5067–5578</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">BD Cytofix/Cytoperm Plus Fixation/Permeabilization Solution Kit</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 554715</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">ChIP-IT High Sensitivity Kit</td><td valign="top">Active Motif</td><td valign="top">Cat# 53040</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">iQ SYBR Green Supermix</td><td valign="top">Bio-Rad</td><td valign="top">Cat# 1708884</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">iScript cDNA Synthesis Kit</td><td valign="top">Bio-Rad</td><td valign="top">Cat# 1708891</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">KAPA Library Preparation Kit (Illumina)</td><td valign="top">Kapa Biosystems</td><td valign="top">Cat# KK8234</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">KAPA Stranded mRNA-Seq Kits</td><td valign="top">Kapa Biosystems</td><td valign="top">Cat# KK8401</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">MinElute PCR purification kit</td><td valign="top">QIAGEN</td><td valign="top">Cat# 28004</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Qubit ssDNA assay kit</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# Q10212</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">RNeasy Micro Kit</td><td valign="top">QIAGEN</td><td valign="top">Cat# 74004</td><td valign="top"/></tr><tr><td valign="top">Genetic reagent (<italic>D. rerio</italic>)</td><td valign="top"><italic>Tg(ptf1a:eGFP)<sup>jh1</sup></italic></td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/16258076">16258076</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">SPRIselect bead</td><td valign="top">Beckman Coulter</td><td valign="top">Cat# B23317</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Activin A</td><td valign="top">R and D Systems</td><td valign="top">Cat# 338-AC/CF</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Human AB Serum</td><td valign="top">Valley Biomedical</td><td valign="top">Cat# HP1022</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Recombinant EGF</td><td valign="top">R and D Systems</td><td valign="top">Cat# 236-EG</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Recombinant Heregulinβ−1</td><td valign="top">Peprotech</td><td valign="top">Cat# 100–03</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Recombinant KGF/FGF7</td><td valign="top">R and D Systems</td><td valign="top">Cat# 251 KG</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Recombinant Mouse Wnt3A</td><td valign="top">R and D Systems</td><td valign="top">Cat# 1324-WN/CF</td><td valign="top"/></tr><tr><td valign="top">Recombinant protein</td><td valign="top">Recombinant Noggin</td><td valign="top">R and D Systems</td><td valign="top">Cat# 3344 NG</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Px333 Plasmid</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.addgene.org/64073/">http://www.addgene.org/64073/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_64073">Addgene_64073</ext-link></td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">LAMA1 Forward</td><td valign="top">This paper</td><td valign="top">qPCR primers</td><td valign="top">GTG ATG GCA ACA GCG CAA A</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">LAMA1 Reverse</td><td valign="top">This paper</td><td valign="top">qPCR primers</td><td valign="top">GAC CCA GTG ATA TTC TCT CCC A</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">CRB2 Forward</td><td valign="top">This paper</td><td valign="top">qPCR primers</td><td valign="top">ACC ACT GTG CTT GTC CTG AG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">CRB2 Reverse</td><td valign="top">This paper</td><td valign="top">qPCR primers</td><td valign="top">TCC AGG GTC GCT AGA TGG AG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">TBP Forward</td><td valign="top">This paper</td><td valign="top">qPCR primers</td><td valign="top">TGT GCA CAG GAG CCA AGA GT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">TBP Reverse</td><td valign="top">This paper</td><td valign="top">qPCR primers</td><td valign="top">ATT TTC TTG CTG CCA GTC TGG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>LAMA1</italic>Enh Upstream Guide</td><td valign="top">This paper</td><td valign="top">CRISPR sgRNA</td><td valign="top">GTC AAA TTG CTA TAA CAC GG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>LAMA1</italic>Enh Downstream Guide</td><td valign="top">This paper</td><td valign="top">CRISPR sgRNA</td><td valign="top">CCA CTT TAA GTA TCT CAG CA</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>CRB2</italic>Enh Upstream Guide</td><td valign="top">This paper</td><td valign="top">CRISPR sgRNA</td><td valign="top">ATA CAA AGC ACG TGA GA</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>CRB2</italic>Enh Downstream Guide</td><td valign="top">This paper</td><td valign="top">CRISPR sgRNA</td><td valign="top">GAA TGC GGA TGA CGC CTG AG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">lama1-ATG</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/16321372">16321372</ext-link></td><td valign="top">Morpholino</td><td valign="top">TCA TCC TCA TCT CCA TCA TCG CTC A <break/>Obtained from GeneTools, LLC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">crb2a-SP</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/16713951">16713951</ext-link></td><td valign="top">Morpholino</td><td valign="top">ACG TTG CCA GTA CCT GTG TAT CCT G <break/>Obtained from GeneTools, LLC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">crb2b-SP</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/16713951">16713951</ext-link></td><td valign="top">Morpholino</td><td valign="top">TAA AGA TGT CCT ACC CAG CTT GAA C <break/>Obtained from GeneTools, LLC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">standard control MO</td><td valign="top">N/A</td><td valign="top">Morpholino</td><td valign="top">CCT CTT ACC TCA GTT ACA ATT TAT A <break/>Obtained from GeneTools, LLC</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Adobe Illustrator v 5.1</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.adobe.com/products/illustrator.html">http://www.adobe.com/products/illustrator.html</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014198">SCR_014198</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Adobe Photoshop v 5.1</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.adobe.com/products/photoshop.html">http://www.adobe.com/products/photoshop.html</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014199">SCR_014199</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">BEDtools v 2.26.0</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://github.com/arq5x/bedtools2">https://github.com/arq5x/bedtools2</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006646">SCR_006646</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Bioconductor</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.bioconductor.org/">https://www.bioconductor.org/</ext-link></td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006442">SCR_006442</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Burrows-Wheeler Aligner v 0.7.13</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://bio-bwa.sourceforge.net/">http://bio-bwa.sourceforge.net/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_010910">SCR_010910</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">CENTIPEDE v 1.2</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://centipede.uchicago.edu/">http://centipede.uchicago.edu/</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Cufflinks v 2.2.1</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://cole-trapnell-lab.github.io/cufflinks/">http://cole-trapnell-lab.github.io/cufflinks/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014597">SCR_014597</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">deepTools2 v 3.1.3</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://deeptools.readthedocs.io/en/develop/content/installation.html">https://deeptools.readthedocs.io/en/develop/content/installation.html</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">DESeq2 v 3.10</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FlowJo v10 software</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link></td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism v 8.1.2</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</ext-link></td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">HOMER v 4.10.4</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://homer.ucsd.edu/homer/">http://homer.ucsd.edu/homer/</ext-link></td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_010881">SCR_010881</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Juicebox Tools v 1.4</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://github.com/aidenlab/Juicebox/wiki/Juicebox-Assembly-Tools">https://github.com/aidenlab/Juicebox/wiki/Juicebox-Assembly-Tools</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MACS2 v 2.1.4</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://liulab.dfci.harvard.edu/MACS/">http://liulab.dfci.harvard.edu/MACS/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013291">SCR_013291</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MEME suite v 5.1.1</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://meme-suite.org/">http://meme-suite.org/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001783">SCR_001783</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Metascape</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://metscape.ncibi.org">http://metscape.ncibi.org</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014687">SCR_014687</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Picard Tools v 1.131</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006525">SCR_006525</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">R Project for Statistical Computing v 3.6.1</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001905">SCR_001905</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">SAMtools v 1.5</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://samtools.sourceforge.net">http://samtools.sourceforge.net</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002105">SCR_002105</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">STAR v 2.4</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://github.com/alexdobin/STAR">https://github.com/alexdobin/STAR</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">UCSC Genome Browser</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_005780">SCR_005780</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">vcf2diploid v 0.2.6a</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://github.com/abyzovlab/vcf2diploid">https://github.com/abyzovlab/vcf2diploid</ext-link></td><td valign="top">N/A</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ZEISS ZEN Digital Imaging for Light Microscopy</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.zeiss.com/microscopy/en_us/products/microscope-software/zen.html#introduction">http://www.zeiss.com/microscopy/en_us/products/microscope-software/zen.html#introduction</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013672">SCR_013672</ext-link></td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Maintenance and differentiation of CyT49 hESCs</title><p>Genomic and gene expression analyses (ChIP-seq, ATAC-seq, RNA-seq) for generation of chromatin maps and target gene identification were performed in CyT49 hESCs (male). Propagation of CyT49 hESCs was carried out by passing cells every 3 to 4 days using Accutase (eBioscience) for enzymatic cell dissociation, and with 10% (v/v) human AB serum (Valley Biomedical) included in the hESC media the day of passage. hESCs were seeded into tissue culture flasks at a density of 50,000 cells/cm<sup>2</sup>. hESC research was approved by the University of California, San Diego, Institutional Review Board and Embryonic Stem Cell Research oversight committee.</p><p>Pancreatic differentiation was performed as previously described (<xref ref-type="bibr" rid="bib72">Schulz et al., 2012</xref>; <xref ref-type="bibr" rid="bib88">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib93">Xie et al., 2013</xref>). Briefly, a suspension-based culture format was used to differentiate cells in aggregate form. Undifferentiated aggregates of hESCs were formed by re-suspending dissociated cells in hESC maintenance medium at a concentration of 1 × 10<sup>6</sup> cells/mL and plating 5.5 mL per well of the cell suspension in 6-well ultra-low attachment plates (Costar). The cells were cultured overnight on an orbital rotator (Innova2000, New Brunswick Scientific) at 95 rpm. After 24 hr the undifferentiated aggregates were washed once with RPMI medium and supplied with 5.5 mL of day 0 differentiation medium. Thereafter, cells were supplied with the fresh medium for the appropriate day of differentiation (see below). Cells were continually rotated at 95 rpm, or 105 rpm on days 4 through 8, and no media change was performed on day 10. Both RPMI (Mediatech) and DMEM High Glucose (HyClone) medium were supplemented with 1X GlutaMAX and 1% penicillin/streptomycin. Human activin A, mouse Wnt3a, human KGF, human noggin, and human EGF were purchased from R and D systems. Other added components included FBS (HyClone), B-27 supplement (Life Technologies), Insulin-Transferrin-Selenium (ITS; Life Technologies), TGFβ R1 kinase inhibitor IV (EMD Bioscience), KAAD-Cyclopamine (KC; Toronto Research Chemicals), and the retinoic receptor agonist TTNPB (RA; Sigma Aldrich). Day-specific differentiation media formulations were as follows:</p><list list-type="simple"><list-item><p>Days 0 and 1: RPMI + 0.2% (v/v) FBS, 100 ng/mL Activin, 50 ng/mL mouse Wnt3a, 1:5000 ITS. Days 1 and 2: RPMI + 0.2% (v/v) FBS, 100 ng/mL Activin, 1:5000 ITS</p></list-item><list-item><p>Days 2 and 3: RPMI + 0.2% (v/v) FBS, 2.5 mM TGFβ R1 kinase inhibitor IV, 25 ng/mL KGF, 1:1000 ITS</p></list-item><list-item><p>Days 3–5: RPMI + 0.2% (v/v) FBS, 25 ng/mL KGF, 1:1000 ITS</p></list-item><list-item><p>Days 5–8: DMEM + 0.5X B-27 Supplement, 3 nM TTNPB, 0.25 mM KAAD-Cyclopamine, 50 ng/mL Noggin</p></list-item><list-item><p>Days 8–10: DMEM/B-27, 50 ng/mL KGF, 50 ng/mL EGF</p></list-item></list><p>Cells at D0 correspond to the embryonic stem cell (ES) stage, cells at D2 correspond to the definitive endoderm (DE) stage, cells at D5 correspond to the gut tube (GT) stage, cells at D7 correspond to the early pancreatic progenitor (PP1) stage, and cells at D10 correspond to the late pancreatic progenitor (PP2) stage.</p></sec><sec id="s4-2"><title>Maintenance and differentiation of H1 hESCs</title><p><italic>∆LAMA1Enh</italic> and <italic>∆CRB2Enh</italic> clonal lines were derived by targeting H1 hESCs (male). Cells were maintained and differentiated as described with some modifications (<xref ref-type="bibr" rid="bib37">Jin et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Rezania et al., 2014</xref>). In brief, hESCs were cultured in mTeSR1 media (Stem Cell Technologies) and propagated by passaging cells every 3–4 days using Accutase (eBioscience) for enzymatic cell dissociation. hESC research was approved by the University of California, San Diego, Institutional Review Board and Embryonic Stem Cell Research Oversight Committee.</p><p>For differentiation, cells were dissociated using Accutase for 10 min, then reaggregated by plating the cells at a concentration of ~5.5 e6 cells/well in a low attachment six-well plate on an orbital shaker (100 rpm) in a 37°C incubator. The following day, undifferentiated cells were washed in base media (see below) and then differentiated using a multi-step protocol with stage-specific media and daily media changes.</p><p>All stage-specific base media were comprised of MCDB 131 medium (Thermo Fisher Scientific) supplemented with NaHCO3, GlutaMAX, D-Glucose, and BSA using the following concentrations:</p><list list-type="simple"><list-item><p>Stage 1/2 medium: MCDB 131 medium, 1.5 g/L NaHCO3, 1X GlutaMAX, 10 mM D-Glucose, 0.5% BSA</p></list-item><list-item><p>Stage 3/4 medium: MCDB 131 medium, 2.5 g/L NaHCO3, 1X GlutaMAX, 10 mM D-glucose, 2% BSA</p></list-item></list><p>Media compositions for each stage were as follows:</p><list list-type="simple"><list-item><p>Stage 1 (day 0–2): base medium, 100 ng/ml Activin A, 25 ng/ml Wnt3a (day 0). Day 1–2: base medium, 100 ng/ml Activin A</p></list-item><list-item><p>Stage 2 (day 3–5): base medium, 0.25 mM L-Ascorbic Acid (Vitamin C), 50 ng/mL FGF7</p></list-item><list-item><p>Stage 3 (day 6–7): base medium, 0.25 mM L-Ascorbic Acid, 50 ng/mL FGF7, 0.25 µM SANT-1, 1 µM Retinoic Acid, 100 nM LDN193189, 1:200 ITS-X, 200 nM TPB</p></list-item><list-item><p>Stage 4 (day 8–10): base medium, 0.25 mM L-Ascorbic Acid, 2 ng/mL FGF7, 0.25 µM SANT-1, 0.1 µM Retinoic Acid, 200 nM LDN193189, 1:200 ITS-X, 100 nM TPB</p></list-item></list><p>Cells at D0 correspond to the embryonic stem cell (ES) stage, cells at D3 correspond to the definitive endoderm (DE) stage, cells at D6 correspond to the gut tube (GT) stage, cells at D8 correspond to the early pancreatic progenitor (PP1) stage, and cells at D11 correspond to the late pancreatic progenitor (PP2) stage.</p></sec><sec id="s4-3"><title>Generation of ∆<italic>LAMA1</italic>Enh, ∆<italic>CRB2</italic>Enh, ∆<italic>LAMA1</italic>, and ∆<italic>CRB2</italic> hESC lines</title><p>To generate clonal homozygous <italic>LAMA1</italic>Enh and <italic>CRB2</italic>Enh deletion hESC lines, sgRNAs targeting each relevant enhancer were designed and cloned into Px333-GFP, a modified version of Px333 (Addgene, #64073). To generate clonal homozygous <italic>LAMA1</italic> and <italic>CRB2</italic> deletion hESC lines, sgRNAs targeting the second exon of each gene were designed and cloned into Px458 (Addgene, #48138). Plasmids expressing the sgRNAs were transfected into H1 hESCs with XtremeGene 9 (Roche). Twenty-four hr later, 8000 GFP<sup>+</sup> cells were sorted into a well of six-well plate. Individual colonies that emerged within 5–7 days after transfection were subsequently transferred manually into 48-well plates for expansion, genomic DNA extraction, PCR genotyping, and Sanger sequencing. sgRNA oligos are listed below.</p><list list-type="simple"><list-item><p><italic>LAMA1</italic>Enh Upstream Guide: <named-content content-type="sequence">GTCAAATTGCTATAACACGG</named-content></p></list-item><list-item><p><italic>LAMA1</italic>Enh Downstream Guide: <named-content content-type="sequence">CCACTTTAAGTATCTCAGCA</named-content></p></list-item><list-item><p><italic>CRB2</italic>Enh Upstream Guide: <named-content content-type="sequence">ATACAAAGCACGTGAGA</named-content></p></list-item><list-item><p><italic>CRB2</italic>Enh Downstream Guide: <named-content content-type="sequence">GAATGCGGATGACGCCTGAG</named-content></p></list-item><list-item><p><italic>LAMA1</italic> Exon 2 Guide: <named-content content-type="sequence">ATCAGCACCAATGCCACCTG</named-content></p></list-item><list-item><p><italic>CRB2</italic> Exon 2 Guide: <named-content content-type="sequence">TCGATGTCCAGCTCGCAGCG</named-content></p></list-item></list></sec><sec id="s4-4"><title>Human tissue</title><p>Human embryonic pancreas tissue was obtained from the Birth Defects Research Laboratory of the University of Washington. Studies for use of embryonic human tissue were approved by the Institutional Review Board of the University of California, San Diego. A pancreas from a 54- and 58-day gestation embryo each were pooled for RNA-seq analysis.</p></sec><sec id="s4-5"><title>Zebrafish husbandry</title><p>Adult zebrafish and embryos were cared for and maintained under standard conditions. All research activity involving zebrafish was reviewed and approved by SBP Medical Discovery Institute Institutional Animal Care and Use Committee. The following transgenic lines were used: <italic>Tg(ptf1a:eGFP)</italic><sup>jh1</sup> (<xref ref-type="bibr" rid="bib28">Godinho et al., 2005</xref>).</p></sec><sec id="s4-6"><title>Morpholino injections in zebrafish</title><p>The following previously validated morpholinos were injected into the yolk at the one-cell stage in a final volume of either 0.5 or 1 nl: 0.75 ng lama1-ATG (5’- <named-content content-type="sequence">TCATCCT CATCTCCATCATCGCTCA</named-content> −3’); 3 ng crb2a-SP, (5’-<named-content content-type="sequence">ACGTTGCCAGTACCTGTGTATCCTG</named-content>-3’) (<xref ref-type="bibr" rid="bib57">Omori and Malicki, 2006</xref>; <xref ref-type="bibr" rid="bib89">Watanabe et al., 2010</xref>); 3 ng crb2b-SP, (5’-<named-content content-type="sequence">TAAAGATGTCCTACCCAGCTTGAAC</named-content>-3’) (<xref ref-type="bibr" rid="bib57">Omori and Malicki, 2006</xref>); 6.75 ng standard control MO (5’- <named-content content-type="sequence">CCTCTTACCTCAGTTACAATTTATA</named-content> −3’). All morpholinos were obtained from GeneTools, LLC.</p></sec><sec id="s4-7"><title>Chromatin immunoprecipitation sequencing (ChIP-seq)</title><p>ChIP-seq was performed using the ChIP-IT High-Sensitivity kit (Active Motif) according to the manufacturer’s instructions. Briefly, for each cell stage and condition analyzed, 5–10 × 10<sup>6</sup> cells were harvested and fixed for 15 min in an 11.1% formaldehyde solution. Cells were lysed and homogenized using a Dounce homogenizer and the lysate was sonicated in a Bioruptor Plus (Diagenode), on high for 3 × 5 min (30 s on, 30 s off). Between 10 and 30 µg of the resulting sheared chromatin was used for each immunoprecipitation. Equal quantities of sheared chromatin from each sample were used for immunoprecipitations carried out at the same time. A total of 4 µg of antibody were used for each ChIP-seq assay. Chromatin was incubated with primary antibodies overnight at 4°C on a rotator followed by incubation with Protein G agarose beads for 3 hr at 4°C on a rotator. Antibodies used were rabbit anti-H3K27ac (Active Motif 39133), rabbit anti-H3K4me1 (Abcam ab8895), rabbit anti-H3K4me3 (Millipore 04–745), rabbit anti-H3K27me3 (Millipore 07–499), goat anti-CTCF (Santa Cruz Biotechnology SC-15914X), goat anti-GATA4 (Santa Cruz SC-1237), rabbit anti-GATA6 (Santa Cruz SC-9055), goat anti-FOXA1 (Abcam Ab5089), goat-anti-FOXA2 (Santa Cruz SC-6554), rabbit anti-PDX1 (BCBC AB1068), rabbit anti-HNF6 (Santa Cruz SC-13050), and rabbit anti-SOX9 (Chemicon AB5535). Reversal of crosslinks and DNA purification were performed according to the ChIP-IT High-Sensitivity instructions, with the modification of incubation at 65°C for 2–3 hr, rather than at 80°C for 2 hr. Sequencing libraries were constructed using KAPA DNA Library Preparation Kits for Illumina (Kapa Biosystems) and library sequencing was performed on either a HiSeq 4000 System (Illumina) or NovaSeq 6000 System (Illumina) with single-end reads of either 50 or 75 base pairs (bp). Sequencing was performed by the Institute for Genomic Medicine (IGM) core research facility at the University of California at San Diego (UCSD). Two replicates from independent hESC differentiations were generated for each ChIP-seq experiment.</p></sec><sec id="s4-8"><title>ChIP-seq data analysis</title><p>ChIP-seq reads were mapped to the human genome consensus build (hg19/GRCh37) and visualized using the UCSC Genome Browser (<xref ref-type="bibr" rid="bib38">Kent et al., 2002</xref>). Burrows-Wheeler Aligner (BWA) (<xref ref-type="bibr" rid="bib45">Li and Durbin, 2009</xref>) version 0.7.13 was used to map data to the genome. Unmapped and low-quality (q &lt; 15) reads were discarded. SAMtools (<xref ref-type="bibr" rid="bib43">Li et al., 2009</xref>) was used to remove duplicate sequences and HOMER (<xref ref-type="bibr" rid="bib32">Heinz et al., 2010</xref>) was used to call peaks using default parameters and to generate tag density plots. Stage- and condition-matched input DNA controls were used as background when calling peaks. The BEDtools suite of programs (<xref ref-type="bibr" rid="bib65">Quinlan and Hall, 2010</xref>) was used to perform genomic algebra operations. For all ChIP-seq experiments, replicates from two independent hESC differentiations were generated. Tag directories were created for each replicate using HOMER. Directories from each replicate were then combined, and peaks were called from the combined replicates. For histone modifications and CTCF peaks, pearson correlations between each pair of replicates were calculated over the called peaks using the command multiBamSummary from the deepTools2 package (<xref ref-type="bibr" rid="bib67">Ramírez et al., 2016</xref>). For pancreatic lineage-determining transcription factors (GATA4, GATA6, FOXA1, FOXA2, HNF6, PDX1, SOX9), correlations were calculated for peaks overlapping PSSE. Calculated Pearson correlations are as follow:</p><p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">H3K4me1</th><th valign="top">H3K27ac</th><th valign="top">CTCF</th><th valign="top">H3K4me3</th><th valign="top">H3K27me3</th></tr></thead><tbody><tr><td valign="top">ES</td><td valign="top">0.90</td><td valign="top">0.91</td><td valign="top">0.87</td><td valign="top">0.81</td><td valign="top">1.00</td></tr><tr><td valign="top">DE</td><td valign="top">0.97</td><td valign="top">0.84</td><td valign="top">0.86</td><td valign="top">0.99</td><td valign="top">0.99</td></tr><tr><td valign="top">GT</td><td valign="top">0.97</td><td valign="top">0.87</td><td valign="top">0.89</td><td valign="top">0.97</td><td valign="top">0.99</td></tr><tr><td valign="top">PP1</td><td valign="top">0.97</td><td valign="top">0.85</td><td valign="top">0.89</td><td valign="top">0.96</td><td valign="top">0.99</td></tr><tr><td valign="top">PP2</td><td valign="top">0.98</td><td valign="top">0.87</td><td valign="top">0.87</td><td valign="top">0.97</td><td valign="top">1.00</td></tr></tbody></table></table-wrap></p><p><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">GATA4</th><th valign="top">GATA6</th><th valign="top">FOXA1</th><th valign="top">FOXA2</th><th valign="top">HNF6</th><th valign="top">PDX1</th><th valign="top">SOX9</th></tr></thead><tbody><tr><td valign="top">PP2</td><td valign="top">0.86</td><td valign="top">0.82</td><td valign="top">0.87</td><td valign="top">0.80</td><td valign="top">0.95</td><td valign="top">0.64</td><td valign="top">0.86</td></tr></tbody></table></table-wrap></p></sec><sec id="s4-9"><title>RNA isolation and sequencing (RNA-seq) and qRT-PCR</title><p>RNA was isolated from cell samples using the RNeasy Micro Kit (Qiagen) according to the manufacturer instructions. For each cell stage and condition analyzed between 0.1 and 1 × 10<sup>6</sup> cells were collected for RNA extraction. For qRT-PCR, cDNA synthesis was first performed using the iScript cDNA Synthesis Kit (Bio-Rad) and 500 ng of isolated RNA per reaction. qRT-PCR reactions were performed in triplicate with 10 ng of template cDNA per reaction using a CFX96 Real-Time PCR Detection System and the iQ SYBR Green Supermix (Bio-Rad). PCR of the TATA binding protein (TBP) coding sequence was used as an internal control and relative expression was quantified via double delta CT analysis. For RNA-seq, stranded, single-end sequencing libraries were constructed from isolated RNA using the TruSeq Stranded mRNA Library Prep Kit (Illumina) and library sequencing was performed on either a HiSeq 4000 System (Illumina) or NovaSeq 6000 System (Illumina) with single-end reads of either 50 or 75 base pairs (bp). Sequencing was performed by the Institute for Genomic Medicine (IGM) core research facility at the University of California at San Diego. A complete list of RT-qPCR primer sequences can be found below.</p><p><table-wrap id="inlinetable3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th><italic>LAMA1</italic> forward</th><th valign="bottom">GTG ATG GCA ACA GCG CAA A</th></tr></thead><tbody><tr><td><italic>LAMA1</italic> reverse</td><td valign="bottom">GAC CCA GTG ATA TTC TCT CCC A</td></tr><tr><td><italic>CRB2</italic> forward</td><td valign="bottom">ACC ACT GTG CTT GTC CTG AG</td></tr><tr><td><italic>CRB2</italic> reverse</td><td valign="bottom">TCC AGG GTC GCT AGA TGG AG</td></tr><tr><td><italic>PDX1</italic> forward</td><td valign="bottom">AAG TCT ACC AAA GCT CAC GCG</td></tr><tr><td><italic>PDX1</italic> reverse</td><td valign="bottom">GTA GGC GCC GCC TGC</td></tr><tr><td><italic>NKX6.1</italic> forward</td><td valign="bottom">CTG GCC TGT ACC CCT CAT CA</td></tr><tr><td><italic>NKX6.1</italic> reverse</td><td valign="bottom">CTT CCC GTC TTT GTC CAA CA</td></tr><tr><td><italic>PROX1</italic> forward</td><td valign="bottom">AAC ATG CAC TAC AAT AAA GCA AAT GAC</td></tr><tr><td><italic>PROX1</italic> reverse</td><td valign="bottom">CAG GAA TCT CTC TGG AAC CTC AAA</td></tr><tr><td><italic>PTF1A</italic> forward</td><td valign="bottom">GAA GGT CAT CAT CTG CCA TC</td></tr><tr><td><italic>PTF1A</italic> reverse</td><td valign="bottom">GGC CAT AAT CAG GGT CGC T</td></tr><tr><td><italic>SOX9</italic> forward</td><td valign="bottom">AGT ACC CGC ACT TGC ACA AC</td></tr><tr><td><italic>SOX9</italic> reverse</td><td valign="bottom">ACT TGT AAT CCG GGT GGT CCT T</td></tr><tr><td valign="top"><italic>TBP</italic> forward</td><td valign="top">TGT GCA CAG GAG CCA AGA GT</td></tr><tr><td valign="top"><italic>TBP</italic> reverse</td><td valign="top">ATT TTC TTG CTG CCA GTC TGG</td></tr></tbody></table></table-wrap></p></sec><sec id="s4-10"><title>RNA-seq data analysis</title><p>Reads were mapped to the human genome consensus build (hg19/GRCh37) using the Spliced Transcripts Alignment to a Reference (STAR) aligner v2.4 (<xref ref-type="bibr" rid="bib14">Dobin et al., 2013</xref>). Normalized gene expression (fragments per kilobase per million mapped reads; FPKM) for each sequence file was determined using Cufflinks v2.2.1 (<xref ref-type="bibr" rid="bib82">Trapnell et al., 2010</xref>) with the parameters: --<monospace>library-type</monospace> fr-firststrand --<monospace>max-bundle-frags</monospace> 10000000. For all RNA-Seq experiments, replicates from two independent hESC differentiations were generated. Pearson correlations between bam files corresponding to each pair of replicates were calculated, and are as follow:</p><p><table-wrap id="inlinetable4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">∆<italic>LAMA1</italic>Enh clone 1 PP2</th><th valign="top">1.00</th></tr></thead><tbody><tr><td valign="top">∆<italic>LAMA1</italic>Enh clone 2 PP2</td><td valign="top">0.99</td></tr><tr><td valign="top">∆<italic>CRB2</italic>Enh clone 1 PP2</td><td valign="top">0.98</td></tr><tr><td valign="top">∆<italic>CRB2</italic>Enh clone 2 PP2</td><td valign="top">0.90</td></tr><tr><td valign="top">∆<italic>LAMA</italic>1Enh control PP2</td><td valign="top">0.92</td></tr><tr><td valign="top">∆<italic>CRB2</italic>Enh control PP2</td><td valign="top">0.99</td></tr></tbody></table></table-wrap></p></sec><sec id="s4-11"><title>Assay for transposase accessible chromatin sequencing (ATAC-seq)</title><p>ATAC-seq (<xref ref-type="bibr" rid="bib5">Buenrostro et al., 2013</xref>) was performed on approximately 50,000 nuclei. The samples were permeabilized in cold permeabilization buffer 0.2% IGEPAL-CA630 (I8896, Sigma), 1 mM DTT (D9779, Sigma), Protease inhibitor (05056489001, Roche), 5% BSA (A7906, Sigma) in PBS (10010–23, Thermo Fisher Scientific) for 10 min on the rotator in the cold room and centrifuged for 5 min at 500 × g at 4°C. The pellet was resuspended in cold tagmentation buffer (33 mM Tris-acetate (pH = 7.8) (BP-152, Thermo Fisher Scientific), 66 mM K-acetate (P5708, Sigma), 11 mM Mg-acetate (M2545, Sigma), 16% DMF (DX1730, EMD Millipore) in Molecular biology water (46000 CM, Corning)) and incubated with tagmentation enzyme (FC-121–1030; Illumina) at 37°C for 30 min with shaking at 500 rpm. The tagmented DNA was purified using MinElute PCR purification kit (28004, QIAGEN). Libraries were amplified using NEBNext High-Fidelity 2X PCR Master Mix (M0541, NEB) with primer extension at 72°C for 5 min, denaturation at 98°C for 30 s, followed by 8 cycles of denaturation at 98°C for 10 s, annealing at 63°C for 30 s and extension at 72°C for 60 s. After the purification of amplified libraries using MinElute PCR purification kit (28004, QIAGEN), double size selection was performed using SPRIselect bead (B23317, Beckman Coulter) with 0.55X beads and 1.5X to sample volume. Finally, libraries were sequenced on HiSeq4000 (Paired-end 50 cycles, Illumina).</p></sec><sec id="s4-12"><title>ATAC-seq data analysis</title><p>ATAC-seq reads were mapped to the human genome (hg19/GRCh37) using Burrows-Wheeler Aligner (BWA) version 0.7.13 (<xref ref-type="bibr" rid="bib45">Li and Durbin, 2009</xref>), and visualized using the UCSC Genome Browser (<xref ref-type="bibr" rid="bib38">Kent et al., 2002</xref>). SAMtools (<xref ref-type="bibr" rid="bib43">Li et al., 2009</xref>) was used to remove unmapped, low-quality (q &lt; 15), and duplicate reads. MACS2 (<xref ref-type="bibr" rid="bib94">Zhang et al., 2008</xref>) was used to call peaks, with parameters ‘shift set to 100 bps, smoothing window of 200 bps’ and with ‘nolambda’ and ‘nomodel’ flags on. MACS2 was also used to call ATAC-Seq summits, using the same parameters combined with the ‘call-summits’ flag.</p><p>For all ATAC-Seq experiments, replicates from two independent hESC differentiations were generated. Bam files for each pair of replicates were merged for downstream analysis using SAMtools, and Pearson correlations between bam files for each individual replicate were calculated over a set of peaks called from the merged bam file. Correlations were performed using the command multiBamSummary from the deepTools2 package (<xref ref-type="bibr" rid="bib67">Ramírez et al., 2016</xref>) with the ‘—removeOutliers’ flag and are as follow:</p><p><table-wrap id="inlinetable5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">ES</th><th valign="top">0.95</th></tr></thead><tbody><tr><td valign="top">DE</td><td valign="top">0.83</td></tr><tr><td valign="top">GT</td><td valign="top">1.00</td></tr><tr><td valign="top">PP1</td><td valign="top">1.00</td></tr><tr><td valign="top">PP2</td><td valign="top">1.00</td></tr></tbody></table></table-wrap></p><p>For downstream analysis, ATAC-seq peaks were merged from two independent differentiations for ES, DE, GT, PP1, and PP2 stage cells and from four donors for primary islets. Primary islet ATAC-seq data was obtained from previously published datasets (<xref ref-type="bibr" rid="bib30">Greenwald et al., 2019</xref>).</p></sec><sec id="s4-13"><title>Hi-C data analysis</title><p>Hi-C data were processed as previously described with some modifications (<xref ref-type="bibr" rid="bib13">Dixon et al., 2015</xref>). Read pairs were aligned to the hg19 reference genome separately using BWA-MEM with default parameters (<xref ref-type="bibr" rid="bib45">Li and Durbin, 2009</xref>). Specifically, chimeric reads were processed to keep only the 5’ position and reads with low mapping quality (&lt;10) were filtered out. Read pairs were then paired using custom scripts. Picard tools were then used to remove PCR duplicates. Bam files with alignments were further processed into text format as required by Juicebox tools (<xref ref-type="bibr" rid="bib18">Durand et al., 2016</xref>). Juicebox tools were then applied to generate hic files containing normalized contact matrices. All downstream analysis was based on 10 Kb resolution KR normalized matrices.</p><p>Chromatin loops were identified by comparing each pixel with its local background, as described previously (<xref ref-type="bibr" rid="bib68">Rao et al., 2014</xref>) with some modifications. Specifically, only the donut region around the pixel was compared to model the expected count. Briefly, the KR-normalized contact matrices at 10 Kb resolution were used as input for loop calling. For each pixel, distance-corrected contact frequencies were calculated for each surrounding bin and the average of all surrounding bins. The expected counts were then transformed to raw counts by multiplying the counts with the raw-to-KR normalization factor. The probability of observing raw expected counts was calculated using Poisson distribution. All pixels with p-value&lt;0.01 and distance less than 10 Kb were selected as candidate pixels. Candidate pixels were then filtered to remove pixels without any neighboring candidate pixels since they were likely false positives. Finally, pixels within 20 Kb of each other were collapsed and only the most significant pixel was selected. The collapsed pixels with p-value&lt;1e-5 were used as the final list of chromatin loops.</p><p>A full set of scripts used for processing Hi-C data (<xref ref-type="bibr" rid="bib64">Qiu, 2021</xref>) is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/MSanderlab/Pancreatic-progenitor-epigenome-maps-prioritize-type-2-diabetes-risk-genes-with-roles-in-development/tree/master">https://github.com/MSanderlab/Pancreatic-progenitor-epigenome-maps-prioritize-type-2-diabetes-risk-genes-with-roles-in-development/tree/master</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:a6d2a396728b95cfe7d889e282e6ca94e4b5aaaa;origin=https://github.com/MSanderlab/Pancreatic-progenitor-epigenome-maps-prioritize-type-2-diabetes-risk-genes-with-roles-in-development;visit=swh:1:snp:55e297be7bed57e636f846f2d990984c05f304da;anchor=swh:1:rev:ba79c687523c2696ea0ef30d8476e28a0d860f18/">swh:1:rev:ba79c687523c2696ea0ef30d8476e28a0d860f18</ext-link>).</p></sec><sec id="s4-14"><title>Definition of chromatin states</title><p>We collected or generated H3K4me1, H3K27ac, H3K4me1, H3K4me3, H3K27me3, and CTCF ChIP-seq data at each developmental stage and in mature islets. Data corresponding to mature islets was downloaded from previously published studies (<xref ref-type="bibr" rid="bib4">Bhandare et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Parker et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Pasquali et al., 2014</xref>). Sequence reads were mapped to the human genome hg19 using bwa (version 0.7.12) (<xref ref-type="bibr" rid="bib45">Li and Durbin, 2009</xref>), and low quality and duplicate reads were filtered using samtools (version 1.3) (<xref ref-type="bibr" rid="bib43">Li et al., 2009</xref>). Using these reads, we then called chromatin states jointly across all data using chromHMM (version 1.12) (<xref ref-type="bibr" rid="bib20">Ernst and Kellis, 2012</xref>) and used a 10-state model and 200 bp bin size, as models with larger state numbers did not empirically resolve any additional informative states. We then assigned state names based on patterns defined by the NIH Epigenome Roadmap (<xref ref-type="bibr" rid="bib41">Kundaje et al., 2015</xref>), which included active promoter/TssA (high H3K4me3, high H3K27ac), flanking TSS/TssFlnk1 (high H3K4me3), flanking TSS/TssFlnk 2 (high H3K4me3, high H3K27ac, high H3K4me1), bivalent Tss/TssBiv (high H3K27me3, high H3K4me3), poised enhancer/EnhP (high H3K4me1), insulator/CTCF (high CTCF), active enhancer/EnhA (high H3K27ac, high H3K4me1), repressor (high H3K27me3), and two quiescent (low signal for all assays) states. The state map with assigned names is shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>.</p><p>We next defined stretch enhancer elements at each developmental stage and in mature islets. For each active enhancer (EnhA) element, we determined the number of consecutive 200 bp bins covered by the enhancer. We then modeled the resulting bin counts for enhancers in each cell type using a Poisson distribution. Enhancers with a p-value less than. 001 were labeled as stretch enhancers and otherwise labeled as traditional enhancers.</p></sec><sec id="s4-15"><title>Permutation-based significance</title><p>A random sampling approach (10,000 iterations) was used to obtain null distributions for enrichment analyses, in order to obtain p-values. Null distributions for enrichments were obtained by randomly shuffling enhancer regions using BEDTools (<xref ref-type="bibr" rid="bib65">Quinlan and Hall, 2010</xref>) and overlapping with ATAC-seq peaks. p-values&lt;0.05 were considered significant.</p></sec><sec id="s4-16"><title>Assignment of enhancer target genes</title><p>Transcriptomes were filtered for genes expressed (FPKM ≥1) at each relevant stage, and BEDTools (<xref ref-type="bibr" rid="bib65">Quinlan and Hall, 2010</xref>) was used to assign each enhancer to the nearest annotated TSS.</p></sec><sec id="s4-17"><title>Gene ontology</title><p>All gene ontology analyses were performed using Metascape (<xref ref-type="bibr" rid="bib95">Zhou et al., 2019</xref>) with default parameters.</p></sec><sec id="s4-18"><title>Motif enrichment analysis</title><p>The findMotifsGenome.pl. command in HOMER (<xref ref-type="bibr" rid="bib32">Heinz et al., 2010</xref>) was used to identify enriched transcription factor binding motifs. de novo motifs were assigned to transcription factors based on suggestions generated by HOMER.</p></sec><sec id="s4-19"><title>T2D-relevant trait enrichment analysis</title><p>GWAS summary statistics for T2D (<xref ref-type="bibr" rid="bib48">Mahajan et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Perry et al., 2012</xref>), metabolic traits (HOMA-B, HOMA-IR [<xref ref-type="bibr" rid="bib17">Dupuis et al., 2010</xref>], fasting glucose, fasting insulin [<xref ref-type="bibr" rid="bib50">Manning et al., 2012</xref>], fasting proinsulin [<xref ref-type="bibr" rid="bib77">Strawbridge et al., 2011</xref>], 2 hr glucose adjusted for BMI [<xref ref-type="bibr" rid="bib71">Saxena et al., 2010</xref>], HbA1c, insulin secretion rate, disposition index, acute insulin response, peak insulin response [<xref ref-type="bibr" rid="bib92">Wood et al., 2017</xref>]), and developmental traits (head circumference [<xref ref-type="bibr" rid="bib79">Taal et al., 2012</xref>], birth length [<xref ref-type="bibr" rid="bib84">van der Valk et al., 2015</xref>], birth weight [<xref ref-type="bibr" rid="bib34">Horikoshi et al., 2016</xref>]) conducted with individuals of European ancestry were obtained from various sources including the MAGIC consortium, EGG consortium, and authors of the studies. Custom LD score annotation files were created for PSSE, PP2 stretch enhancers, and islet stretch enhancers using LD score regression version 1.0.1 (<xref ref-type="bibr" rid="bib7">Bulik-Sullivan et al., 2015</xref>). Enrichments for GWAS trait-associated variants within PSSE, PP2 stretch enhancers, and islet stretch enhancers were estimated with stratified LD score regression (<xref ref-type="bibr" rid="bib22">Finucane et al., 2015</xref>). We next determined enrichment in the proportion of variants in accessible chromatin sites within islet SE and PSSE with nominal association to beta cell-related glycemic traits. For each trait, we calculated a 2 × 2 table of variants mapping in and outside of islet SE or PSSE and with or without nominal association and then determined significance using a chi-square test.</p></sec><sec id="s4-20"><title>Adipocyte differentiation analysis</title><p>Chromatin states for human adipose stromal cell (hASC) differentiation stages (1-4) were obtained from a published study (<xref ref-type="bibr" rid="bib86">Varshney et al., 2017</xref>). PSSE were intersected with hASC chromatin states using BEDTools intersect (version 2.26.0) (<xref ref-type="bibr" rid="bib65">Quinlan and Hall, 2010</xref>) with default parameters.</p></sec><sec id="s4-21"><title>Identification of T2D risk loci intersecting PSSE</title><p>T2D GWAS summary statistics were obtained from the DIAMANTE consortium (<xref ref-type="bibr" rid="bib48">Mahajan et al., 2018</xref>). Intersection of variants and PSSE was performed using BEDTools intersect (version 2.26.0) (<xref ref-type="bibr" rid="bib65">Quinlan and Hall, 2010</xref>) with default parameters. The adjusted significance threshold was set at p&lt;4.66 × 10<sup>−6</sup> (Bonferroni correction for 10,738 variants mapping in PSSE). Putative novel loci were defined as those with (1) at least one variant in a PSSE reaching the adjusted significance threshold and (2) mapping at least 500 kb away from a known T2D locus.</p></sec><sec id="s4-22"><title>ATAC-seq footprinting analysis</title><p>ATAC-seq footprinting was performed as previously described (<xref ref-type="bibr" rid="bib3">Aylward et al., 2018</xref>). In brief, diploid genomes for CyT49 were created using vcf2diploid (version 0.2.6a) (<xref ref-type="bibr" rid="bib70">Rozowsky et al., 2011</xref>) and genotypes called from whole genome sequencing and scanned for a compiled database of TF sequence motifs from JASPAR (<xref ref-type="bibr" rid="bib52">Mathelier et al., 2016</xref>) and ENCODE (<xref ref-type="bibr" rid="bib19">ENCODE Project Consortium, 2012</xref>) with FIMO (version 4.12.0) (<xref ref-type="bibr" rid="bib29">Grant et al., 2011</xref>) using default parameters for p-value threshold and a 40.9% GC content based on the hg19 human reference genome. Footprints within ATAC-seq peaks were discovered with CENTIPEDE (version 1.2) (<xref ref-type="bibr" rid="bib61">Pique-Regi et al., 2011</xref>) using cut-site matrices containing Tn5 integration counts within a ± 100 bp window around each motif occurrence. Footprints were defined as those with a posterior probability ≥0.99.</p></sec><sec id="s4-23"><title>Generation of similarity matrices for total transcriptomes</title><p>For each replicate, FPKM values corresponding to total transcriptome were filtered for genes expressed (FPKM ≥1) in ≥1 replicate. For expressed genes, log(FPKM+1) values were used to calculate Pearson correlations.</p></sec><sec id="s4-24"><title>Immunofluorescence analysis</title><p>Cell aggregates derived from hESCs were allowed to settle in microcentrifuge tubes and washed twice with PBS before fixation with 4% paraformaldehyde (PFA) for 30 min at room temperature. Fixed samples were washed twice with PBS and incubated overnight at 4°C in 30% (w/v) sucrose in PBS. Samples were then loaded into disposable embedding molds (VWR), covered in Tissue-Tek O.C.T. Sakura Finetek compound (VWR) and flash frozen on dry ice to prepare frozen blocks. The blocks were sectioned at 10 µm and sections were placed on Superfrost Plus (Thermo Fisher) microscope slides and washed with PBS for 10 min. Slide-mounted cell sections were permeabilized and blocked with blocking buffer, consisting of 0.15% (v/v) Triton X-100 (Sigma) and 1% (v/v) normal donkey serum (Jackson Immuno Research Laboratories) in PBS, for 1 hr at room temperature. Slides were then incubated overnight at 4°C with primary antibody solutions. The following day slides were washed five times with PBS and incubated for 1 hr at room temperature with secondary antibody solutions. Cells were washed five times with PBS before coverslips were applied.</p><p>All antibodies were diluted in blocking buffer at the ratios indicated below. Primary antibodies used were goat anti-PDX1 (1:500 dilution, Abcam ab47383), mouse anti-NKX6.1 (1:300 dilution, Developmental Studies Hybridoma Bank F64A6B4), rabbit anti-Laminin (1:30, Sigma L-9393), and rabbit anti-CRB2 (1:500, Sigma SAB1301340). Secondary antibodies against goat and mouse were Alexa488- and Cy3-conjugated donkey antibodies, respectively (Jackson Immuno Research Laboratories 705-545-003 and 715-165-150, respectively), and were used at dilutions of 1:500 (anti-goat Alexa488) or 1:1000 (anti-mouse Cy3). Cell nuclei were stained with Hoechst 33342 (1:3000, Invitrogen). Representative images were obtained with a Zeiss Axio-Observer-Z1 microscope equipped with a Zeiss ApoTome and AxioCam digital camera. Figures were prepared in Adobe Creative Suite 5.</p></sec><sec id="s4-25"><title>Flow cytometry analysis</title><p>Cell aggregates derived from hESCs were allowed to settle in microcentrifuge tubes and washed with PBS. Cell aggregates were incubated with Accutase at room temperature until a single-cell suspension was obtained. Cells were washed with 1 mL ice-cold flow buffer comprised of 0.2% BSA in PBS and centrifuged at 200 g for 5 min. BD Cytofix/Cytoperm Plus Fixation/Permeabilization Solution Kit was used to fix and stain cells for flow cytometry according to the manufacturer's instructions. Briefly, cell pellets were re-suspended in ice-cold BD Fixation/Permeabilization solution (300 µL per microcentrifuge tube). Cells were incubated for 20 min at 4°C. Cells were washed twice with 1 mL ice-cold 1 × BD Perm/Wash Buffer and centrifuged at 10°C and 200 × g for 5 min. Cells were re-suspended in 50 µL ice-cold 1 × BD Perm/Wash Buffer containing diluted antibodies, for each staining performed. Cells were incubated at 4°C in the dark for 1–3 hr. Cells were washed with 1.25 mL ice-cold 1X BD Wash Buffer and centrifuged at 200 × g for 5 min. Cell pellets were re-suspended in 300 µL ice-cold flow buffer and analyzed in a FACSCanto II (BD Biosciences). Antibodies used were PE-conjugated anti-PDX1 (1:10 dilution, BD Biosciences); and AlexaFluor 647-conjugated anti-NKX6.1 (1:5 dilution, BD Biosciences). Data were processed using FlowJo software v10.</p></sec><sec id="s4-26"><title>Whole mount immunohistochemistry</title><p>Zebrafish larvae were fixed and stained according to published protocols (<xref ref-type="bibr" rid="bib42">Lancman et al., 2013</xref>) using the following antibodies: chicken anti-GFP (1:200; Aves Labs; GFP-1020), guinea pig anti-insulin (1:200; Biomeda; v2024), mouse anti-Crb2a (1:100; ZIRC; zs-4), rabbit anti-panCrb (1:100; provided by Dr. Abbie M. Jensen at University of Massachusetts, Amherst; <xref ref-type="bibr" rid="bib35">Hsu and Jensen, 2010</xref>), rabbit anti-Laminin (1:100; Sigma;L9393), mouse anti-Nkx6.1 (1:10; DSHB; F55A10), and DAPI (1:200; 500 mg/ml, Invitrogen; D1306).</p></sec><sec id="s4-27"><title>Imaging and quantification of beta cell numbers in zebrafish</title><p>To quantify beta cell numbers, 50 and 78 hpf zebrafish larvae were stained for confocal imaging using DAPI and guinea pig anti-insulin antibody (1:200; Biomeda; v2024). Whole mount fluorescent confocal Z-stacks (0.9 μm steps) images were collected for the entire islet with optical slices captured at a focal depth of 1.8 μm. Samples were imaged using a Zeiss 710 confocal microscope running Zen 2010 (Black) software. Final images were generated using Adobe Photoshop CS6 and/or ImageJ64 (vs.1.48b).</p></sec><sec id="s4-28"><title>Data sources</title><p>The following datasets used in this study were downloaded from the GEO and ArrayExpress repositories:</p><p>RNA-seq: Pancreatic differentiation of CyT49 hESC line (E-MTAB-1086); primary islet data (GSE115327).</p><p>ChIP-seq: H3K27ac data in primary islets (E-MTAB-1919 and GSE51311); H3K27ac data in pancreatic differentiation of CyT49 hESC line (GSE54471); H3K4me1 data in pancreatic differentiation of CyT49 hESC line (GSE54471); H3K4me1 data in primary islets (E-MTAB-1919 and E-MTAB 189); H3K27me3 and H3K4me3 in pancreatic differentiation of CyT49 hESC line (E-MTAB-1086); H3K4me3 and H3K27me3 in primary islets (E-MTAB-189); CTCF in primary islets (E-MTAB-1919); PDX1 in CyT49 PP2 (GSE54471); samples from ROADMAP consortium: <ext-link ext-link-type="uri" xlink:href="http://ncbi.nlm.nih.gov/geo/roadmap/epigenomics">http://ncbi.nlm.nih.gov/geo/roadmap/epigenomics</ext-link>.</p><p>ATAC-seq: primary islet data (PRJN527099); CyT49 PP2 (GSE115327).</p><p>Hi-C datasets were generated in collaboration with the Ren laboratory at University of California, San Diego as a component of the 4D Nucleome Project (<xref ref-type="bibr" rid="bib12">Dekker et al., 2017</xref>) under accession number 4DNES0LVRKBM.</p></sec><sec id="s4-29"><title>Quantification and statistical analyses</title><p>Statistical analyses were performed using GraphPad Prism (v8.1.2), and R (v3.6.1). Statistical parameters, such as the value of n, mean, standard deviation (SD), standard error of the mean (SEM), significance level (*p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001), and the statistical tests used, are reported in the figures and figure legends. The ‘n’ refers to the number of independent pancreatic differentiation experiments analyzed (biological replicates).</p><p>Statistically significant gene expression changes were determined with DESeq2 (<xref ref-type="bibr" rid="bib46">Love et al., 2014</xref>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Ileana Matta for assistance with ATAC-seq assays and library preparations, as well as the Sander and Gaulton laboratories for helpful discussions. We also thank Dr. Abbie Jensen at University of Massachusetts, Amherst for the anti-panCrb antibody. We acknowledge support of the UCSD Human Embryonic Stem Cell Core for cell sorting, as well as K Jepsen and the UCSD Institute for Genomic Medicine for library preparation and sequencing. This work was supported by NIH grants T32 GM008666 (RJG), P30 DK064391 (KJ, MS), R01 DK068471 (MS), 1DP2DK098092 (PDSD), and U01 DK105541 (MS, BR, PDSD); as well as the WM Keck Foundation 2017–01 (PDSD), and Diabetes Research Connection Project #08 (JJL)</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>This author consults for Genentech.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Validation, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Data curation</p></fn><fn fn-type="con" id="con10"><p>Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con12"><p>Supervision, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Adult zebrafish and embryos were cared for and maintained under standard conditions. All research activity involving zebrafish was reviewed and approved by SBP Medical Discovery Institute Institutional Animal Care and Use Committee under protocol #18-014. hESC research was approved by the University of California, San Diego, Institutional Review Board and Embryonic Stem Cell Research oversight committee under project #090165ZX.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-59067-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All mRNA-seq, ChIP-seq, and ATAC-seq datasets generated for this study have been deposited at GEO under the accession number GSE149148. Source data files have been provided for Figures 2, 4, and 5.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Geusz</surname><given-names>RJ</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Chiou</surname><given-names>J</given-names></name><name><surname>Lancman</surname><given-names>JJ</given-names></name><name><surname>Wetton</surname><given-names>N</given-names></name><name><surname>Kefalopoulou</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Aylward</surname><given-names>A</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Si Dong</surname><given-names>PD</given-names></name><name><surname>Gaulton</surname><given-names>KJ</given-names></name><name><surname>Sander</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Pancreatic progenitor epigenome maps prioritize type 2 diabetes risk genes with roles in development</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149148">GSE149148</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>R</given-names></name><name><surname>Everett</surname><given-names>LJ</given-names></name><name><surname>Lim</surname><given-names>HW</given-names></name><name><surname>Patel</surname><given-names>NA</given-names></name><name><surname>Schug</surname><given-names>J</given-names></name><name><surname>Kroon</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>OG</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>D'Amour</surname><given-names>KA</given-names></name><name><surname>Robins</surname><given-names>AJ</given-names></name><name><surname>Won</surname><given-names>KJ</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Sander</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>ChIP-seq and RNA-seq of coding RNA of the progression of human embryonic stem cells to beta cells to characterize the epigenetic programs that underlie pancreas differentiation</data-title><source>ArrayExpress</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1086/">E-MTAB-1086</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Mulas</surname><given-names>F</given-names></name><name><surname>Gaertner</surname><given-names>B</given-names></name><name><surname>Sui</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Matta</surname><given-names>I</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Vinckier</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Nguyen-Ngoc</surname><given-names>K</given-names></name><name><surname>Chiou</surname><given-names>J</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Frazer</surname><given-names>KA</given-names></name><name><surname>Carrano</surname><given-names>AC</given-names></name><name><surname>Shih</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Identification of microRNA-dependent gene regulatory networks driving human pancreatic endocrine cell differentiation</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115327">GSE115327</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Pasquali</surname><given-names>L</given-names></name><name><surname>Gaulton</surname><given-names>KJ</given-names></name><name><surname>Rodríguez-Seguí</surname><given-names>SA</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Miguel-Escalada</surname><given-names>I</given-names></name><name><surname>Akerman</surname><given-names>I</given-names></name><name><surname>Tena</surname><given-names>JJ</given-names></name><name><surname>Morán</surname><given-names>I</given-names></name><name><surname>Gómez-Marín</surname><given-names>C</given-names></name><name><surname>van de Bunt</surname><given-names>M</given-names></name><name><surname>Ponsa-Cobas</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>N</given-names></name><name><surname>Nammo</surname><given-names>T</given-names></name><name><surname>Cebola</surname><given-names>I</given-names></name><name><surname>García-Hurtado</surname><given-names>J</given-names></name><name><surname>Maestro</surname><given-names>MA</given-names></name><name><surname>Pattou</surname><given-names>F</given-names></name><name><surname>Piemonti</surname><given-names>L</given-names></name><name><surname>Berney</surname><given-names>T</given-names></name><name><surname>Gloyn</surname><given-names>AL</given-names></name><name><surname>Ravassard</surname><given-names>P</given-names></name><name><surname>Gómez-Skarmeta</surname><given-names>JL</given-names></name><name><surname>Müller</surname><given-names>F</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><data-title>Pancreatic islet epigenomics reveals enhancer clusters that are enriched in Type 2 diabetes risk variants</data-title><source>ArrayExpress</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1919/">E-MTAB-1919</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>SC</given-names></name><name><surname>Stitzel</surname><given-names>ML</given-names></name><name><surname>Taylor</surname><given-names>DL</given-names></name><name><surname>Orozco</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants (ChIP-seq)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51311">GSE51311</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Yue</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Developmental Competence Encoded at the Level of Enhancers</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54471">GSE54471</pub-id></element-citation></p><p><element-citation id="dataset7" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Bhandare</surname><given-names>R</given-names></name><name><surname>Schug</surname><given-names>J</given-names></name><name><surname>Lay</surname><given-names>JL</given-names></name><name><surname>Fox</surname><given-names>A</given-names></name><name><surname>Smirnova</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Naji</surname><given-names>A</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>ChIP-Seq of human normal pancreatic islets with anti-histone antibodies to analyse histone modifications</data-title><source>ArrayExpress</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-189/">E-MTAB-189</pub-id></element-citation></p><p><element-citation id="dataset8" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>University of California San Diego</collab></person-group><year iso-8601-date="2015">2015</year><data-title>ATAC-seq in pancreatic islet cells</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/527099">PRJNA527099</pub-id></element-citation></p><p><element-citation id="dataset9" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>4DN Network</collab><collab>Ren Laboratory</collab></person-group><year iso-8601-date="2020">2020</year><data-title>Replicates of Hi-C on CyT49 cells differentiated to pancreatic endoderm</data-title><source>4D Nucleome</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://data.4dnucleome.org/experiment-set-replicates/4DNESOLVRKBM/#processed-files">Sample4DNES0LVRKBM</pub-id></element-citation></p><p><element-citation id="dataset10" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Lister</surname><given-names>R</given-names></name><name><surname>Pelizzola</surname><given-names>M</given-names></name><name><surname>Dowen</surname><given-names>RH</given-names></name><name><surname>Hawkins</surname><given-names>RD</given-names></name><name><surname>Hon</surname><given-names>G</given-names></name><name><surname>Tonti-Filippini</surname><given-names>J</given-names></name><name><surname>Nery</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Ngo</surname><given-names>Q</given-names></name><name><surname>Edsall</surname><given-names>L</given-names></name><name><surname>Antosiewicz-Bourget</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Ruotti</surname><given-names>V</given-names></name><name><surname>Millar</surname><given-names>AH</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2009">2009</year><data-title>UCSD Human Reference Epigenome Mapping Projec</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16256">GSE16256</pub-id></element-citation></p><p><element-citation id="dataset11" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name><name><surname>Costello</surname><given-names>JF</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Milosavljevic</surname><given-names>A</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mikkelsen</surname><given-names>TJ</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>UCSF-UBC Human Reference Epigenome Mapping Project</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16368">GSE16368</pub-id></element-citation></p><p><element-citation id="dataset12" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name><name><surname>Costello</surname><given-names>JF</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Milosavljevic</surname><given-names>A</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mikkelsen</surname><given-names>TJ</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2009">2009</year><data-title>BI Human Reference Epigenome Mapping Project</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17312">GSE17312</pub-id></element-citation></p><p><element-citation id="dataset13" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name><name><surname>Costello</surname><given-names>JF</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Milosavljevic</surname><given-names>A</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mikkelsen</surname><given-names>TJ</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>University of Washington Human Reference Epigenome Mapping Project</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18927">GSE18927</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahnfelt-Rønne</surname> <given-names>J</given-names></name><name><surname>Ravassard</surname> <given-names>P</given-names></name><name><surname>Pardanaud-Glavieux</surname> <given-names>C</given-names></name><name><surname>Scharfmann</surname> <given-names>R</given-names></name><name><surname>Serup</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mesenchymal bone morphogenetic protein signaling is required for normal pancreas development</article-title><source>Diabetes</source><volume>59</volume><fpage>1948</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.2337/db09-1010</pub-id><pub-id pub-id-type="pmid">20522595</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alves</surname> <given-names>CH</given-names></name><name><surname>Bossers</surname> <given-names>K</given-names></name><name><surname>Vos</surname> <given-names>RM</given-names></name><name><surname>Essing</surname> <given-names>AH</given-names></name><name><surname>Swagemakers</surname> <given-names>S</given-names></name><name><surname>van der Spek</surname> <given-names>PJ</given-names></name><name><surname>Verhaagen</surname> <given-names>J</given-names></name><name><surname>Wijnholds</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Microarray and morphological analysis of early postnatal CRB2 mutant retinas on a pure C57BL/6J genetic background</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e82532</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0082532</pub-id><pub-id pub-id-type="pmid">24324803</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aylward</surname> <given-names>A</given-names></name><name><surname>Chiou</surname> <given-names>J</given-names></name><name><surname>Okino</surname> <given-names>M-L</given-names></name><name><surname>Kadakia</surname> <given-names>N</given-names></name><name><surname>Gaulton</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Shared genetic risk contributes to type 1 and type 2 diabetes etiology</article-title><source>Human Molecular Genetics</source><volume>7</volume><elocation-id>314</elocation-id><pub-id pub-id-type="doi">10.1093/hmg/ddy314</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhandare</surname> <given-names>R</given-names></name><name><surname>Schug</surname> <given-names>J</given-names></name><name><surname>Le Lay</surname> <given-names>J</given-names></name><name><surname>Fox</surname> <given-names>A</given-names></name><name><surname>Smirnova</surname> <given-names>O</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Naji</surname> <given-names>A</given-names></name><name><surname>Kaestner</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genome-wide analysis of histone modifications in human pancreatic islets</article-title><source>Genome Research</source><volume>20</volume><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1101/gr.102038.109</pub-id><pub-id pub-id-type="pmid">20181961</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Giresi</surname> <given-names>PG</given-names></name><name><surname>Zaba</surname> <given-names>LC</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Greenleaf</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position</article-title><source>Nature Methods</source><volume>10</volume><fpage>1213</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2688</pub-id><pub-id pub-id-type="pmid">24097267</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulgakova</surname> <given-names>NA</given-names></name><name><surname>Knust</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The crumbs complex: from epithelial-cell polarity to retinal degeneration</article-title><source>Journal of Cell Science</source><volume>122</volume><fpage>2587</fpage><lpage>2596</lpage><pub-id pub-id-type="doi">10.1242/jcs.023648</pub-id><pub-id pub-id-type="pmid">19625503</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulik-Sullivan</surname> <given-names>BK</given-names></name><name><surname>Loh</surname> <given-names>PR</given-names></name><name><surname>Finucane</surname> <given-names>HK</given-names></name><name><surname>Ripke</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Patterson</surname> <given-names>N</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Price</surname> <given-names>AL</given-names></name><name><surname>Neale</surname> <given-names>BM</given-names></name><collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>LD score regression distinguishes confounding from polygenicity in genome-wide association studies</article-title><source>Nature Genetics</source><volume>47</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/ng.3211</pub-id><pub-id pub-id-type="pmid">25642630</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cebola</surname> <given-names>I</given-names></name><name><surname>Rodríguez-Seguí</surname> <given-names>SA</given-names></name><name><surname>Cho</surname> <given-names>CH</given-names></name><name><surname>Bessa</surname> <given-names>J</given-names></name><name><surname>Rovira</surname> <given-names>M</given-names></name><name><surname>Luengo</surname> <given-names>M</given-names></name><name><surname>Chhatriwala</surname> <given-names>M</given-names></name><name><surname>Berry</surname> <given-names>A</given-names></name><name><surname>Ponsa-Cobas</surname> <given-names>J</given-names></name><name><surname>Maestro</surname> <given-names>MA</given-names></name><name><surname>Jennings</surname> <given-names>RE</given-names></name><name><surname>Pasquali</surname> <given-names>L</given-names></name><name><surname>Morán</surname> <given-names>I</given-names></name><name><surname>Castro</surname> <given-names>N</given-names></name><name><surname>Hanley</surname> <given-names>NA</given-names></name><name><surname>Gomez-Skarmeta</surname> <given-names>JL</given-names></name><name><surname>Vallier</surname> <given-names>L</given-names></name><name><surname>Ferrer</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>615</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1038/ncb3160</pub-id><pub-id pub-id-type="pmid">25915126</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Chiou</surname> <given-names>J</given-names></name><name><surname>Zeng</surname> <given-names>C</given-names></name><name><surname>Cheng</surname> <given-names>Z</given-names></name><name><surname>Han</surname> <given-names>JY</given-names></name><name><surname>Schlichting</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Sui</surname> <given-names>Y</given-names></name><name><surname>Deogaygay</surname> <given-names>A</given-names></name><name><surname>Okino</surname> <given-names>M-L</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Kudtarkar</surname> <given-names>P</given-names></name><name><surname>Fang</surname> <given-names>R</given-names></name><name><surname>Preissl</surname> <given-names>S</given-names></name><name><surname>Sander</surname> <given-names>M</given-names></name><name><surname>Gorkin</surname> <given-names>D</given-names></name><name><surname>Gaulton</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single cell chromatin accessibility reveals pancreatic islet cell type- and state-specific regulatory programs of diabetes risk</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/693671</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claussnitzer</surname> <given-names>M</given-names></name><name><surname>Dankel</surname> <given-names>SN</given-names></name><name><surname>Klocke</surname> <given-names>B</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Glunk</surname> <given-names>V</given-names></name><name><surname>Berulava</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Oskolkov</surname> <given-names>N</given-names></name><name><surname>Fadista</surname> <given-names>J</given-names></name><name><surname>Ehlers</surname> <given-names>K</given-names></name><name><surname>Wahl</surname> <given-names>S</given-names></name><name><surname>Hoffmann</surname> <given-names>C</given-names></name><name><surname>Qian</surname> <given-names>K</given-names></name><name><surname>Rönn</surname> <given-names>T</given-names></name><name><surname>Riess</surname> <given-names>H</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Bretschneider</surname> <given-names>N</given-names></name><name><surname>Schroeder</surname> <given-names>T</given-names></name><name><surname>Skurk</surname> <given-names>T</given-names></name><name><surname>Horsthemke</surname> <given-names>B</given-names></name><name><surname>Spieler</surname> <given-names>D</given-names></name><name><surname>Klingenspor</surname> <given-names>M</given-names></name><name><surname>Seifert</surname> <given-names>M</given-names></name><name><surname>Kern</surname> <given-names>MJ</given-names></name><name><surname>Mejhert</surname> <given-names>N</given-names></name><name><surname>Dahlman</surname> <given-names>I</given-names></name><name><surname>Hansson</surname> <given-names>O</given-names></name><name><surname>Hauck</surname> <given-names>SM</given-names></name><name><surname>Blüher</surname> <given-names>M</given-names></name><name><surname>Arner</surname> <given-names>P</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Suhre</surname> <given-names>K</given-names></name><name><surname>Hsu</surname> <given-names>YH</given-names></name><name><surname>Mellgren</surname> <given-names>G</given-names></name><name><surname>Hauner</surname> <given-names>H</given-names></name><name><surname>Laumen</surname> <given-names>H</given-names></name><collab>DIAGRAM+Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Leveraging cross-species transcription factor binding site patterns: from diabetes risk loci to disease mechanisms</article-title><source>Cell</source><volume>156</volume><fpage>343</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.10.058</pub-id><pub-id pub-id-type="pmid">24439387</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname> <given-names>E</given-names></name><name><surname>Stein</surname> <given-names>R</given-names></name><name><surname>Hunter</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Revealing transcription factors during human pancreatic β cell development</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>25</volume><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2014.03.013</pub-id><pub-id pub-id-type="pmid">24831984</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekker</surname> <given-names>J</given-names></name><name><surname>Belmont</surname> <given-names>AS</given-names></name><name><surname>Guttman</surname> <given-names>M</given-names></name><name><surname>Leshyk</surname> <given-names>VO</given-names></name><name><surname>Lis</surname> <given-names>JT</given-names></name><name><surname>Lomvardas</surname> <given-names>S</given-names></name><name><surname>Mirny</surname> <given-names>LA</given-names></name><name><surname>O'Shea</surname> <given-names>CC</given-names></name><name><surname>Park</surname> <given-names>PJ</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Politz</surname> <given-names>JCR</given-names></name><name><surname>Shendure</surname> <given-names>J</given-names></name><name><surname>Zhong</surname> <given-names>S</given-names></name><collab>4D Nucleome Network</collab></person-group><year iso-8601-date="2017">2017</year><article-title>The 4D nucleome project</article-title><source>Nature</source><volume>549</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/nature23884</pub-id><pub-id pub-id-type="pmid">28905911</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname> <given-names>JR</given-names></name><name><surname>Jung</surname> <given-names>I</given-names></name><name><surname>Selvaraj</surname> <given-names>S</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Antosiewicz-Bourget</surname> <given-names>JE</given-names></name><name><surname>Lee</surname> <given-names>AY</given-names></name><name><surname>Ye</surname> <given-names>Z</given-names></name><name><surname>Kim</surname> <given-names>A</given-names></name><name><surname>Rajagopal</surname> <given-names>N</given-names></name><name><surname>Xie</surname> <given-names>W</given-names></name><name><surname>Diao</surname> <given-names>Y</given-names></name><name><surname>Liang</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Lobanenkov</surname> <given-names>VV</given-names></name><name><surname>Ecker</surname> <given-names>JR</given-names></name><name><surname>Thomson</surname> <given-names>JA</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chromatin architecture reorganization during stem cell differentiation</article-title><source>Nature</source><volume>518</volume><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/nature14222</pub-id><pub-id pub-id-type="pmid">25693564</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>PD</given-names></name><name><surname>Provost</surname> <given-names>E</given-names></name><name><surname>Leach</surname> <given-names>SD</given-names></name><name><surname>Stainier</surname> <given-names>DY</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Graded levels of Ptf1a differentially regulate endocrine and exocrine fates in the developing pancreas</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>1445</fpage><lpage>1450</lpage><pub-id pub-id-type="doi">10.1101/gad.1663208</pub-id><pub-id pub-id-type="pmid">18519637</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudok</surname> <given-names>JJ</given-names></name><name><surname>Murtaza</surname> <given-names>M</given-names></name><name><surname>Henrique Alves</surname> <given-names>C</given-names></name><name><surname>Rashbass</surname> <given-names>P</given-names></name><name><surname>Wijnholds</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Crumbs 2 prevents cortical abnormalities in mouse dorsal telencephalon</article-title><source>Neuroscience Research</source><volume>108</volume><fpage>12</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.neures.2016.01.001</pub-id><pub-id pub-id-type="pmid">26802325</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Wheeler</surname> <given-names>E</given-names></name><name><surname>Glazer</surname> <given-names>NL</given-names></name><name><surname>Bouatia-Naji</surname> <given-names>N</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Mägi</surname> <given-names>R</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Randall</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>T</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Henneman</surname> <given-names>P</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Dehghan</surname> <given-names>A</given-names></name><name><surname>Hottenga</surname> <given-names>JJ</given-names></name><name><surname>Franklin</surname> <given-names>CS</given-names></name><name><surname>Navarro</surname> <given-names>P</given-names></name><name><surname>Song</surname> <given-names>K</given-names></name><name><surname>Goel</surname> <given-names>A</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Egan</surname> <given-names>JM</given-names></name><name><surname>Lajunen</surname> <given-names>T</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Sparsø</surname> <given-names>T</given-names></name><name><surname>Doney</surname> <given-names>A</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Shrader</surname> <given-names>P</given-names></name><name><surname>Cavalcanti-Proença</surname> <given-names>C</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Zabena</surname> <given-names>C</given-names></name><name><surname>Rocheleau</surname> <given-names>G</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>An</surname> <given-names>P</given-names></name><name><surname>O'Connell</surname> <given-names>J</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Elliott</surname> <given-names>A</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>Payne</surname> <given-names>F</given-names></name><name><surname>Roccasecca</surname> <given-names>RM</given-names></name><name><surname>Pattou</surname> <given-names>F</given-names></name><name><surname>Sethupathy</surname> <given-names>P</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Ariyurek</surname> <given-names>Y</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Barter</surname> <given-names>P</given-names></name><name><surname>Beilby</surname> <given-names>JP</given-names></name><name><surname>Ben-Shlomo</surname> <given-names>Y</given-names></name><name><surname>Benediktsson</surname> <given-names>R</given-names></name><name><surname>Bennett</surname> <given-names>AJ</given-names></name><name><surname>Bergmann</surname> <given-names>S</given-names></name><name><surname>Bochud</surname> <given-names>M</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Bonnefond</surname> <given-names>A</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Borch-Johnsen</surname> <given-names>K</given-names></name><name><surname>Böttcher</surname> <given-names>Y</given-names></name><name><surname>Brunner</surname> <given-names>E</given-names></name><name><surname>Bumpstead</surname> <given-names>SJ</given-names></name><name><surname>Charpentier</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>YD</given-names></name><name><surname>Chines</surname> <given-names>P</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Coin</surname> <given-names>LJ</given-names></name><name><surname>Cooper</surname> <given-names>MN</given-names></name><name><surname>Cornelis</surname> <given-names>M</given-names></name><name><surname>Crawford</surname> <given-names>G</given-names></name><name><surname>Crisponi</surname> <given-names>L</given-names></name><name><surname>Day</surname> <given-names>IN</given-names></name><name><surname>de Geus</surname> <given-names>EJ</given-names></name><name><surname>Delplanque</surname> <given-names>J</given-names></name><name><surname>Dina</surname> <given-names>C</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Fedson</surname> <given-names>AC</given-names></name><name><surname>Fischer-Rosinsky</surname> <given-names>A</given-names></name><name><surname>Forouhi</surname> <given-names>NG</given-names></name><name><surname>Fox</surname> <given-names>CS</given-names></name><name><surname>Frants</surname> <given-names>R</given-names></name><name><surname>Franzosi</surname> <given-names>MG</given-names></name><name><surname>Galan</surname> <given-names>P</given-names></name><name><surname>Goodarzi</surname> <given-names>MO</given-names></name><name><surname>Graessler</surname> <given-names>J</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Grundy</surname> <given-names>S</given-names></name><name><surname>Gwilliam</surname> <given-names>R</given-names></name><name><surname>Gyllensten</surname> <given-names>U</given-names></name><name><surname>Hadjadj</surname> <given-names>S</given-names></name><name><surname>Hallmans</surname> <given-names>G</given-names></name><name><surname>Hammond</surname> <given-names>N</given-names></name><name><surname>Han</surname> <given-names>X</given-names></name><name><surname>Hartikainen</surname> <given-names>AL</given-names></name><name><surname>Hassanali</surname> <given-names>N</given-names></name><name><surname>Hayward</surname> <given-names>C</given-names></name><name><surname>Heath</surname> <given-names>SC</given-names></name><name><surname>Hercberg</surname> <given-names>S</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Hicks</surname> <given-names>AA</given-names></name><name><surname>Hillman</surname> <given-names>DR</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Hui</surname> <given-names>J</given-names></name><name><surname>Hung</surname> <given-names>J</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Johnson</surname> <given-names>PR</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Jula</surname> <given-names>A</given-names></name><name><surname>Kaakinen</surname> <given-names>M</given-names></name><name><surname>Kaprio</surname> <given-names>J</given-names></name><name><surname>Kesaniemi</surname> <given-names>YA</given-names></name><name><surname>Kivimaki</surname> <given-names>M</given-names></name><name><surname>Knight</surname> <given-names>B</given-names></name><name><surname>Koskinen</surname> <given-names>S</given-names></name><name><surname>Kovacs</surname> <given-names>P</given-names></name><name><surname>Kyvik</surname> <given-names>KO</given-names></name><name><surname>Lathrop</surname> <given-names>GM</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Le Bacquer</surname> <given-names>O</given-names></name><name><surname>Lecoeur</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Mahley</surname> <given-names>R</given-names></name><name><surname>Mangino</surname> <given-names>M</given-names></name><name><surname>Manning</surname> <given-names>AK</given-names></name><name><surname>Martínez-Larrad</surname> <given-names>MT</given-names></name><name><surname>McAteer</surname> <given-names>JB</given-names></name><name><surname>McCulloch</surname> <given-names>LJ</given-names></name><name><surname>McPherson</surname> <given-names>R</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Melzer</surname> <given-names>D</given-names></name><name><surname>Meyre</surname> <given-names>D</given-names></name><name><surname>Mitchell</surname> <given-names>BD</given-names></name><name><surname>Morken</surname> <given-names>MA</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Naitza</surname> <given-names>S</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Neville</surname> <given-names>MJ</given-names></name><name><surname>Oostra</surname> <given-names>BA</given-names></name><name><surname>Orrù</surname> <given-names>M</given-names></name><name><surname>Pakyz</surname> <given-names>R</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Paolisso</surname> <given-names>G</given-names></name><name><surname>Pattaro</surname> <given-names>C</given-names></name><name><surname>Pearson</surname> <given-names>D</given-names></name><name><surname>Peden</surname> <given-names>JF</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Pfeiffer</surname> <given-names>AF</given-names></name><name><surname>Pichler</surname> <given-names>I</given-names></name><name><surname>Polasek</surname> <given-names>O</given-names></name><name><surname>Posthuma</surname> <given-names>D</given-names></name><name><surname>Potter</surname> <given-names>SC</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>Province</surname> <given-names>MA</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Rathmann</surname> <given-names>W</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Rice</surname> <given-names>K</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Rivadeneira</surname> <given-names>F</given-names></name><name><surname>Roden</surname> <given-names>M</given-names></name><name><surname>Rolandsson</surname> <given-names>O</given-names></name><name><surname>Sandbaek</surname> <given-names>A</given-names></name><name><surname>Sandhu</surname> <given-names>M</given-names></name><name><surname>Sanna</surname> <given-names>S</given-names></name><name><surname>Sayer</surname> <given-names>AA</given-names></name><name><surname>Scheet</surname> <given-names>P</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Seedorf</surname> <given-names>U</given-names></name><name><surname>Sharp</surname> <given-names>SJ</given-names></name><name><surname>Shields</surname> <given-names>B</given-names></name><name><surname>Sigurethsson</surname> <given-names>G</given-names></name><name><surname>Sijbrands</surname> <given-names>EJ</given-names></name><name><surname>Silveira</surname> <given-names>A</given-names></name><name><surname>Simpson</surname> <given-names>L</given-names></name><name><surname>Singleton</surname> <given-names>A</given-names></name><name><surname>Smith</surname> <given-names>NL</given-names></name><name><surname>Sovio</surname> <given-names>U</given-names></name><name><surname>Swift</surname> <given-names>A</given-names></name><name><surname>Syddall</surname> <given-names>H</given-names></name><name><surname>Syvänen</surname> <given-names>AC</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Tichet</surname> <given-names>J</given-names></name><name><surname>Tönjes</surname> <given-names>A</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>van Dijk</surname> <given-names>KW</given-names></name><name><surname>van Hoek</surname> <given-names>M</given-names></name><name><surname>Varma</surname> <given-names>D</given-names></name><name><surname>Visvikis-Siest</surname> <given-names>S</given-names></name><name><surname>Vitart</surname> <given-names>V</given-names></name><name><surname>Vogelzangs</surname> <given-names>N</given-names></name><name><surname>Waeber</surname> <given-names>G</given-names></name><name><surname>Wagner</surname> <given-names>PJ</given-names></name><name><surname>Walley</surname> <given-names>A</given-names></name><name><surname>Walters</surname> <given-names>GB</given-names></name><name><surname>Ward</surname> <given-names>KL</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Wild</surname> <given-names>SH</given-names></name><name><surname>Willemsen</surname> <given-names>G</given-names></name><name><surname>Witteman</surname> <given-names>JC</given-names></name><name><surname>Yarnell</surname> <given-names>JW</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Zelenika</surname> <given-names>D</given-names></name><name><surname>Zethelius</surname> <given-names>B</given-names></name><name><surname>Zhai</surname> <given-names>G</given-names></name><name><surname>Zhao</surname> <given-names>JH</given-names></name><name><surname>Zillikens</surname> <given-names>MC</given-names></name><name><surname>Borecki</surname> <given-names>IB</given-names></name><name><surname>Loos</surname> <given-names>RJ</given-names></name><name><surname>Meneton</surname> <given-names>P</given-names></name><name><surname>Magnusson</surname> <given-names>PK</given-names></name><name><surname>Nathan</surname> <given-names>DM</given-names></name><name><surname>Williams</surname> <given-names>GH</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Silander</surname> <given-names>K</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Bornstein</surname> <given-names>SR</given-names></name><name><surname>Schwarz</surname> <given-names>P</given-names></name><name><surname>Spranger</surname> <given-names>J</given-names></name><name><surname>Karpe</surname> <given-names>F</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Cooper</surname> <given-names>C</given-names></name><name><surname>Dedoussis</surname> <given-names>GV</given-names></name><name><surname>Serrano-Ríos</surname> <given-names>M</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Palmer</surname> <given-names>LJ</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Franks</surname> <given-names>PW</given-names></name><name><surname>Ebrahim</surname> <given-names>S</given-names></name><name><surname>Marmot</surname> <given-names>M</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>Sampson</surname> <given-names>MJ</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Wichmann</surname> <given-names>HE</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Wright</surname> <given-names>AF</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Buchanan</surname> <given-names>TA</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Valle</surname> <given-names>TT</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Siscovick</surname> <given-names>DS</given-names></name><name><surname>Penninx</surname> <given-names>BW</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Kong</surname> <given-names>A</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Aulchenko</surname> <given-names>YS</given-names></name><name><surname>Cao</surname> <given-names>A</given-names></name><name><surname>Scuteri</surname> <given-names>A</given-names></name><name><surname>Schlessinger</surname> <given-names>D</given-names></name><name><surname>Uda</surname> <given-names>M</given-names></name><name><surname>Ruokonen</surname> <given-names>A</given-names></name><name><surname>Jarvelin</surname> <given-names>MR</given-names></name><name><surname>Waterworth</surname> <given-names>DM</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Peltonen</surname> <given-names>L</given-names></name><name><surname>Mooser</surname> <given-names>V</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><collab>DIAGRAM Consortium</collab><collab>GIANT Consortium</collab><collab>Global BPgen Consortium</collab><collab>Anders Hamsten on behalf of Procardis Consortium</collab><collab>MAGIC investigators</collab></person-group><year iso-8601-date="2010">2010</year><article-title>New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk</article-title><source>Nature Genetics</source><volume>42</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1038/ng.520</pub-id><pub-id pub-id-type="pmid">20081858</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname> <given-names>NC</given-names></name><name><surname>Robinson</surname> <given-names>JT</given-names></name><name><surname>Shamim</surname> <given-names>MS</given-names></name><name><surname>Machol</surname> <given-names>I</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Aiden</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Juicebox provides a visualization system for Hi-C contact maps with unlimited zoom</article-title><source>Cell Systems</source><volume>3</volume><fpage>99</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.07.012</pub-id><pub-id pub-id-type="pmid">27467250</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ENCODE Project Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>An integrated encyclopedia of DNA elements in the human genome</article-title><source>Nature</source><volume>489</volume><fpage>57</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nature11247</pub-id><pub-id pub-id-type="pmid">22955616</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname> <given-names>J</given-names></name><name><surname>Kellis</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ChromHMM: automating chromatin-state discovery and characterization</article-title><source>Nature Methods</source><volume>9</volume><fpage>215</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1906</pub-id><pub-id pub-id-type="pmid">22373907</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname> <given-names>HA</given-names></name><name><surname>Dong</surname> <given-names>PD</given-names></name><name><surname>Beis</surname> <given-names>D</given-names></name><name><surname>Stainier</surname> <given-names>DY</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Formation of the digestive system in zebrafish II pancreas morphogenesis</article-title><source>Developmental Biology</source><volume>261</volume><fpage>197</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0012-1606(03)00308-7</pub-id><pub-id pub-id-type="pmid">12941629</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finucane</surname> <given-names>HK</given-names></name><name><surname>Bulik-Sullivan</surname> <given-names>B</given-names></name><name><surname>Gusev</surname> <given-names>A</given-names></name><name><surname>Trynka</surname> <given-names>G</given-names></name><name><surname>Reshef</surname> <given-names>Y</given-names></name><name><surname>Loh</surname> <given-names>PR</given-names></name><name><surname>Anttila</surname> <given-names>V</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Zang</surname> <given-names>C</given-names></name><name><surname>Farh</surname> <given-names>K</given-names></name><name><surname>Ripke</surname> <given-names>S</given-names></name><name><surname>Day</surname> <given-names>FR</given-names></name><name><surname>Purcell</surname> <given-names>S</given-names></name><name><surname>Stahl</surname> <given-names>E</given-names></name><name><surname>Lindstrom</surname> <given-names>S</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Okada</surname> <given-names>Y</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Patterson</surname> <given-names>N</given-names></name><name><surname>Neale</surname> <given-names>BM</given-names></name><name><surname>Price</surname> <given-names>AL</given-names></name><collab>ReproGen Consortium</collab><collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab><collab>RACI Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Partitioning heritability by functional annotation using genome-wide association summary statistics</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1228</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1038/ng.3404</pub-id><pub-id pub-id-type="pmid">26414678</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flannick</surname> <given-names>J</given-names></name><name><surname>Mercader</surname> <given-names>JM</given-names></name><name><surname>Fuchsberger</surname> <given-names>C</given-names></name><name><surname>Udler</surname> <given-names>MS</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Wessel</surname> <given-names>J</given-names></name><name><surname>Teslovich</surname> <given-names>TM</given-names></name><name><surname>Caulkins</surname> <given-names>L</given-names></name><name><surname>Koesterer</surname> <given-names>R</given-names></name><name><surname>Barajas-Olmos</surname> <given-names>F</given-names></name><name><surname>Blackwell</surname> <given-names>TW</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Brody</surname> <given-names>JA</given-names></name><name><surname>Centeno-Cruz</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Contreras-Cubas</surname> <given-names>C</given-names></name><name><surname>Córdova</surname> <given-names>E</given-names></name><name><surname>Correa</surname> <given-names>A</given-names></name><name><surname>Cortes</surname> <given-names>M</given-names></name><name><surname>DeFronzo</surname> <given-names>RA</given-names></name><name><surname>Dolan</surname> <given-names>L</given-names></name><name><surname>Drews</surname> <given-names>KL</given-names></name><name><surname>Elliott</surname> <given-names>A</given-names></name><name><surname>Floyd</surname> <given-names>JS</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Garay-Sevilla</surname> <given-names>ME</given-names></name><name><surname>García-Ortiz</surname> <given-names>H</given-names></name><name><surname>Gross</surname> <given-names>M</given-names></name><name><surname>Han</surname> <given-names>S</given-names></name><name><surname>Heard-Costa</surname> <given-names>NL</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Jørgensen</surname> <given-names>ME</given-names></name><name><surname>Kang</surname> <given-names>HM</given-names></name><name><surname>Kelsey</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>BJ</given-names></name><name><surname>Koistinen</surname> <given-names>HA</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Leader</surname> <given-names>JB</given-names></name><name><surname>Linneberg</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>CT</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Manning</surname> <given-names>AK</given-names></name><name><surname>Marcketta</surname> <given-names>A</given-names></name><name><surname>Malacara-Hernandez</surname> <given-names>JM</given-names></name><name><surname>Martínez-Hernández</surname> <given-names>A</given-names></name><name><surname>Matsuo</surname> <given-names>K</given-names></name><name><surname>Mayer-Davis</surname> <given-names>E</given-names></name><name><surname>Mendoza-Caamal</surname> <given-names>E</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Morrison</surname> <given-names>AC</given-names></name><name><surname>Ndungu</surname> <given-names>A</given-names></name><name><surname>Ng</surname> <given-names>MCY</given-names></name><name><surname>O'Dushlaine</surname> <given-names>C</given-names></name><name><surname>Payne</surname> <given-names>AJ</given-names></name><name><surname>Pihoker</surname> <given-names>C</given-names></name><name><surname>Post</surname> <given-names>WS</given-names></name><name><surname>Preuss</surname> <given-names>M</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Vasan</surname> <given-names>RS</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Reiner</surname> <given-names>AP</given-names></name><name><surname>Revilla-Monsalve</surname> <given-names>C</given-names></name><name><surname>Robertson</surname> <given-names>NR</given-names></name><name><surname>Santoro</surname> <given-names>N</given-names></name><name><surname>Schurmann</surname> <given-names>C</given-names></name><name><surname>So</surname> <given-names>WY</given-names></name><name><surname>Soberón</surname> <given-names>X</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Strom</surname> <given-names>TM</given-names></name><name><surname>Tam</surname> <given-names>CHT</given-names></name><name><surname>Thameem</surname> <given-names>F</given-names></name><name><surname>Tomlinson</surname> <given-names>B</given-names></name><name><surname>Torres</surname> <given-names>JM</given-names></name><name><surname>Tracy</surname> <given-names>RP</given-names></name><name><surname>van Dam</surname> <given-names>RM</given-names></name><name><surname>Vujkovic</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Welch</surname> <given-names>RP</given-names></name><name><surname>Witte</surname> <given-names>DR</given-names></name><name><surname>Wong</surname> <given-names>TY</given-names></name><name><surname>Atzmon</surname> <given-names>G</given-names></name><name><surname>Barzilai</surname> <given-names>N</given-names></name><name><surname>Blangero</surname> <given-names>J</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Bowden</surname> <given-names>DW</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name><name><surname>Chan</surname> <given-names>E</given-names></name><name><surname>Cheng</surname> <given-names>CY</given-names></name><name><surname>Cho</surname> <given-names>YS</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>de Vries</surname> <given-names>PS</given-names></name><name><surname>Duggirala</surname> <given-names>R</given-names></name><name><surname>Glaser</surname> <given-names>B</given-names></name><name><surname>Gonzalez</surname> <given-names>C</given-names></name><name><surname>Gonzalez</surname> <given-names>ME</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Kwak</surname> <given-names>SH</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Lehman</surname> <given-names>DM</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Tai</surname> <given-names>ES</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Wilson</surname> <given-names>JG</given-names></name><name><surname>Aguilar-Salinas</surname> <given-names>CA</given-names></name><name><surname>Bottinger</surname> <given-names>E</given-names></name><name><surname>Burke</surname> <given-names>B</given-names></name><name><surname>Carey</surname> <given-names>DJ</given-names></name><name><surname>Chan</surname> <given-names>JCN</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Frossard</surname> <given-names>P</given-names></name><name><surname>Heckbert</surname> <given-names>SR</given-names></name><name><surname>Hwang</surname> <given-names>MY</given-names></name><name><surname>Kim</surname> <given-names>YJ</given-names></name><name><surname>Kirchner</surname> <given-names>HL</given-names></name><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Loos</surname> <given-names>RJF</given-names></name><name><surname>Ma</surname> <given-names>RCW</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>O'Donnell</surname> <given-names>CJ</given-names></name><name><surname>Palmer</surname> <given-names>CNA</given-names></name><name><surname>Pankow</surname> <given-names>J</given-names></name><name><surname>Park</surname> <given-names>KS</given-names></name><name><surname>Rasheed</surname> <given-names>A</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>Sim</surname> <given-names>X</given-names></name><name><surname>Small</surname> <given-names>KS</given-names></name><name><surname>Teo</surname> <given-names>YY</given-names></name><name><surname>Haiman</surname> <given-names>C</given-names></name><name><surname>Hanis</surname> <given-names>CL</given-names></name><name><surname>Henderson</surname> <given-names>BE</given-names></name><name><surname>Orozco</surname> <given-names>L</given-names></name><name><surname>Tusié-Luna</surname> <given-names>T</given-names></name><name><surname>Dewey</surname> <given-names>FE</given-names></name><name><surname>Baras</surname> <given-names>A</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Strauch</surname> <given-names>K</given-names></name><name><surname>Lange</surname> <given-names>L</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Zeitler</surname> <given-names>P</given-names></name><name><surname>Dabelea</surname> <given-names>D</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Bell</surname> <given-names>GI</given-names></name><name><surname>Cox</surname> <given-names>NJ</given-names></name><name><surname>Seielstad</surname> <given-names>M</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Rich</surname> <given-names>SS</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Burtt</surname> <given-names>NP</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><collab>Broad Genomics Platform</collab><collab>DiscovEHR Collaboration</collab><collab>CHARGE</collab><collab>LuCamp</collab><collab>ProDiGY</collab><collab>GoT2D</collab><collab>ESP</collab><collab>SIGMA-T2D</collab><collab>T2D-GENES</collab><collab>AMP-T2D-GENES</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls</article-title><source>Nature</source><volume>570</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1231-2</pub-id><pub-id pub-id-type="pmid">31118516</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchsberger</surname> <given-names>C</given-names></name><name><surname>Flannick</surname> <given-names>J</given-names></name><name><surname>Teslovich</surname> <given-names>TM</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Agarwala</surname> <given-names>V</given-names></name><name><surname>Gaulton</surname> <given-names>KJ</given-names></name><name><surname>Ma</surname> <given-names>C</given-names></name><name><surname>Fontanillas</surname> <given-names>P</given-names></name><name><surname>Moutsianas</surname> <given-names>L</given-names></name><name><surname>McCarthy</surname> <given-names>DJ</given-names></name><name><surname>Rivas</surname> <given-names>MA</given-names></name><name><surname>Perry</surname> <given-names>JRB</given-names></name><name><surname>Sim</surname> <given-names>X</given-names></name><name><surname>Blackwell</surname> <given-names>TW</given-names></name><name><surname>Robertson</surname> <given-names>NR</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Cingolani</surname> <given-names>P</given-names></name><name><surname>Locke</surname> <given-names>AE</given-names></name><name><surname>Tajes</surname> <given-names>JF</given-names></name><name><surname>Highland</surname> <given-names>HM</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Hartl</surname> <given-names>C</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Huyghe</surname> <given-names>JR</given-names></name><name><surname>van de Bunt</surname> <given-names>M</given-names></name><name><surname>Pearson</surname> <given-names>RD</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Gamazon</surname> <given-names>ER</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Below</surname> <given-names>JE</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Go</surname> <given-names>MJ</given-names></name><name><surname>Stitzel</surname> <given-names>ML</given-names></name><name><surname>Pasko</surname> <given-names>D</given-names></name><name><surname>Parker</surname> <given-names>SCJ</given-names></name><name><surname>Varga</surname> <given-names>TV</given-names></name><name><surname>Green</surname> <given-names>T</given-names></name><name><surname>Beer</surname> <given-names>NL</given-names></name><name><surname>Day-Williams</surname> <given-names>AG</given-names></name><name><surname>Ferreira</surname> <given-names>T</given-names></name><name><surname>Fingerlin</surname> <given-names>T</given-names></name><name><surname>Horikoshi</surname> <given-names>M</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Huh</surname> <given-names>I</given-names></name><name><surname>Ikram</surname> <given-names>MK</given-names></name><name><surname>Kim</surname> <given-names>BJ</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>YJ</given-names></name><name><surname>Kwon</surname> <given-names>MS</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>KH</given-names></name><name><surname>Maxwell</surname> <given-names>TJ</given-names></name><name><surname>Nagai</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Welch</surname> <given-names>RP</given-names></name><name><surname>Yoon</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Barzilai</surname> <given-names>N</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Han</surname> <given-names>BG</given-names></name><name><surname>Jenkinson</surname> <given-names>CP</given-names></name><name><surname>Kuulasmaa</surname> <given-names>T</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Manning</surname> <given-names>A</given-names></name><name><surname>Ng</surname> <given-names>MCY</given-names></name><name><surname>Palmer</surname> <given-names>ND</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Abboud</surname> <given-names>HE</given-names></name><name><surname>Boeing</surname> <given-names>H</given-names></name><name><surname>Giedraitis</surname> <given-names>V</given-names></name><name><surname>Prabhakaran</surname> <given-names>D</given-names></name><name><surname>Gottesman</surname> <given-names>O</given-names></name><name><surname>Scott</surname> <given-names>J</given-names></name><name><surname>Carey</surname> <given-names>J</given-names></name><name><surname>Kwan</surname> <given-names>P</given-names></name><name><surname>Grant</surname> <given-names>G</given-names></name><name><surname>Smith</surname> <given-names>JD</given-names></name><name><surname>Neale</surname> <given-names>BM</given-names></name><name><surname>Purcell</surname> <given-names>S</given-names></name><name><surname>Butterworth</surname> <given-names>AS</given-names></name><name><surname>Howson</surname> <given-names>JMM</given-names></name><name><surname>Lee</surname> <given-names>HM</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Kwak</surname> <given-names>SH</given-names></name><name><surname>Zhao</surname> <given-names>W</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Lam</surname> <given-names>VKL</given-names></name><name><surname>Park</surname> <given-names>KS</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>So</surname> <given-names>WY</given-names></name><name><surname>Tam</surname> <given-names>CHT</given-names></name><name><surname>Afzal</surname> <given-names>U</given-names></name><name><surname>Aguilar</surname> <given-names>D</given-names></name><name><surname>Arya</surname> <given-names>R</given-names></name><name><surname>Aung</surname> <given-names>T</given-names></name><name><surname>Chan</surname> <given-names>E</given-names></name><name><surname>Navarro</surname> <given-names>C</given-names></name><name><surname>Cheng</surname> <given-names>CY</given-names></name><name><surname>Palli</surname> <given-names>D</given-names></name><name><surname>Correa</surname> <given-names>A</given-names></name><name><surname>Curran</surname> <given-names>JE</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Farook</surname> <given-names>VS</given-names></name><name><surname>Fowler</surname> <given-names>SP</given-names></name><name><surname>Freedman</surname> <given-names>BI</given-names></name><name><surname>Griswold</surname> <given-names>M</given-names></name><name><surname>Hale</surname> <given-names>DE</given-names></name><name><surname>Hicks</surname> <given-names>PJ</given-names></name><name><surname>Khor</surname> <given-names>CC</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Lehne</surname> <given-names>B</given-names></name><name><surname>Thuillier</surname> <given-names>D</given-names></name><name><surname>Lim</surname> <given-names>WY</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>van der Schouw</surname> <given-names>YT</given-names></name><name><surname>Loh</surname> <given-names>M</given-names></name><name><surname>Musani</surname> <given-names>SK</given-names></name><name><surname>Puppala</surname> <given-names>S</given-names></name><name><surname>Scott</surname> <given-names>WR</given-names></name><name><surname>Yengo</surname> <given-names>L</given-names></name><name><surname>Tan</surname> <given-names>ST</given-names></name><name><surname>Taylor</surname> <given-names>HA</given-names></name><name><surname>Thameem</surname> <given-names>F</given-names></name><name><surname>Wilson</surname> <given-names>G</given-names></name><name><surname>Wong</surname> <given-names>TY</given-names></name><name><surname>Njølstad</surname> <given-names>PR</given-names></name><name><surname>Levy</surname> <given-names>JC</given-names></name><name><surname>Mangino</surname> <given-names>M</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Schwarzmayr</surname> <given-names>T</given-names></name><name><surname>Fadista</surname> <given-names>J</given-names></name><name><surname>Surdulescu</surname> <given-names>GL</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Wieland</surname> <given-names>T</given-names></name><name><surname>Bork-Jensen</surname> <given-names>J</given-names></name><name><surname>Brandslund</surname> <given-names>I</given-names></name><name><surname>Christensen</surname> <given-names>C</given-names></name><name><surname>Koistinen</surname> <given-names>HA</given-names></name><name><surname>Doney</surname> <given-names>ASF</given-names></name><name><surname>Kinnunen</surname> <given-names>L</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Farmer</surname> <given-names>AJ</given-names></name><name><surname>Hakaste</surname> <given-names>L</given-names></name><name><surname>Hodgkiss</surname> <given-names>D</given-names></name><name><surname>Kravic</surname> <given-names>J</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Hollensted</surname> <given-names>M</given-names></name><name><surname>Jørgensen</surname> <given-names>ME</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Ladenvall</surname> <given-names>C</given-names></name><name><surname>Justesen</surname> <given-names>JM</given-names></name><name><surname>Käräjämäki</surname> <given-names>A</given-names></name><name><surname>Kriebel</surname> <given-names>J</given-names></name><name><surname>Rathmann</surname> <given-names>W</given-names></name><name><surname>Lannfelt</surname> <given-names>L</given-names></name><name><surname>Lauritzen</surname> <given-names>T</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Linneberg</surname> <given-names>A</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Milani</surname> <given-names>L</given-names></name><name><surname>Neville</surname> <given-names>M</given-names></name><name><surname>Orho-Melander</surname> <given-names>M</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Qi</surname> <given-names>Q</given-names></name><name><surname>Roden</surname> <given-names>M</given-names></name><name><surname>Rolandsson</surname> <given-names>O</given-names></name><name><surname>Swift</surname> <given-names>A</given-names></name><name><surname>Rosengren</surname> <given-names>AH</given-names></name><name><surname>Stirrups</surname> <given-names>K</given-names></name><name><surname>Wood</surname> <given-names>AR</given-names></name><name><surname>Mihailov</surname> <given-names>E</given-names></name><name><surname>Blancher</surname> <given-names>C</given-names></name><name><surname>Carneiro</surname> <given-names>MO</given-names></name><name><surname>Maguire</surname> <given-names>J</given-names></name><name><surname>Poplin</surname> <given-names>R</given-names></name><name><surname>Shakir</surname> <given-names>K</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>DePristo</surname> <given-names>M</given-names></name><name><surname>de Angelis</surname> <given-names>MH</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Gjesing</surname> <given-names>AP</given-names></name><name><surname>Jun</surname> <given-names>G</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Murphy</surname> <given-names>J</given-names></name><name><surname>Onofrio</surname> <given-names>R</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Karpe</surname> <given-names>F</given-names></name><name><surname>Liang</surname> <given-names>L</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Huth</surname> <given-names>C</given-names></name><name><surname>O'Rahilly</surname> <given-names>SP</given-names></name><name><surname>Palmer</surname> <given-names>CNA</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Rauramaa</surname> <given-names>R</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>Syvänen</surname> <given-names>AC</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Bharadwaj</surname> <given-names>D</given-names></name><name><surname>Bottinger</surname> <given-names>EP</given-names></name><name><surname>Cho</surname> <given-names>YS</given-names></name><name><surname>Chandak</surname> <given-names>GR</given-names></name><name><surname>Chan</surname> <given-names>JCN</given-names></name><name><surname>Chia</surname> <given-names>KS</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Ebrahim</surname> <given-names>SB</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Jablonski</surname> <given-names>KA</given-names></name><name><surname>Lehman</surname> <given-names>DM</given-names></name><name><surname>Jia</surname> <given-names>W</given-names></name><name><surname>Ma</surname> <given-names>RCW</given-names></name><name><surname>Pollin</surname> <given-names>TI</given-names></name><name><surname>Sandhu</surname> <given-names>M</given-names></name><name><surname>Tandon</surname> <given-names>N</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Teo</surname> <given-names>YY</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Loos</surname> <given-names>RJF</given-names></name><name><surname>Small</surname> <given-names>KS</given-names></name><name><surname>Ried</surname> <given-names>JS</given-names></name><name><surname>DeFronzo</surname> <given-names>RA</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Glaser</surname> <given-names>B</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Walker</surname> <given-names>M</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Im</surname> <given-names>HK</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Franks</surname> <given-names>PW</given-names></name><name><surname>Buck</surname> <given-names>G</given-names></name><name><surname>Trakalo</surname> <given-names>J</given-names></name><name><surname>Buck</surname> <given-names>D</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Mägi</surname> <given-names>R</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Farjoun</surname> <given-names>Y</given-names></name><name><surname>Owen</surname> <given-names>KR</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Strauch</surname> <given-names>K</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Park</surname> <given-names>T</given-names></name><name><surname>Donnelly</surname> <given-names>P</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Bowden</surname> <given-names>DW</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Atzmon</surname> <given-names>G</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Strom</surname> <given-names>TM</given-names></name><name><surname>Bell</surname> <given-names>GI</given-names></name><name><surname>Blangero</surname> <given-names>J</given-names></name><name><surname>Duggirala</surname> <given-names>R</given-names></name><name><surname>Tai</surname> <given-names>ES</given-names></name><name><surname>McVean</surname> <given-names>G</given-names></name><name><surname>Hanis</surname> <given-names>CL</given-names></name><name><surname>Wilson</surname> <given-names>JG</given-names></name><name><surname>Seielstad</surname> <given-names>M</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Cox</surname> <given-names>NJ</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Burtt</surname> <given-names>NP</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Kang</surname> <given-names>HM</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The genetic architecture of type 2 diabetes</article-title><source>Nature</source><volume>536</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nature18642</pub-id><pub-id pub-id-type="pmid">27398621</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaertner</surname> <given-names>B</given-names></name><name><surname>Carrano</surname> <given-names>AC</given-names></name><name><surname>Sander</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human stem cell models: lessons for pancreatic development and disease</article-title><source>Genes &amp; Development</source><volume>33</volume><fpage>1475</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1101/gad.331397.119</pub-id><pub-id pub-id-type="pmid">31676735</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname> <given-names>KJ</given-names></name><name><surname>Nammo</surname> <given-names>T</given-names></name><name><surname>Pasquali</surname> <given-names>L</given-names></name><name><surname>Simon</surname> <given-names>JM</given-names></name><name><surname>Giresi</surname> <given-names>PG</given-names></name><name><surname>Fogarty</surname> <given-names>MP</given-names></name><name><surname>Panhuis</surname> <given-names>TM</given-names></name><name><surname>Mieczkowski</surname> <given-names>P</given-names></name><name><surname>Secchi</surname> <given-names>A</given-names></name><name><surname>Bosco</surname> <given-names>D</given-names></name><name><surname>Berney</surname> <given-names>T</given-names></name><name><surname>Montanya</surname> <given-names>E</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Lieb</surname> <given-names>JD</given-names></name><name><surname>Ferrer</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A map of open chromatin in human pancreatic islets</article-title><source>Nature Genetics</source><volume>42</volume><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/ng.530</pub-id><pub-id pub-id-type="pmid">20118932</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname> <given-names>KJ</given-names></name><name><surname>Ferreira</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>Y</given-names></name><name><surname>Raimondo</surname> <given-names>A</given-names></name><name><surname>Mägi</surname> <given-names>R</given-names></name><name><surname>Reschen</surname> <given-names>ME</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Locke</surname> <given-names>A</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Robertson</surname> <given-names>N</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Green</surname> <given-names>T</given-names></name><name><surname>Sparso</surname> <given-names>T</given-names></name><name><surname>Thuillier</surname> <given-names>D</given-names></name><name><surname>Yengo</surname> <given-names>L</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Wahl</surname> <given-names>S</given-names></name><name><surname>Frånberg</surname> <given-names>M</given-names></name><name><surname>Strawbridge</surname> <given-names>RJ</given-names></name><name><surname>Kestler</surname> <given-names>H</given-names></name><name><surname>Chheda</surname> <given-names>H</given-names></name><name><surname>Eisele</surname> <given-names>L</given-names></name><name><surname>Gustafsson</surname> <given-names>S</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Karssen</surname> <given-names>LC</given-names></name><name><surname>van Leeuwen</surname> <given-names>EM</given-names></name><name><surname>Willems</surname> <given-names>SM</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Fuchsberger</surname> <given-names>C</given-names></name><name><surname>Kwan</surname> <given-names>P</given-names></name><name><surname>Ma</surname> <given-names>C</given-names></name><name><surname>Linderman</surname> <given-names>M</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Thomsen</surname> <given-names>SK</given-names></name><name><surname>Rundle</surname> <given-names>JK</given-names></name><name><surname>Beer</surname> <given-names>NL</given-names></name><name><surname>van de Bunt</surname> <given-names>M</given-names></name><name><surname>Chalisey</surname> <given-names>A</given-names></name><name><surname>Kang</surname> <given-names>HM</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Baldassarre</surname> <given-names>D</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Benediktsson</surname> <given-names>R</given-names></name><name><surname>Blüher</surname> <given-names>M</given-names></name><name><surname>Boeing</surname> <given-names>H</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Bottinger</surname> <given-names>EP</given-names></name><name><surname>Burtt</surname> <given-names>NP</given-names></name><name><surname>Carey</surname> <given-names>J</given-names></name><name><surname>Charpentier</surname> <given-names>G</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Cornelis</surname> <given-names>MC</given-names></name><name><surname>Couper</surname> <given-names>DJ</given-names></name><name><surname>Crenshaw</surname> <given-names>AT</given-names></name><name><surname>van Dam</surname> <given-names>RM</given-names></name><name><surname>Doney</surname> <given-names>AS</given-names></name><name><surname>Dorkhan</surname> <given-names>M</given-names></name><name><surname>Edkins</surname> <given-names>S</given-names></name><name><surname>Eriksson</surname> <given-names>JG</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Eury</surname> <given-names>E</given-names></name><name><surname>Fadista</surname> <given-names>J</given-names></name><name><surname>Flannick</surname> <given-names>J</given-names></name><name><surname>Fontanillas</surname> <given-names>P</given-names></name><name><surname>Fox</surname> <given-names>C</given-names></name><name><surname>Franks</surname> <given-names>PW</given-names></name><name><surname>Gertow</surname> <given-names>K</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Gigante</surname> <given-names>B</given-names></name><name><surname>Gottesman</surname> <given-names>O</given-names></name><name><surname>Grant</surname> <given-names>GB</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Hassinen</surname> <given-names>M</given-names></name><name><surname>Have</surname> <given-names>CT</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Holmen</surname> <given-names>OL</given-names></name><name><surname>Hreidarsson</surname> <given-names>AB</given-names></name><name><surname>Humphries</surname> <given-names>SE</given-names></name><name><surname>Hunter</surname> <given-names>DJ</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Jonsson</surname> <given-names>A</given-names></name><name><surname>Jørgensen</surname> <given-names>ME</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Kerrison</surname> <given-names>ND</given-names></name><name><surname>Kinnunen</surname> <given-names>L</given-names></name><name><surname>Klopp</surname> <given-names>N</given-names></name><name><surname>Kong</surname> <given-names>A</given-names></name><name><surname>Kovacs</surname> <given-names>P</given-names></name><name><surname>Kraft</surname> <given-names>P</given-names></name><name><surname>Kravic</surname> <given-names>J</given-names></name><name><surname>Langford</surname> <given-names>C</given-names></name><name><surname>Leander</surname> <given-names>K</given-names></name><name><surname>Liang</surname> <given-names>L</given-names></name><name><surname>Lichtner</surname> <given-names>P</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Lindholm</surname> <given-names>E</given-names></name><name><surname>Linneberg</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>CT</given-names></name><name><surname>Lobbens</surname> <given-names>S</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Männistö</surname> <given-names>S</given-names></name><name><surname>McLeod</surname> <given-names>O</given-names></name><name><surname>Meyer</surname> <given-names>J</given-names></name><name><surname>Mihailov</surname> <given-names>E</given-names></name><name><surname>Mirza</surname> <given-names>G</given-names></name><name><surname>Mühleisen</surname> <given-names>TW</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Navarro</surname> <given-names>C</given-names></name><name><surname>Nöthen</surname> <given-names>MM</given-names></name><name><surname>Oskolkov</surname> <given-names>NN</given-names></name><name><surname>Owen</surname> <given-names>KR</given-names></name><name><surname>Palli</surname> <given-names>D</given-names></name><name><surname>Pechlivanis</surname> <given-names>S</given-names></name><name><surname>Peltonen</surname> <given-names>L</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Platou</surname> <given-names>CG</given-names></name><name><surname>Roden</surname> <given-names>M</given-names></name><name><surname>Ruderfer</surname> <given-names>D</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>van der Schouw</surname> <given-names>YT</given-names></name><name><surname>Sennblad</surname> <given-names>B</given-names></name><name><surname>Sigurðsson</surname> <given-names>G</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Steinbach</surname> <given-names>G</given-names></name><name><surname>Storm</surname> <given-names>P</given-names></name><name><surname>Strauch</surname> <given-names>K</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Tikkanen</surname> <given-names>E</given-names></name><name><surname>Tonjes</surname> <given-names>A</given-names></name><name><surname>Trakalo</surname> <given-names>J</given-names></name><name><surname>Tremoli</surname> <given-names>E</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Wennauer</surname> <given-names>R</given-names></name><name><surname>Wiltshire</surname> <given-names>S</given-names></name><name><surname>Wood</surname> <given-names>AR</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Dunham</surname> <given-names>I</given-names></name><name><surname>Birney</surname> <given-names>E</given-names></name><name><surname>Pasquali</surname> <given-names>L</given-names></name><name><surname>Ferrer</surname> <given-names>J</given-names></name><name><surname>Loos</surname> <given-names>RJ</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>van Duijn</surname> <given-names>C</given-names></name><name><surname>Sijbrands</surname> <given-names>E</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Lakka</surname> <given-names>TA</given-names></name><name><surname>Rauramaa</surname> <given-names>R</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Keinanen-Kiukaanniemi</surname> <given-names>SM</given-names></name><name><surname>Korpi-Hyövälti</surname> <given-names>E</given-names></name><name><surname>Saaristo</surname> <given-names>TE</given-names></name><name><surname>Saltevo</surname> <given-names>J</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Erbel</surname> <given-names>R</given-names></name><name><surname>Jöcke</surname> <given-names>KH</given-names></name><name><surname>Moebus</surname> <given-names>S</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Boehm</surname> <given-names>BO</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Koistinen</surname> <given-names>H</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Hveem</surname> <given-names>K</given-names></name><name><surname>Njølstad</surname> <given-names>I</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Donnelly</surname> <given-names>PJ</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Cauchi</surname> <given-names>S</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Nilsson</surname> <given-names>PM</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>O'Callaghan</surname> <given-names>CA</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Teslovich</surname> <given-names>TM</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><collab>DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1415</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1038/ng.3437</pub-id><pub-id pub-id-type="pmid">26551672</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godinho</surname> <given-names>L</given-names></name><name><surname>Mumm</surname> <given-names>JS</given-names></name><name><surname>Williams</surname> <given-names>PR</given-names></name><name><surname>Schroeter</surname> <given-names>EH</given-names></name><name><surname>Koerber</surname> <given-names>A</given-names></name><name><surname>Park</surname> <given-names>SW</given-names></name><name><surname>Leach</surname> <given-names>SD</given-names></name><name><surname>Wong</surname> <given-names>RO</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Targeting of amacrine cell neurites to appropriate synaptic laminae in the developing zebrafish retina</article-title><source>Development</source><volume>132</volume><fpage>5069</fpage><lpage>5079</lpage><pub-id pub-id-type="doi">10.1242/dev.02075</pub-id><pub-id pub-id-type="pmid">16258076</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname> <given-names>CE</given-names></name><name><surname>Bailey</surname> <given-names>TL</given-names></name><name><surname>Noble</surname> <given-names>WS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>FIMO: scanning for occurrences of a given motif</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1017</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr064</pub-id><pub-id pub-id-type="pmid">21330290</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwald</surname> <given-names>WW</given-names></name><name><surname>Chiou</surname> <given-names>J</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Dai</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>A</given-names></name><name><surname>Nariai</surname> <given-names>N</given-names></name><name><surname>Aylward</surname> <given-names>A</given-names></name><name><surname>Han</surname> <given-names>JY</given-names></name><name><surname>Kadakia</surname> <given-names>N</given-names></name><name><surname>Regue</surname> <given-names>L</given-names></name><name><surname>Okino</surname> <given-names>ML</given-names></name><name><surname>Drees</surname> <given-names>F</given-names></name><name><surname>Kramer</surname> <given-names>D</given-names></name><name><surname>Vinckier</surname> <given-names>N</given-names></name><name><surname>Minichiello</surname> <given-names>L</given-names></name><name><surname>Gorkin</surname> <given-names>D</given-names></name><name><surname>Avruch</surname> <given-names>J</given-names></name><name><surname>Frazer</surname> <given-names>KA</given-names></name><name><surname>Sander</surname> <given-names>M</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Gaulton</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pancreatic islet chromatin accessibility and conformation reveals distal enhancer networks of type 2 diabetes risk</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2078</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09975-4</pub-id><pub-id pub-id-type="pmid">31064983</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halban</surname> <given-names>PA</given-names></name><name><surname>Polonsky</surname> <given-names>KS</given-names></name><name><surname>Bowden</surname> <given-names>DW</given-names></name><name><surname>Hawkins</surname> <given-names>MA</given-names></name><name><surname>Ling</surname> <given-names>C</given-names></name><name><surname>Mather</surname> <given-names>KJ</given-names></name><name><surname>Powers</surname> <given-names>AC</given-names></name><name><surname>Rhodes</surname> <given-names>CJ</given-names></name><name><surname>Sussel</surname> <given-names>L</given-names></name><name><surname>Weir</surname> <given-names>GC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment</article-title><source>Diabetes Care</source><volume>37</volume><fpage>1751</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.2337/dc14-0396</pub-id><pub-id pub-id-type="pmid">24812433</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname> <given-names>S</given-names></name><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Spann</surname> <given-names>N</given-names></name><name><surname>Bertolino</surname> <given-names>E</given-names></name><name><surname>Lin</surname> <given-names>YC</given-names></name><name><surname>Laslo</surname> <given-names>P</given-names></name><name><surname>Cheng</surname> <given-names>JX</given-names></name><name><surname>Murre</surname> <given-names>C</given-names></name><name><surname>Singh</surname> <given-names>H</given-names></name><name><surname>Glass</surname> <given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title><source>Molecular Cell</source><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id><pub-id pub-id-type="pmid">20513432</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heymans</surname> <given-names>C</given-names></name><name><surname>Degosserie</surname> <given-names>J</given-names></name><name><surname>Spourquet</surname> <given-names>C</given-names></name><name><surname>Pierreux</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pancreatic acinar differentiation is guided by differential laminin deposition</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>2711</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-39077-6</pub-id><pub-id pub-id-type="pmid">30804366</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horikoshi</surname> <given-names>M</given-names></name><name><surname>Beaumont</surname> <given-names>RN</given-names></name><name><surname>Day</surname> <given-names>FR</given-names></name><name><surname>Warrington</surname> <given-names>NM</given-names></name><name><surname>Kooijman</surname> <given-names>MN</given-names></name><name><surname>Fernandez-Tajes</surname> <given-names>J</given-names></name><name><surname>Feenstra</surname> <given-names>B</given-names></name><name><surname>van Zuydam</surname> <given-names>NR</given-names></name><name><surname>Gaulton</surname> <given-names>KJ</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Bradfield</surname> <given-names>JP</given-names></name><name><surname>Strachan</surname> <given-names>DP</given-names></name><name><surname>Li-Gao</surname> <given-names>R</given-names></name><name><surname>Ahluwalia</surname> <given-names>TS</given-names></name><name><surname>Kreiner</surname> <given-names>E</given-names></name><name><surname>Rueedi</surname> <given-names>R</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Cousminer</surname> <given-names>DL</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Thiering</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>CA</given-names></name><name><surname>Have</surname> <given-names>CT</given-names></name><name><surname>Hottenga</surname> <given-names>JJ</given-names></name><name><surname>Vilor-Tejedor</surname> <given-names>N</given-names></name><name><surname>Joshi</surname> <given-names>PK</given-names></name><name><surname>Boh</surname> <given-names>ETH</given-names></name><name><surname>Ntalla</surname> <given-names>I</given-names></name><name><surname>Pitkänen</surname> <given-names>N</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>van Leeuwen</surname> <given-names>EM</given-names></name><name><surname>Joro</surname> <given-names>R</given-names></name><name><surname>Lagou</surname> <given-names>V</given-names></name><name><surname>Nodzenski</surname> <given-names>M</given-names></name><name><surname>Diver</surname> <given-names>LA</given-names></name><name><surname>Zondervan</surname> <given-names>KT</given-names></name><name><surname>Bustamante</surname> <given-names>M</given-names></name><name><surname>Marques-Vidal</surname> <given-names>P</given-names></name><name><surname>Mercader</surname> <given-names>JM</given-names></name><name><surname>Bennett</surname> <given-names>AJ</given-names></name><name><surname>Rahmioglu</surname> <given-names>N</given-names></name><name><surname>Nyholt</surname> <given-names>DR</given-names></name><name><surname>Ma</surname> <given-names>RCW</given-names></name><name><surname>Tam</surname> <given-names>CHT</given-names></name><name><surname>Tam</surname> <given-names>WH</given-names></name><name><surname>Ganesh</surname> <given-names>SK</given-names></name><name><surname>van Rooij</surname> <given-names>FJ</given-names></name><name><surname>Jones</surname> <given-names>SE</given-names></name><name><surname>Loh</surname> <given-names>PR</given-names></name><name><surname>Ruth</surname> <given-names>KS</given-names></name><name><surname>Tuke</surname> <given-names>MA</given-names></name><name><surname>Tyrrell</surname> <given-names>J</given-names></name><name><surname>Wood</surname> <given-names>AR</given-names></name><name><surname>Yaghootkar</surname> <given-names>H</given-names></name><name><surname>Scholtens</surname> <given-names>DM</given-names></name><name><surname>Paternoster</surname> <given-names>L</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Kovacs</surname> <given-names>P</given-names></name><name><surname>Atalay</surname> <given-names>M</given-names></name><name><surname>Willems</surname> <given-names>SM</given-names></name><name><surname>Panoutsopoulou</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Carstensen</surname> <given-names>L</given-names></name><name><surname>Geller</surname> <given-names>F</given-names></name><name><surname>Schraut</surname> <given-names>KE</given-names></name><name><surname>Murcia</surname> <given-names>M</given-names></name><name><surname>van Beijsterveldt</surname> <given-names>CE</given-names></name><name><surname>Willemsen</surname> <given-names>G</given-names></name><name><surname>Appel</surname> <given-names>EVR</given-names></name><name><surname>Fonvig</surname> <given-names>CE</given-names></name><name><surname>Trier</surname> <given-names>C</given-names></name><name><surname>Tiesler</surname> <given-names>CM</given-names></name><name><surname>Standl</surname> <given-names>M</given-names></name><name><surname>Kutalik</surname> <given-names>Z</given-names></name><name><surname>Bonas-Guarch</surname> <given-names>S</given-names></name><name><surname>Hougaard</surname> <given-names>DM</given-names></name><name><surname>Sánchez</surname> <given-names>F</given-names></name><name><surname>Torrents</surname> <given-names>D</given-names></name><name><surname>Waage</surname> <given-names>J</given-names></name><name><surname>Hollegaard</surname> <given-names>MV</given-names></name><name><surname>de Haan</surname> <given-names>HG</given-names></name><name><surname>Rosendaal</surname> <given-names>FR</given-names></name><name><surname>Medina-Gomez</surname> <given-names>C</given-names></name><name><surname>Ring</surname> <given-names>SM</given-names></name><name><surname>Hemani</surname> <given-names>G</given-names></name><name><surname>McMahon</surname> <given-names>G</given-names></name><name><surname>Robertson</surname> <given-names>NR</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Zhao</surname> <given-names>JH</given-names></name><name><surname>Mentch</surname> <given-names>FD</given-names></name><name><surname>MacKenzie</surname> <given-names>SM</given-names></name><name><surname>Reynolds</surname> <given-names>RM</given-names></name><name><surname>Lowe</surname> <given-names>WL</given-names></name><name><surname>Tönjes</surname> <given-names>A</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>Lindi</surname> <given-names>V</given-names></name><name><surname>Lakka</surname> <given-names>TA</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Kiess</surname> <given-names>W</given-names></name><name><surname>Körner</surname> <given-names>A</given-names></name><name><surname>Sørensen</surname> <given-names>TI</given-names></name><name><surname>Niinikoski</surname> <given-names>H</given-names></name><name><surname>Pahkala</surname> <given-names>K</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Dedoussis</surname> <given-names>GV</given-names></name><name><surname>Teo</surname> <given-names>YY</given-names></name><name><surname>Saw</surname> <given-names>SM</given-names></name><name><surname>Melbye</surname> <given-names>M</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Vrijheid</surname> <given-names>M</given-names></name><name><surname>de Geus</surname> <given-names>EJ</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Kadarmideen</surname> <given-names>HN</given-names></name><name><surname>Holm</surname> <given-names>JC</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Sebert</surname> <given-names>S</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Beilin</surname> <given-names>LJ</given-names></name><name><surname>Newnham</surname> <given-names>JP</given-names></name><name><surname>Pennell</surname> <given-names>CE</given-names></name><name><surname>Heinrich</surname> <given-names>J</given-names></name><name><surname>Adair</surname> <given-names>LS</given-names></name><name><surname>Borja</surname> <given-names>JB</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Eriksson</surname> <given-names>JG</given-names></name><name><surname>Widén</surname> <given-names>EE</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Viikari</surname> <given-names>JS</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Bønnelykke</surname> <given-names>K</given-names></name><name><surname>Bisgaard</surname> <given-names>H</given-names></name><name><surname>Mook-Kanamori</surname> <given-names>DO</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Rivadeneira</surname> <given-names>F</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Pisinger</surname> <given-names>C</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Power</surname> <given-names>C</given-names></name><name><surname>Hyppönen</surname> <given-names>E</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Davies</surname> <given-names>E</given-names></name><name><surname>Walker</surname> <given-names>BR</given-names></name><name><surname>Jaddoe</surname> <given-names>VW</given-names></name><name><surname>Jarvelin</surname> <given-names>MR</given-names></name><name><surname>Grant</surname> <given-names>SF</given-names></name><name><surname>Vaag</surname> <given-names>AA</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Ong</surname> <given-names>KK</given-names></name><name><surname>Felix</surname> <given-names>JF</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Evans</surname> <given-names>DM</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Freathy</surname> <given-names>RM</given-names></name><collab>CHARGE Consortium Hematology Working Group</collab><collab>Early Growth Genetics (EGG) Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Genome-wide associations for birth weight and correlations with adult disease</article-title><source>Nature</source><volume>538</volume><fpage>248</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/nature19806</pub-id><pub-id pub-id-type="pmid">27680694</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname> <given-names>YC</given-names></name><name><surname>Jensen</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Multiple domains in the crumbs homolog 2a (Crb2a) protein are required for regulating rod photoreceptor size</article-title><source>BMC Cell Biology</source><volume>11</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2121-11-60</pub-id><pub-id pub-id-type="pmid">20670434</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez-Amilburu</surname> <given-names>V</given-names></name><name><surname>Stainier</surname> <given-names>DYR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The transmembrane protein Crb2a regulates cardiomyocyte apicobasal polarity and adhesion in zebrafish</article-title><source>Development</source><volume>146</volume><elocation-id>dev171207</elocation-id><pub-id pub-id-type="doi">10.1242/dev.171207</pub-id><pub-id pub-id-type="pmid">30992276</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>W</given-names></name><name><surname>Mulas</surname> <given-names>F</given-names></name><name><surname>Gaertner</surname> <given-names>B</given-names></name><name><surname>Sui</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Matta</surname> <given-names>I</given-names></name><name><surname>Zeng</surname> <given-names>C</given-names></name><name><surname>Vinckier</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>A</given-names></name><name><surname>Nguyen-Ngoc</surname> <given-names>KV</given-names></name><name><surname>Chiou</surname> <given-names>J</given-names></name><name><surname>Kaestner</surname> <given-names>KH</given-names></name><name><surname>Frazer</surname> <given-names>KA</given-names></name><name><surname>Carrano</surname> <given-names>AC</given-names></name><name><surname>Shih</surname> <given-names>HP</given-names></name><name><surname>Sander</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A network of microRNAs acts to promote cell cycle exit and differentiation of human pancreatic endocrine cells</article-title><source>iScience</source><volume>21</volume><fpage>681</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.isci.2019.10.063</pub-id><pub-id pub-id-type="pmid">31733514</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname> <given-names>WJ</given-names></name><name><surname>Sugnet</surname> <given-names>CW</given-names></name><name><surname>Furey</surname> <given-names>TS</given-names></name><name><surname>Roskin</surname> <given-names>KM</given-names></name><name><surname>Pringle</surname> <given-names>TH</given-names></name><name><surname>Zahler</surname> <given-names>AM</given-names></name><name><surname>Haussler</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The human genome browser at UCSC</article-title><source>Genome Research</source><volume>12</volume><fpage>996</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1101/gr.229102</pub-id><pub-id pub-id-type="pmid">12045153</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khetan</surname> <given-names>S</given-names></name><name><surname>Kursawe</surname> <given-names>R</given-names></name><name><surname>Youn</surname> <given-names>A</given-names></name><name><surname>Lawlor</surname> <given-names>N</given-names></name><name><surname>Jillette</surname> <given-names>A</given-names></name><name><surname>Marquez</surname> <given-names>EJ</given-names></name><name><surname>Ucar</surname> <given-names>D</given-names></name><name><surname>Stitzel</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Type 2 Diabetes-Associated genetic variants regulate chromatin accessibility in human islets</article-title><source>Diabetes</source><volume>67</volume><fpage>2466</fpage><lpage>2477</lpage><pub-id pub-id-type="doi">10.2337/db18-0393</pub-id><pub-id pub-id-type="pmid">30181159</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimmel</surname> <given-names>RA</given-names></name><name><surname>Dobler</surname> <given-names>S</given-names></name><name><surname>Schmitner</surname> <given-names>N</given-names></name><name><surname>Walsen</surname> <given-names>T</given-names></name><name><surname>Freudenblum</surname> <given-names>J</given-names></name><name><surname>Meyer</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Diabetic pdx1-mutant zebrafish show conserved responses to nutrient overload and anti-glycemic treatment</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>14241</elocation-id><pub-id pub-id-type="doi">10.1038/srep14241</pub-id><pub-id pub-id-type="pmid">26384018</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundaje</surname> <given-names>A</given-names></name><name><surname>Meuleman</surname> <given-names>W</given-names></name><name><surname>Ernst</surname> <given-names>J</given-names></name><name><surname>Bilenky</surname> <given-names>M</given-names></name><name><surname>Yen</surname> <given-names>A</given-names></name><name><surname>Heravi-Moussavi</surname> <given-names>A</given-names></name><name><surname>Kheradpour</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ziller</surname> <given-names>MJ</given-names></name><name><surname>Amin</surname> <given-names>V</given-names></name><name><surname>Whitaker</surname> <given-names>JW</given-names></name><name><surname>Schultz</surname> <given-names>MD</given-names></name><name><surname>Ward</surname> <given-names>LD</given-names></name><name><surname>Sarkar</surname> <given-names>A</given-names></name><name><surname>Quon</surname> <given-names>G</given-names></name><name><surname>Sandstrom</surname> <given-names>RS</given-names></name><name><surname>Eaton</surname> <given-names>ML</given-names></name><name><surname>Wu</surname> <given-names>YC</given-names></name><name><surname>Pfenning</surname> <given-names>AR</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Claussnitzer</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Coarfa</surname> <given-names>C</given-names></name><name><surname>Harris</surname> <given-names>RA</given-names></name><name><surname>Shoresh</surname> <given-names>N</given-names></name><name><surname>Epstein</surname> <given-names>CB</given-names></name><name><surname>Gjoneska</surname> <given-names>E</given-names></name><name><surname>Leung</surname> <given-names>D</given-names></name><name><surname>Xie</surname> <given-names>W</given-names></name><name><surname>Hawkins</surname> <given-names>RD</given-names></name><name><surname>Lister</surname> <given-names>R</given-names></name><name><surname>Hong</surname> <given-names>C</given-names></name><name><surname>Gascard</surname> <given-names>P</given-names></name><name><surname>Mungall</surname> <given-names>AJ</given-names></name><name><surname>Moore</surname> <given-names>R</given-names></name><name><surname>Chuah</surname> <given-names>E</given-names></name><name><surname>Tam</surname> <given-names>A</given-names></name><name><surname>Canfield</surname> <given-names>TK</given-names></name><name><surname>Hansen</surname> <given-names>RS</given-names></name><name><surname>Kaul</surname> <given-names>R</given-names></name><name><surname>Sabo</surname> <given-names>PJ</given-names></name><name><surname>Bansal</surname> <given-names>MS</given-names></name><name><surname>Carles</surname> <given-names>A</given-names></name><name><surname>Dixon</surname> <given-names>JR</given-names></name><name><surname>Farh</surname> <given-names>KH</given-names></name><name><surname>Feizi</surname> <given-names>S</given-names></name><name><surname>Karlic</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>AR</given-names></name><name><surname>Kulkarni</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Lowdon</surname> <given-names>R</given-names></name><name><surname>Elliott</surname> <given-names>G</given-names></name><name><surname>Mercer</surname> <given-names>TR</given-names></name><name><surname>Neph</surname> <given-names>SJ</given-names></name><name><surname>Onuchic</surname> <given-names>V</given-names></name><name><surname>Polak</surname> <given-names>P</given-names></name><name><surname>Rajagopal</surname> <given-names>N</given-names></name><name><surname>Ray</surname> <given-names>P</given-names></name><name><surname>Sallari</surname> <given-names>RC</given-names></name><name><surname>Siebenthall</surname> <given-names>KT</given-names></name><name><surname>Sinnott-Armstrong</surname> <given-names>NA</given-names></name><name><surname>Stevens</surname> <given-names>M</given-names></name><name><surname>Thurman</surname> <given-names>RE</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Beaudet</surname> <given-names>AE</given-names></name><name><surname>Boyer</surname> <given-names>LA</given-names></name><name><surname>De Jager</surname> <given-names>PL</given-names></name><name><surname>Farnham</surname> <given-names>PJ</given-names></name><name><surname>Fisher</surname> <given-names>SJ</given-names></name><name><surname>Haussler</surname> <given-names>D</given-names></name><name><surname>Jones</surname> <given-names>SJ</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>McManus</surname> <given-names>MT</given-names></name><name><surname>Sunyaev</surname> <given-names>S</given-names></name><name><surname>Thomson</surname> <given-names>JA</given-names></name><name><surname>Tlsty</surname> <given-names>TD</given-names></name><name><surname>Tsai</surname> <given-names>LH</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Waterland</surname> <given-names>RA</given-names></name><name><surname>Zhang</surname> <given-names>MQ</given-names></name><name><surname>Chadwick</surname> <given-names>LH</given-names></name><name><surname>Bernstein</surname> <given-names>BE</given-names></name><name><surname>Costello</surname> <given-names>JF</given-names></name><name><surname>Ecker</surname> <given-names>JR</given-names></name><name><surname>Hirst</surname> <given-names>M</given-names></name><name><surname>Meissner</surname> <given-names>A</given-names></name><name><surname>Milosavljevic</surname> <given-names>A</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Stamatoyannopoulos</surname> <given-names>JA</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Kellis</surname> <given-names>M</given-names></name><collab>Roadmap Epigenomics Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Integrative analysis of 111 reference human epigenomes</article-title><source>Nature</source><volume>518</volume><fpage>317</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/nature14248</pub-id><pub-id pub-id-type="pmid">25693563</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancman</surname> <given-names>JJ</given-names></name><name><surname>Zvenigorodsky</surname> <given-names>N</given-names></name><name><surname>Gates</surname> <given-names>KP</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Solomon</surname> <given-names>K</given-names></name><name><surname>Humphrey</surname> <given-names>RK</given-names></name><name><surname>Kuo</surname> <given-names>T</given-names></name><name><surname>Setiawan</surname> <given-names>L</given-names></name><name><surname>Verkade</surname> <given-names>H</given-names></name><name><surname>Chi</surname> <given-names>YI</given-names></name><name><surname>Jhala</surname> <given-names>US</given-names></name><name><surname>Wright</surname> <given-names>CV</given-names></name><name><surname>Stainier</surname> <given-names>DY</given-names></name><name><surname>Dong</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Specification of hepatopancreas progenitors in zebrafish by <italic>hnf1ba</italic> and <italic>wnt2bb</italic></article-title><source>Development</source><volume>140</volume><fpage>2669</fpage><lpage>2679</lpage><pub-id pub-id-type="doi">10.1242/dev.090993</pub-id><pub-id pub-id-type="pmid">23720049</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Handsaker</surname> <given-names>B</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Ruan</surname> <given-names>J</given-names></name><name><surname>Homer</surname> <given-names>N</given-names></name><name><surname>Marth</surname> <given-names>G</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>XY</given-names></name><name><surname>Zhai</surname> <given-names>WJ</given-names></name><name><surname>Teng</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Notch signaling in pancreatic development</article-title><source>International Journal of Molecular Sciences</source><volume>17</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17010048</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="pmid">19451168</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lumey</surname> <given-names>LH</given-names></name><name><surname>Khalangot</surname> <given-names>MD</given-names></name><name><surname>Vaiserman</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Association between type 2 diabetes and prenatal exposure to the Ukraine famine of 1932-33: a retrospective cohort study</article-title><source>The Lancet Diabetes &amp; Endocrinology</source><volume>3</volume><fpage>787</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(15)00279-X</pub-id><pub-id pub-id-type="pmid">26342852</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Taliun</surname> <given-names>D</given-names></name><name><surname>Thurner</surname> <given-names>M</given-names></name><name><surname>Robertson</surname> <given-names>NR</given-names></name><name><surname>Torres</surname> <given-names>JM</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Payne</surname> <given-names>AJ</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Cook</surname> <given-names>JP</given-names></name><name><surname>Schmidt</surname> <given-names>EM</given-names></name><name><surname>Wuttke</surname> <given-names>M</given-names></name><name><surname>Sarnowski</surname> <given-names>C</given-names></name><name><surname>Mägi</surname> <given-names>R</given-names></name><name><surname>Nano</surname> <given-names>J</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Trompet</surname> <given-names>S</given-names></name><name><surname>Lecoeur</surname> <given-names>C</given-names></name><name><surname>Preuss</surname> <given-names>MH</given-names></name><name><surname>Prins</surname> <given-names>BP</given-names></name><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Bielak</surname> <given-names>LF</given-names></name><name><surname>Below</surname> <given-names>JE</given-names></name><name><surname>Bowden</surname> <given-names>DW</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name><name><surname>Kim</surname> <given-names>YJ</given-names></name><name><surname>Ng</surname> <given-names>MCY</given-names></name><name><surname>Petty</surname> <given-names>LE</given-names></name><name><surname>Sim</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Bennett</surname> <given-names>AJ</given-names></name><name><surname>Bork-Jensen</surname> <given-names>J</given-names></name><name><surname>Brummett</surname> <given-names>CM</given-names></name><name><surname>Canouil</surname> <given-names>M</given-names></name><name><surname>Ec Kardt</surname> <given-names>KU</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Kardia</surname> <given-names>SLR</given-names></name><name><surname>Kronenberg</surname> <given-names>F</given-names></name><name><surname>Läll</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>CT</given-names></name><name><surname>Locke</surname> <given-names>AE</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Ntalla</surname> <given-names>I</given-names></name><name><surname>Nylander</surname> <given-names>V</given-names></name><name><surname>Schönherr</surname> <given-names>S</given-names></name><name><surname>Schurmann</surname> <given-names>C</given-names></name><name><surname>Yengo</surname> <given-names>L</given-names></name><name><surname>Bottinger</surname> <given-names>EP</given-names></name><name><surname>Brandslund</surname> <given-names>I</given-names></name><name><surname>Christensen</surname> <given-names>C</given-names></name><name><surname>Dedoussis</surname> <given-names>G</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Franco</surname> <given-names>OH</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Giedraitis</surname> <given-names>V</given-names></name><name><surname>Hackinger</surname> <given-names>S</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Ikram</surname> <given-names>MA</given-names></name><name><surname>Ingelsson</surname> <given-names>M</given-names></name><name><surname>Jørgensen</surname> <given-names>ME</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Kriebel</surname> <given-names>J</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Ligthart</surname> <given-names>S</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Linneberg</surname> <given-names>A</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Mamakou</surname> <given-names>V</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Nadkarni</surname> <given-names>G</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Strauch</surname> <given-names>K</given-names></name><name><surname>Taylor</surname> <given-names>KD</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Witte</surname> <given-names>DR</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Peyser</surname> <given-names>PA</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Loos</surname> <given-names>RJF</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Palmer</surname> <given-names>CNA</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Dehghan</surname> <given-names>A</given-names></name><name><surname>Köttgen</surname> <given-names>A</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Marchini</surname> <given-names>J</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps</article-title><source>Nature Genetics</source><volume>50</volume><fpage>1505</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0241-6</pub-id><pub-id pub-id-type="pmid">30297969</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamidi</surname> <given-names>A</given-names></name><name><surname>Prawiro</surname> <given-names>C</given-names></name><name><surname>Seymour</surname> <given-names>PA</given-names></name><name><surname>de Lichtenberg</surname> <given-names>KH</given-names></name><name><surname>Jackson</surname> <given-names>A</given-names></name><name><surname>Serup</surname> <given-names>P</given-names></name><name><surname>Semb</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanosignalling via integrins directs fate decisions of pancreatic progenitors</article-title><source>Nature</source><volume>564</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0762-2</pub-id><pub-id pub-id-type="pmid">30487608</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname> <given-names>AK</given-names></name><name><surname>Hivert</surname> <given-names>MF</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Grimsby</surname> <given-names>JL</given-names></name><name><surname>Bouatia-Naji</surname> <given-names>N</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Liu</surname> <given-names>CT</given-names></name><name><surname>Bielak</surname> <given-names>LF</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Amin</surname> <given-names>N</given-names></name><name><surname>Barnes</surname> <given-names>D</given-names></name><name><surname>Cadby</surname> <given-names>G</given-names></name><name><surname>Hottenga</surname> <given-names>JJ</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Johnson</surname> <given-names>T</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Ladenvall</surname> <given-names>C</given-names></name><name><surname>Lagou</surname> <given-names>V</given-names></name><name><surname>Lahti</surname> <given-names>J</given-names></name><name><surname>Lecoeur</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Martinez-Larrad</surname> <given-names>MT</given-names></name><name><surname>Montasser</surname> <given-names>ME</given-names></name><name><surname>Navarro</surname> <given-names>P</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Rasmussen-Torvik</surname> <given-names>LJ</given-names></name><name><surname>Salo</surname> <given-names>P</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Shungin</surname> <given-names>D</given-names></name><name><surname>Strawbridge</surname> <given-names>RJ</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>An</surname> <given-names>P</given-names></name><name><surname>de Andrade</surname> <given-names>M</given-names></name><name><surname>Andrews</surname> <given-names>JS</given-names></name><name><surname>Aspelund</surname> <given-names>T</given-names></name><name><surname>Atalay</surname> <given-names>M</given-names></name><name><surname>Aulchenko</surname> <given-names>Y</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Bandinelli</surname> <given-names>S</given-names></name><name><surname>Beckmann</surname> <given-names>JS</given-names></name><name><surname>Beilby</surname> <given-names>JP</given-names></name><name><surname>Bellis</surname> <given-names>C</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Blangero</surname> <given-names>J</given-names></name><name><surname>Boban</surname> <given-names>M</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Borecki</surname> <given-names>IB</given-names></name><name><surname>Böttcher</surname> <given-names>Y</given-names></name><name><surname>Bouchard</surname> <given-names>C</given-names></name><name><surname>Brunner</surname> <given-names>E</given-names></name><name><surname>Budimir</surname> <given-names>D</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Carlson</surname> <given-names>O</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Corbatón-Anchuelo</surname> <given-names>A</given-names></name><name><surname>Couper</surname> <given-names>D</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Dedoussis</surname> <given-names>GV</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Dimitriou</surname> <given-names>M</given-names></name><name><surname>Egan</surname> <given-names>JM</given-names></name><name><surname>Eiriksdottir</surname> <given-names>G</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Eriksson</surname> <given-names>JG</given-names></name><name><surname>Eury</surname> <given-names>E</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Forouhi</surname> <given-names>NG</given-names></name><name><surname>Fox</surname> <given-names>CS</given-names></name><name><surname>Franzosi</surname> <given-names>MG</given-names></name><name><surname>Franks</surname> <given-names>PW</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Galan</surname> <given-names>P</given-names></name><name><surname>de Geus</surname> <given-names>E</given-names></name><name><surname>Gigante</surname> <given-names>B</given-names></name><name><surname>Glazer</surname> <given-names>NL</given-names></name><name><surname>Goel</surname> <given-names>A</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Hallmans</surname> <given-names>G</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Hansson</surname> <given-names>O</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Hayward</surname> <given-names>C</given-names></name><name><surname>Heath</surname> <given-names>S</given-names></name><name><surname>Hercberg</surname> <given-names>S</given-names></name><name><surname>Hicks</surname> <given-names>AA</given-names></name><name><surname>Hingorani</surname> <given-names>A</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Hui</surname> <given-names>J</given-names></name><name><surname>Hung</surname> <given-names>J</given-names></name><name><surname>Jarvelin</surname> <given-names>MR</given-names></name><name><surname>Jhun</surname> <given-names>MA</given-names></name><name><surname>Johnson</surname> <given-names>PC</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Jula</surname> <given-names>A</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Kaprio</surname> <given-names>J</given-names></name><name><surname>Kardia</surname> <given-names>SL</given-names></name><name><surname>Keinanen-Kiukaanniemi</surname> <given-names>S</given-names></name><name><surname>Kivimaki</surname> <given-names>M</given-names></name><name><surname>Kolcic</surname> <given-names>I</given-names></name><name><surname>Kovacs</surname> <given-names>P</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Kyvik</surname> <given-names>KO</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Lakka</surname> <given-names>T</given-names></name><name><surname>Lannfelt</surname> <given-names>L</given-names></name><name><surname>Lathrop</surname> <given-names>GM</given-names></name><name><surname>Launer</surname> <given-names>LJ</given-names></name><name><surname>Leander</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Lindstrom</surname> <given-names>J</given-names></name><name><surname>Lobbens</surname> <given-names>S</given-names></name><name><surname>Loos</surname> <given-names>RJ</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Mägi</surname> <given-names>R</given-names></name><name><surname>Magnusson</surname> <given-names>PK</given-names></name><name><surname>Marmot</surname> <given-names>M</given-names></name><name><surname>Meneton</surname> <given-names>P</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Mooser</surname> <given-names>V</given-names></name><name><surname>Morken</surname> <given-names>MA</given-names></name><name><surname>Miljkovic</surname> <given-names>I</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>O'Connell</surname> <given-names>J</given-names></name><name><surname>Ong</surname> <given-names>KK</given-names></name><name><surname>Oostra</surname> <given-names>BA</given-names></name><name><surname>Palmer</surname> <given-names>LJ</given-names></name><name><surname>Palotie</surname> <given-names>A</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>Peden</surname> <given-names>JF</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Pehlic</surname> <given-names>M</given-names></name><name><surname>Peltonen</surname> <given-names>L</given-names></name><name><surname>Penninx</surname> <given-names>B</given-names></name><name><surname>Pericic</surname> <given-names>M</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Perusse</surname> <given-names>L</given-names></name><name><surname>Peyser</surname> <given-names>PA</given-names></name><name><surname>Polasek</surname> <given-names>O</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Province</surname> <given-names>MA</given-names></name><name><surname>Räikkönen</surname> <given-names>K</given-names></name><name><surname>Rauramaa</surname> <given-names>R</given-names></name><name><surname>Rehnberg</surname> <given-names>E</given-names></name><name><surname>Rice</surname> <given-names>K</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Ruokonen</surname> <given-names>A</given-names></name><name><surname>Saaristo</surname> <given-names>T</given-names></name><name><surname>Sabater-Lleal</surname> <given-names>M</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Savage</surname> <given-names>DB</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Schwarz</surname> <given-names>P</given-names></name><name><surname>Seedorf</surname> <given-names>U</given-names></name><name><surname>Sennblad</surname> <given-names>B</given-names></name><name><surname>Serrano-Rios</surname> <given-names>M</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Sijbrands</surname> <given-names>EJ</given-names></name><name><surname>Siscovick</surname> <given-names>DS</given-names></name><name><surname>Smit</surname> <given-names>JH</given-names></name><name><surname>Small</surname> <given-names>KS</given-names></name><name><surname>Smith</surname> <given-names>NL</given-names></name><name><surname>Smith</surname> <given-names>AV</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Stirrups</surname> <given-names>K</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>YV</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Tönjes</surname> <given-names>A</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Trompet</surname> <given-names>S</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Uusitupa</surname> <given-names>M</given-names></name><name><surname>Vikström</surname> <given-names>M</given-names></name><name><surname>Vitart</surname> <given-names>V</given-names></name><name><surname>Vohl</surname> <given-names>MC</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Waeber</surname> <given-names>G</given-names></name><name><surname>Waterworth</surname> <given-names>DM</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Wheeler</surname> <given-names>E</given-names></name><name><surname>Widen</surname> <given-names>E</given-names></name><name><surname>Wild</surname> <given-names>SH</given-names></name><name><surname>Willems</surname> <given-names>SM</given-names></name><name><surname>Willemsen</surname> <given-names>G</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Witteman</surname> <given-names>JC</given-names></name><name><surname>Wright</surname> <given-names>AF</given-names></name><name><surname>Yaghootkar</surname> <given-names>H</given-names></name><name><surname>Zelenika</surname> <given-names>D</given-names></name><name><surname>Zemunik</surname> <given-names>T</given-names></name><name><surname>Zgaga</surname> <given-names>L</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><collab>DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium</collab><collab>Multiple Tissue Human Expression Resource (MUTHER) Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance</article-title><source>Nature Genetics</source><volume>44</volume><fpage>659</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/ng.2274</pub-id><pub-id pub-id-type="pmid">22581228</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masui</surname> <given-names>T</given-names></name><name><surname>Long</surname> <given-names>Q</given-names></name><name><surname>Beres</surname> <given-names>TM</given-names></name><name><surname>Magnuson</surname> <given-names>MA</given-names></name><name><surname>MacDonald</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Early pancreatic development requires the vertebrate suppressor of hairless (RBPJ) in the PTF1 bHLH complex</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>2629</fpage><lpage>2643</lpage><pub-id pub-id-type="doi">10.1101/gad.1575207</pub-id><pub-id pub-id-type="pmid">17938243</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathelier</surname> <given-names>A</given-names></name><name><surname>Fornes</surname> <given-names>O</given-names></name><name><surname>Arenillas</surname> <given-names>DJ</given-names></name><name><surname>Chen</surname> <given-names>CY</given-names></name><name><surname>Denay</surname> <given-names>G</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name><name><surname>Shyr</surname> <given-names>C</given-names></name><name><surname>Tan</surname> <given-names>G</given-names></name><name><surname>Worsley-Hunt</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>AW</given-names></name><name><surname>Parcy</surname> <given-names>F</given-names></name><name><surname>Lenhard</surname> <given-names>B</given-names></name><name><surname>Sandelin</surname> <given-names>A</given-names></name><name><surname>Wasserman</surname> <given-names>WW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D110</fpage><lpage>D115</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1176</pub-id><pub-id pub-id-type="pmid">26531826</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikkelsen</surname> <given-names>TS</given-names></name><name><surname>Xu</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Gimble</surname> <given-names>JM</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Rosen</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Comparative epigenomic analysis of murine and human adipogenesis</article-title><source>Cell</source><volume>143</volume><fpage>156</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.09.006</pub-id><pub-id pub-id-type="pmid">20887899</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murtaugh</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The what, where, when and how of wnt/β-catenin signaling in pancreas development</article-title><source>Organogenesis</source><volume>4</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.4161/org.4.2.5853</pub-id><pub-id pub-id-type="pmid">18953422</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname> <given-names>JH</given-names></name><name><surname>Haase</surname> <given-names>TN</given-names></name><name><surname>Jaksch</surname> <given-names>C</given-names></name><name><surname>Nalla</surname> <given-names>A</given-names></name><name><surname>Søstrup</surname> <given-names>B</given-names></name><name><surname>Nalla</surname> <given-names>AA</given-names></name><name><surname>Larsen</surname> <given-names>L</given-names></name><name><surname>Rasmussen</surname> <given-names>M</given-names></name><name><surname>Dalgaard</surname> <given-names>LT</given-names></name><name><surname>Gaarn</surname> <given-names>LW</given-names></name><name><surname>Thams</surname> <given-names>P</given-names></name><name><surname>Kofod</surname> <given-names>H</given-names></name><name><surname>Billestrup</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Impact of fetal and neonatal environment on beta cell function and development of diabetes</article-title><source>Acta Obstetricia Et Gynecologica Scandinavica</source><volume>93</volume><fpage>1109</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1111/aogs.12504</pub-id><pub-id pub-id-type="pmid">25225114</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolova</surname> <given-names>G</given-names></name><name><surname>Jabs</surname> <given-names>N</given-names></name><name><surname>Konstantinova</surname> <given-names>I</given-names></name><name><surname>Domogatskaya</surname> <given-names>A</given-names></name><name><surname>Tryggvason</surname> <given-names>K</given-names></name><name><surname>Sorokin</surname> <given-names>L</given-names></name><name><surname>Fässler</surname> <given-names>R</given-names></name><name><surname>Gu</surname> <given-names>G</given-names></name><name><surname>Gerber</surname> <given-names>HP</given-names></name><name><surname>Ferrara</surname> <given-names>N</given-names></name><name><surname>Melton</surname> <given-names>DA</given-names></name><name><surname>Lammert</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The vascular basement membrane: a niche for insulin gene expression and beta cell proliferation</article-title><source>Developmental Cell</source><volume>10</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2006.01.015</pub-id><pub-id pub-id-type="pmid">16516842</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omori</surname> <given-names>Y</given-names></name><name><surname>Malicki</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Oko meduzy and related crumbs genes are determinants of apical cell features in the vertebrate embryo</article-title><source>Current Biology</source><volume>16</volume><fpage>945</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2006.03.058</pub-id><pub-id pub-id-type="pmid">16713951</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname> <given-names>SC</given-names></name><name><surname>Stitzel</surname> <given-names>ML</given-names></name><name><surname>Taylor</surname> <given-names>DL</given-names></name><name><surname>Orozco</surname> <given-names>JM</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Akiyama</surname> <given-names>JA</given-names></name><name><surname>van Bueren</surname> <given-names>KL</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Black</surname> <given-names>BL</given-names></name><name><surname>Visel</surname> <given-names>A</given-names></name><name><surname>Pennacchio</surname> <given-names>LA</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><collab>NISC Comparative Sequencing Program</collab><collab>National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program Authors</collab><collab>NISC Comparative Sequencing Program Authors</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants</article-title><source>PNAS</source><volume>110</volume><fpage>17921</fpage><lpage>17926</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317023110</pub-id><pub-id pub-id-type="pmid">24127591</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquali</surname> <given-names>L</given-names></name><name><surname>Gaulton</surname> <given-names>KJ</given-names></name><name><surname>Rodríguez-Seguí</surname> <given-names>SA</given-names></name><name><surname>Mularoni</surname> <given-names>L</given-names></name><name><surname>Miguel-Escalada</surname> <given-names>I</given-names></name><name><surname>Akerman</surname> <given-names>İ</given-names></name><name><surname>Tena</surname> <given-names>JJ</given-names></name><name><surname>Morán</surname> <given-names>I</given-names></name><name><surname>Gómez-Marín</surname> <given-names>C</given-names></name><name><surname>van de Bunt</surname> <given-names>M</given-names></name><name><surname>Ponsa-Cobas</surname> <given-names>J</given-names></name><name><surname>Castro</surname> <given-names>N</given-names></name><name><surname>Nammo</surname> <given-names>T</given-names></name><name><surname>Cebola</surname> <given-names>I</given-names></name><name><surname>García-Hurtado</surname> <given-names>J</given-names></name><name><surname>Maestro</surname> <given-names>MA</given-names></name><name><surname>Pattou</surname> <given-names>F</given-names></name><name><surname>Piemonti</surname> <given-names>L</given-names></name><name><surname>Berney</surname> <given-names>T</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Ravassard</surname> <given-names>P</given-names></name><name><surname>Skarmeta</surname> <given-names>JLG</given-names></name><name><surname>Müller</surname> <given-names>F</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Ferrer</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants</article-title><source>Nature Genetics</source><volume>46</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/ng.2870</pub-id><pub-id pub-id-type="pmid">24413736</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Yengo</surname> <given-names>L</given-names></name><name><surname>Amin</surname> <given-names>N</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Ganser</surname> <given-names>M</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Navarro</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Arking</surname> <given-names>DE</given-names></name><name><surname>Aulchenko</surname> <given-names>Y</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Benediktsson</surname> <given-names>R</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Bonnycastle</surname> <given-names>L</given-names></name><name><surname>Burtt</surname> <given-names>NP</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Charpentier</surname> <given-names>G</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Green</surname> <given-names>T</given-names></name><name><surname>Hadjadj</surname> <given-names>S</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Johnson</surname> <given-names>AD</given-names></name><name><surname>Kottgen</surname> <given-names>A</given-names></name><name><surname>Kraft</surname> <given-names>P</given-names></name><name><surname>Labrune</surname> <given-names>Y</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Manning</surname> <given-names>AK</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Oostra</surname> <given-names>B</given-names></name><name><surname>Pankow</surname> <given-names>J</given-names></name><name><surname>Petersen</surname> <given-names>AK</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Rathmann</surname> <given-names>W</given-names></name><name><surname>Rayner</surname> <given-names>W</given-names></name><name><surname>Roden</surname> <given-names>M</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Sigurdsson</surname> <given-names>G</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Vivequin</surname> <given-names>S</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Wright</surname> <given-names>AF</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Kao</surname> <given-names>L</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>van Duijn</surname> <given-names>C</given-names></name><name><surname>Altschuler</surname> <given-names>D</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Cauchi</surname> <given-names>S</given-names></name><collab>MAGIC</collab><collab>DIAGRAM Consortium</collab><collab>GIANT Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002741</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002741</pub-id><pub-id pub-id-type="pmid">22693455</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pique-Regi</surname> <given-names>R</given-names></name><name><surname>Degner</surname> <given-names>JF</given-names></name><name><surname>Pai</surname> <given-names>AA</given-names></name><name><surname>Gaffney</surname> <given-names>DJ</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Accurate inference of transcription factor binding from DNA sequence and chromatin accessibility data</article-title><source>Genome Research</source><volume>21</volume><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1101/gr.112623.110</pub-id><pub-id pub-id-type="pmid">21106904</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname> <given-names>SM</given-names></name><name><surname>Parsons</surname> <given-names>MJ</given-names></name><name><surname>Kamei</surname> <given-names>M</given-names></name><name><surname>Kettleborough</surname> <given-names>RN</given-names></name><name><surname>Thomas</surname> <given-names>KA</given-names></name><name><surname>Pham</surname> <given-names>VN</given-names></name><name><surname>Bae</surname> <given-names>MK</given-names></name><name><surname>Scott</surname> <given-names>A</given-names></name><name><surname>Weinstein</surname> <given-names>BM</given-names></name><name><surname>Stemple</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Essential and overlapping roles for laminin alpha chains in notochord and blood vessel formation</article-title><source>Developmental Biology</source><volume>289</volume><fpage>64</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2005.10.006</pub-id><pub-id pub-id-type="pmid">16321372</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portha</surname> <given-names>B</given-names></name><name><surname>Chavey</surname> <given-names>A</given-names></name><name><surname>Movassat</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Early-Life origins of type 2 diabetes: fetal programming of the Beta-Cell mass</article-title><source>Experimental Diabetes Research</source><volume>2011</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1155/2011/105076</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Qiu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Pancreatic-Progenitor-Epigenome-Maps-Prioritize-Type-2-Diabetes-Risk-Genes-with-Roles-in-Development</data-title><source>Github</source><version designator="3.0">3.0</version><ext-link ext-link-type="uri" xlink:href="https://github.com/MSanderlab/Pancreatic-progenitor-epigenome-maps-prioritize-type-2-diabetes-risk-genes-with-roles-in-development">https://github.com/MSanderlab/Pancreatic-progenitor-epigenome-maps-prioritize-type-2-diabetes-risk-genes-with-roles-in-development</ext-link></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname> <given-names>AR</given-names></name><name><surname>Hall</surname> <given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rada-Iglesias</surname> <given-names>A</given-names></name><name><surname>Bajpai</surname> <given-names>R</given-names></name><name><surname>Swigut</surname> <given-names>T</given-names></name><name><surname>Brugmann</surname> <given-names>SA</given-names></name><name><surname>Flynn</surname> <given-names>RA</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A unique chromatin signature uncovers early developmental enhancers in humans</article-title><source>Nature</source><volume>470</volume><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/nature09692</pub-id><pub-id pub-id-type="pmid">21160473</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez</surname> <given-names>F</given-names></name><name><surname>Ryan</surname> <given-names>DP</given-names></name><name><surname>Grüning</surname> <given-names>B</given-names></name><name><surname>Bhardwaj</surname> <given-names>V</given-names></name><name><surname>Kilpert</surname> <given-names>F</given-names></name><name><surname>Richter</surname> <given-names>AS</given-names></name><name><surname>Heyne</surname> <given-names>S</given-names></name><name><surname>Dündar</surname> <given-names>F</given-names></name><name><surname>Manke</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>deepTools2: a next generation web server for deep-sequencing data analysis</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W160</fpage><lpage>W165</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw257</pub-id><pub-id pub-id-type="pmid">27079975</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname> <given-names>SS</given-names></name><name><surname>Huntley</surname> <given-names>MH</given-names></name><name><surname>Durand</surname> <given-names>NC</given-names></name><name><surname>Stamenova</surname> <given-names>EK</given-names></name><name><surname>Bochkov</surname> <given-names>ID</given-names></name><name><surname>Robinson</surname> <given-names>JT</given-names></name><name><surname>Sanborn</surname> <given-names>AL</given-names></name><name><surname>Machol</surname> <given-names>I</given-names></name><name><surname>Omer</surname> <given-names>AD</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Aiden</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A 3D map of the human genome at Kilobase resolution reveals principles of chromatin looping</article-title><source>Cell</source><volume>159</volume><fpage>1665</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.11.021</pub-id><pub-id pub-id-type="pmid">25497547</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezania</surname> <given-names>A</given-names></name><name><surname>Bruin</surname> <given-names>JE</given-names></name><name><surname>Arora</surname> <given-names>P</given-names></name><name><surname>Rubin</surname> <given-names>A</given-names></name><name><surname>Batushansky</surname> <given-names>I</given-names></name><name><surname>Asadi</surname> <given-names>A</given-names></name><name><surname>O'Dwyer</surname> <given-names>S</given-names></name><name><surname>Quiskamp</surname> <given-names>N</given-names></name><name><surname>Mojibian</surname> <given-names>M</given-names></name><name><surname>Albrecht</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>YH</given-names></name><name><surname>Johnson</surname> <given-names>JD</given-names></name><name><surname>Kieffer</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>1121</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/nbt.3033</pub-id><pub-id pub-id-type="pmid">25211370</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozowsky</surname> <given-names>J</given-names></name><name><surname>Abyzov</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Alves</surname> <given-names>P</given-names></name><name><surname>Raha</surname> <given-names>D</given-names></name><name><surname>Harmanci</surname> <given-names>A</given-names></name><name><surname>Leng</surname> <given-names>J</given-names></name><name><surname>Bjornson</surname> <given-names>R</given-names></name><name><surname>Kong</surname> <given-names>Y</given-names></name><name><surname>Kitabayashi</surname> <given-names>N</given-names></name><name><surname>Bhardwaj</surname> <given-names>N</given-names></name><name><surname>Rubin</surname> <given-names>M</given-names></name><name><surname>Snyder</surname> <given-names>M</given-names></name><name><surname>Gerstein</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>AlleleSeq: analysis of allele-specific expression and binding in a network framework</article-title><source>Molecular Systems Biology</source><volume>7</volume><elocation-id>522</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2011.54</pub-id><pub-id pub-id-type="pmid">21811232</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Hivert</surname> <given-names>MF</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Bouatia-Naji</surname> <given-names>N</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Glazer</surname> <given-names>NL</given-names></name><name><surname>Manning</surname> <given-names>AK</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Johnson</surname> <given-names>T</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Boesgaard</surname> <given-names>TW</given-names></name><name><surname>Lecoeur</surname> <given-names>C</given-names></name><name><surname>Shrader</surname> <given-names>P</given-names></name><name><surname>O'Connell</surname> <given-names>J</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Couper</surname> <given-names>DJ</given-names></name><name><surname>Rice</surname> <given-names>K</given-names></name><name><surname>Song</surname> <given-names>K</given-names></name><name><surname>Andreasen</surname> <given-names>CH</given-names></name><name><surname>Dina</surname> <given-names>C</given-names></name><name><surname>Köttgen</surname> <given-names>A</given-names></name><name><surname>Le Bacquer</surname> <given-names>O</given-names></name><name><surname>Pattou</surname> <given-names>F</given-names></name><name><surname>Taneera</surname> <given-names>J</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Sampson</surname> <given-names>M</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>van Hoek</surname> <given-names>M</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Aulchenko</surname> <given-names>YS</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Bielinski</surname> <given-names>SJ</given-names></name><name><surname>Bonnefond</surname> <given-names>A</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Borch-Johnsen</surname> <given-names>K</given-names></name><name><surname>Böttcher</surname> <given-names>Y</given-names></name><name><surname>Brunner</surname> <given-names>E</given-names></name><name><surname>Buchanan</surname> <given-names>TA</given-names></name><name><surname>Bumpstead</surname> <given-names>SJ</given-names></name><name><surname>Cavalcanti-Proença</surname> <given-names>C</given-names></name><name><surname>Charpentier</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>YD</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Cornelis</surname> <given-names>M</given-names></name><name><surname>J Crawford</surname> <given-names>G</given-names></name><name><surname>Delplanque</surname> <given-names>J</given-names></name><name><surname>Doney</surname> <given-names>A</given-names></name><name><surname>Egan</surname> <given-names>JM</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Firmann</surname> <given-names>M</given-names></name><name><surname>Forouhi</surname> <given-names>NG</given-names></name><name><surname>Fox</surname> <given-names>CS</given-names></name><name><surname>Goodarzi</surname> <given-names>MO</given-names></name><name><surname>Graessler</surname> <given-names>J</given-names></name><name><surname>Hingorani</surname> <given-names>A</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Kivimaki</surname> <given-names>M</given-names></name><name><surname>Kovacs</surname> <given-names>P</given-names></name><name><surname>Krohn</surname> <given-names>K</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Lauritzen</surname> <given-names>T</given-names></name><name><surname>Lévy-Marchal</surname> <given-names>C</given-names></name><name><surname>Mayor</surname> <given-names>V</given-names></name><name><surname>McAteer</surname> <given-names>JB</given-names></name><name><surname>Meyre</surname> <given-names>D</given-names></name><name><surname>Mitchell</surname> <given-names>BD</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Morken</surname> <given-names>MA</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Pakyz</surname> <given-names>R</given-names></name><name><surname>Pascoe</surname> <given-names>L</given-names></name><name><surname>Payne</surname> <given-names>F</given-names></name><name><surname>Pearson</surname> <given-names>D</given-names></name><name><surname>Rathmann</surname> <given-names>W</given-names></name><name><surname>Sandbaek</surname> <given-names>A</given-names></name><name><surname>Sayer</surname> <given-names>AA</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Sharp</surname> <given-names>SJ</given-names></name><name><surname>Sijbrands</surname> <given-names>E</given-names></name><name><surname>Singleton</surname> <given-names>A</given-names></name><name><surname>Siscovick</surname> <given-names>DS</given-names></name><name><surname>Smith</surname> <given-names>NL</given-names></name><name><surname>Sparsø</surname> <given-names>T</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Syddall</surname> <given-names>H</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Tönjes</surname> <given-names>A</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Valle</surname> <given-names>TT</given-names></name><name><surname>Waeber</surname> <given-names>G</given-names></name><name><surname>Walley</surname> <given-names>A</given-names></name><name><surname>Waterworth</surname> <given-names>DM</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Zhao</surname> <given-names>JH</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Wichmann</surname> <given-names>HE</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>van Duijn</surname> <given-names>C</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Syvänen</surname> <given-names>AC</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Walker</surname> <given-names>M</given-names></name><name><surname>Bornstein</surname> <given-names>SR</given-names></name><name><surname>Schwarz</surname> <given-names>P</given-names></name><name><surname>Williams</surname> <given-names>GH</given-names></name><name><surname>Nathan</surname> <given-names>DM</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Cooper</surname> <given-names>C</given-names></name><name><surname>Marmot</surname> <given-names>M</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Mooser</surname> <given-names>V</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>Loos</surname> <given-names>RJ</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><collab>GIANT consortium</collab><collab>MAGIC investigators</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge</article-title><source>Nature Genetics</source><volume>42</volume><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/ng.521</pub-id><pub-id pub-id-type="pmid">20081857</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname> <given-names>TC</given-names></name><name><surname>Young</surname> <given-names>HY</given-names></name><name><surname>Agulnick</surname> <given-names>AD</given-names></name><name><surname>Babin</surname> <given-names>MJ</given-names></name><name><surname>Baetge</surname> <given-names>EE</given-names></name><name><surname>Bang</surname> <given-names>AG</given-names></name><name><surname>Bhoumik</surname> <given-names>A</given-names></name><name><surname>Cepa</surname> <given-names>I</given-names></name><name><surname>Cesario</surname> <given-names>RM</given-names></name><name><surname>Haakmeester</surname> <given-names>C</given-names></name><name><surname>Kadoya</surname> <given-names>K</given-names></name><name><surname>Kelly</surname> <given-names>JR</given-names></name><name><surname>Kerr</surname> <given-names>J</given-names></name><name><surname>Martinson</surname> <given-names>LA</given-names></name><name><surname>McLean</surname> <given-names>AB</given-names></name><name><surname>Moorman</surname> <given-names>MA</given-names></name><name><surname>Payne</surname> <given-names>JK</given-names></name><name><surname>Richardson</surname> <given-names>M</given-names></name><name><surname>Ross</surname> <given-names>KG</given-names></name><name><surname>Sherrer</surname> <given-names>ES</given-names></name><name><surname>Song</surname> <given-names>X</given-names></name><name><surname>Wilson</surname> <given-names>AZ</given-names></name><name><surname>Brandon</surname> <given-names>EP</given-names></name><name><surname>Green</surname> <given-names>CE</given-names></name><name><surname>Kroon</surname> <given-names>EJ</given-names></name><name><surname>Kelly</surname> <given-names>OG</given-names></name><name><surname>D'Amour</surname> <given-names>KA</given-names></name><name><surname>Robins</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A scalable system for production of functional pancreatic progenitors from human embryonic stem cells</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e37004</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0037004</pub-id><pub-id pub-id-type="pmid">22623968</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname> <given-names>N</given-names></name><name><surname>Vanderhooft</surname> <given-names>J</given-names></name><name><surname>Straubhaar</surname> <given-names>J</given-names></name><name><surname>Mueller</surname> <given-names>J</given-names></name><name><surname>Chawla</surname> <given-names>R</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Engquist</surname> <given-names>EN</given-names></name><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Gifford</surname> <given-names>DK</given-names></name><name><surname>Melton</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Wnt signaling separates the progenitor and endocrine compartments during pancreas development</article-title><source>Cell Reports</source><volume>27</volume><fpage>2281</fpage><lpage>2291</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.04.083</pub-id><pub-id pub-id-type="pmid">31116975</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>ZD</given-names></name><name><surname>Lee</surname> <given-names>K</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Amin</surname> <given-names>S</given-names></name><name><surname>Verma</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>QV</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Soh</surname> <given-names>CL</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Evans</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Huangfu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome editing in hPSCs reveals GATA6 haploinsufficiency and a genetic interaction with GATA4 in human pancreatic development</article-title><source>Cell Stem Cell</source><volume>20</volume><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2017.01.001</pub-id><pub-id pub-id-type="pmid">28196600</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slavotinek</surname> <given-names>A</given-names></name><name><surname>Kaylor</surname> <given-names>J</given-names></name><name><surname>Pierce</surname> <given-names>H</given-names></name><name><surname>Cahr</surname> <given-names>M</given-names></name><name><surname>DeWard</surname> <given-names>SJ</given-names></name><name><surname>Schneidman-Duhovny</surname> <given-names>D</given-names></name><name><surname>Alsadah</surname> <given-names>A</given-names></name><name><surname>Salem</surname> <given-names>F</given-names></name><name><surname>Schmajuk</surname> <given-names>G</given-names></name><name><surname>Mehta</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CRB2 mutations produce a phenotype resembling congenital nephrosis, finnish type, with cerebral ventriculomegaly and raised alpha-fetoprotein</article-title><source>The American Journal of Human Genetics</source><volume>96</volume><fpage>162</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2014.11.013</pub-id><pub-id pub-id-type="pmid">25557780</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Sulem</surname> <given-names>P</given-names></name><name><surname>Helgason</surname> <given-names>H</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Sigurdsson</surname> <given-names>A</given-names></name><name><surname>Helgadottir</surname> <given-names>HT</given-names></name><name><surname>Johannsdottir</surname> <given-names>H</given-names></name><name><surname>Magnusson</surname> <given-names>OT</given-names></name><name><surname>Gudjonsson</surname> <given-names>SA</given-names></name><name><surname>Justesen</surname> <given-names>JM</given-names></name><name><surname>Harder</surname> <given-names>MN</given-names></name><name><surname>Jørgensen</surname> <given-names>ME</given-names></name><name><surname>Christensen</surname> <given-names>C</given-names></name><name><surname>Brandslund</surname> <given-names>I</given-names></name><name><surname>Sandbæk</surname> <given-names>A</given-names></name><name><surname>Lauritzen</surname> <given-names>T</given-names></name><name><surname>Vestergaard</surname> <given-names>H</given-names></name><name><surname>Linneberg</surname> <given-names>A</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Daneshpour</surname> <given-names>MS</given-names></name><name><surname>Fallah</surname> <given-names>MS</given-names></name><name><surname>Hreidarsson</surname> <given-names>AB</given-names></name><name><surname>Sigurdsson</surname> <given-names>G</given-names></name><name><surname>Azizi</surname> <given-names>F</given-names></name><name><surname>Benediktsson</surname> <given-names>R</given-names></name><name><surname>Masson</surname> <given-names>G</given-names></name><name><surname>Helgason</surname> <given-names>A</given-names></name><name><surname>Kong</surname> <given-names>A</given-names></name><name><surname>Gudbjartsson</surname> <given-names>DF</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes</article-title><source>Nature Genetics</source><volume>46</volume><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/ng.2882</pub-id><pub-id pub-id-type="pmid">24464100</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strawbridge</surname> <given-names>RJ</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Barker</surname> <given-names>A</given-names></name><name><surname>Ahlqvist</surname> <given-names>E</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Petrie</surname> <given-names>JR</given-names></name><name><surname>Travers</surname> <given-names>ME</given-names></name><name><surname>Bouatia-Naji</surname> <given-names>N</given-names></name><name><surname>Dimas</surname> <given-names>AS</given-names></name><name><surname>Nica</surname> <given-names>A</given-names></name><name><surname>Wheeler</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Taneera</surname> <given-names>J</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Peden</surname> <given-names>JF</given-names></name><name><surname>Turrini</surname> <given-names>F</given-names></name><name><surname>Gustafsson</surname> <given-names>S</given-names></name><name><surname>Zabena</surname> <given-names>C</given-names></name><name><surname>Almgren</surname> <given-names>P</given-names></name><name><surname>Barker</surname> <given-names>DJP</given-names></name><name><surname>Barnes</surname> <given-names>D</given-names></name><name><surname>Dennison</surname> <given-names>EM</given-names></name><name><surname>Eriksson</surname> <given-names>JG</given-names></name><name><surname>Eriksson</surname> <given-names>P</given-names></name><name><surname>Eury</surname> <given-names>E</given-names></name><name><surname>Folkersen</surname> <given-names>L</given-names></name><name><surname>Fox</surname> <given-names>CS</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Goel</surname> <given-names>A</given-names></name><name><surname>Gu</surname> <given-names>HF</given-names></name><name><surname>Horikoshi</surname> <given-names>M</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Jameson</surname> <given-names>KA</given-names></name><name><surname>Kajantie</surname> <given-names>E</given-names></name><name><surname>Kerr-Conte</surname> <given-names>J</given-names></name><name><surname>Kuulasmaa</surname> <given-names>T</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Loos</surname> <given-names>RJF</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Makrilakis</surname> <given-names>K</given-names></name><name><surname>Manning</surname> <given-names>AK</given-names></name><name><surname>Martinez-Larrad</surname> <given-names>MT</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Nastase Mannila</surname> <given-names>M</given-names></name><name><surname>Ohrvik</surname> <given-names>J</given-names></name><name><surname>Osmond</surname> <given-names>C</given-names></name><name><surname>Pascoe</surname> <given-names>L</given-names></name><name><surname>Payne</surname> <given-names>F</given-names></name><name><surname>Sayer</surname> <given-names>AA</given-names></name><name><surname>Sennblad</surname> <given-names>B</given-names></name><name><surname>Silveira</surname> <given-names>A</given-names></name><name><surname>Stancakova</surname> <given-names>A</given-names></name><name><surname>Stirrups</surname> <given-names>K</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Syvanen</surname> <given-names>A-C</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>van 't Hooft</surname> <given-names>FM</given-names></name><name><surname>Walker</surname> <given-names>M</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Xie</surname> <given-names>W</given-names></name><name><surname>Zethelius</surname> <given-names>B</given-names></name><name><surname>Ongen</surname> <given-names>H</given-names></name><name><surname>Malarstig</surname> <given-names>A</given-names></name><name><surname>Hopewell</surname> <given-names>JC</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>Chambers</surname> <given-names>J</given-names></name><name><surname>Parish</surname> <given-names>S</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Kooner</surname> <given-names>J</given-names></name><name><surname>Ostenson</surname> <given-names>C-G</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Cooper</surname> <given-names>CC</given-names></name><name><surname>Serrano-Rios</surname> <given-names>M</given-names></name><name><surname>Ferrannini</surname> <given-names>E</given-names></name><name><surname>Forsen</surname> <given-names>TJ</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Franzosi</surname> <given-names>MG</given-names></name><name><surname>Seedorf</surname> <given-names>U</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Johnson</surname> <given-names>P</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Dermitzakis</surname> <given-names>ET</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Pattou</surname> <given-names>F</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Dedoussis</surname> <given-names>GV</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genome-Wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes</article-title><source>Diabetes</source><volume>60</volume><fpage>2624</fpage><lpage>2634</lpage><pub-id pub-id-type="doi">10.2337/db11-0415</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname> <given-names>L</given-names></name><name><surname>Geens</surname> <given-names>M</given-names></name><name><surname>Sermon</surname> <given-names>K</given-names></name><name><surname>Bouwens</surname> <given-names>L</given-names></name><name><surname>Mfopou</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of BMP signaling in pancreatic progenitor differentiation from human embryonic stem cells</article-title><source>Stem Cell Reviews and Reports</source><volume>9</volume><fpage>569</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1007/s12015-013-9435-6</pub-id><pub-id pub-id-type="pmid">23468018</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taal</surname> <given-names>HR</given-names></name><name><surname>Pourcain</surname> <given-names>BS</given-names></name><name><surname>Thiering</surname> <given-names>E</given-names></name><name><surname>Das</surname> <given-names>S</given-names></name><name><surname>Mook-Kanamori</surname> <given-names>DO</given-names></name><name><surname>Warrington</surname> <given-names>NM</given-names></name><name><surname>Kaakinen</surname> <given-names>M</given-names></name><name><surname>Kreiner-Møller</surname> <given-names>E</given-names></name><name><surname>Bradfield</surname> <given-names>JP</given-names></name><name><surname>Freathy</surname> <given-names>RM</given-names></name><name><surname>Geller</surname> <given-names>F</given-names></name><name><surname>Guxens</surname> <given-names>M</given-names></name><name><surname>Cousminer</surname> <given-names>DL</given-names></name><name><surname>Kerkhof</surname> <given-names>M</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Ikram</surname> <given-names>MA</given-names></name><name><surname>Beilin</surname> <given-names>LJ</given-names></name><name><surname>Bønnelykke</surname> <given-names>K</given-names></name><name><surname>Buxton</surname> <given-names>JL</given-names></name><name><surname>Charoen</surname> <given-names>P</given-names></name><name><surname>Chawes</surname> <given-names>BLK</given-names></name><name><surname>Eriksson</surname> <given-names>J</given-names></name><name><surname>Evans</surname> <given-names>DM</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Kemp</surname> <given-names>JP</given-names></name><name><surname>Kim</surname> <given-names>CE</given-names></name><name><surname>Klopp</surname> <given-names>N</given-names></name><name><surname>Lahti</surname> <given-names>J</given-names></name><name><surname>Lye</surname> <given-names>SJ</given-names></name><name><surname>McMahon</surname> <given-names>G</given-names></name><name><surname>Mentch</surname> <given-names>FD</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name><name><surname>O'Reilly</surname> <given-names>PF</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Rivadeneira</surname> <given-names>F</given-names></name><name><surname>Steegers</surname> <given-names>EAP</given-names></name><name><surname>Sunyer</surname> <given-names>J</given-names></name><name><surname>Tiesler</surname> <given-names>C</given-names></name><name><surname>Yaghootkar</surname> <given-names>H</given-names></name><name><surname>Breteler</surname> <given-names>MMB</given-names></name><name><surname>Debette</surname> <given-names>S</given-names></name><name><surname>Fornage</surname> <given-names>M</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Launer</surname> <given-names>LJ</given-names></name><name><surname>van der Lugt</surname> <given-names>A</given-names></name><name><surname>Mosley</surname> <given-names>TH</given-names></name><name><surname>Seshadri</surname> <given-names>S</given-names></name><name><surname>Smith</surname> <given-names>AV</given-names></name><name><surname>Vernooij</surname> <given-names>MW</given-names></name><name><surname>Blakemore</surname> <given-names>AI</given-names></name><name><surname>Chiavacci</surname> <given-names>RM</given-names></name><name><surname>Feenstra</surname> <given-names>B</given-names></name><name><surname>Fernandez-Benet</surname> <given-names>J</given-names></name><name><surname>Grant</surname> <given-names>SFA</given-names></name><name><surname>Hartikainen</surname> <given-names>AL</given-names></name><name><surname>van der Heijden</surname> <given-names>AJ</given-names></name><name><surname>Iñiguez</surname> <given-names>C</given-names></name><name><surname>Lathrop</surname> <given-names>M</given-names></name><name><surname>McArdle</surname> <given-names>WL</given-names></name><name><surname>Mølgaard</surname> <given-names>A</given-names></name><name><surname>Newnham</surname> <given-names>JP</given-names></name><name><surname>Palmer</surname> <given-names>LJ</given-names></name><name><surname>Palotie</surname> <given-names>A</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>Ring</surname> <given-names>SM</given-names></name><name><surname>Sovio</surname> <given-names>U</given-names></name><name><surname>Standl</surname> <given-names>M</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Wichmann</surname> <given-names>HE</given-names></name><name><surname>Vissing</surname> <given-names>NH</given-names></name><name><surname>DeCarli</surname> <given-names>C</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Koppelman</surname> <given-names>GH</given-names></name><name><surname>Estivill</surname> <given-names>X</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Melbye</surname> <given-names>M</given-names></name><name><surname>Bisgaard</surname> <given-names>H</given-names></name><name><surname>Pennell</surname> <given-names>CE</given-names></name><name><surname>Widen</surname> <given-names>E</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Heinrich</surname> <given-names>J</given-names></name><name><surname>Jarvelin</surname> <given-names>MR</given-names></name><name><surname>Jaddoe</surname> <given-names>VWV</given-names></name><collab>Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Consortium</collab><collab>Early Genetics &amp; Lifecourse Epidemiology (EAGLE) consortium</collab><collab>Early Growth Genetics (EGG) Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Common variants at 12q15 and 12q24 are associated with infant head circumference</article-title><source>Nature Genetics</source><volume>44</volume><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/ng.2238</pub-id><pub-id pub-id-type="pmid">22504419</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurner</surname> <given-names>M</given-names></name><name><surname>van de Bunt</surname> <given-names>M</given-names></name><name><surname>Torres</surname> <given-names>JM</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Nylander</surname> <given-names>V</given-names></name><name><surname>Bennett</surname> <given-names>AJ</given-names></name><name><surname>Gaulton</surname> <given-names>KJ</given-names></name><name><surname>Barrett</surname> <given-names>A</given-names></name><name><surname>Burrows</surname> <given-names>C</given-names></name><name><surname>Bell</surname> <given-names>CG</given-names></name><name><surname>Lowe</surname> <given-names>R</given-names></name><name><surname>Beck</surname> <given-names>S</given-names></name><name><surname>Rakyan</surname> <given-names>VK</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Integration of human pancreatic islet genomic data refines regulatory mechanisms at type 2 diabetes susceptibility loci</article-title><source>eLife</source><volume>7</volume><elocation-id>e31977</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.31977</pub-id><pub-id pub-id-type="pmid">29412141</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiyaboonchai</surname> <given-names>A</given-names></name><name><surname>Cardenas-Diaz</surname> <given-names>FL</given-names></name><name><surname>Ying</surname> <given-names>L</given-names></name><name><surname>Maguire</surname> <given-names>JA</given-names></name><name><surname>Sim</surname> <given-names>X</given-names></name><name><surname>Jobaliya</surname> <given-names>C</given-names></name><name><surname>Gagne</surname> <given-names>AL</given-names></name><name><surname>Kishore</surname> <given-names>S</given-names></name><name><surname>Stanescu</surname> <given-names>DE</given-names></name><name><surname>Hughes</surname> <given-names>N</given-names></name><name><surname>De Leon</surname> <given-names>DD</given-names></name><name><surname>French</surname> <given-names>DL</given-names></name><name><surname>Gadue</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GATA6 plays an important role in the induction of human definitive endoderm, development of the pancreas, and functionality of pancreatic β Cells</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>589</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2016.12.026</pub-id><pub-id pub-id-type="pmid">28196690</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Williams</surname> <given-names>BA</given-names></name><name><surname>Pertea</surname> <given-names>G</given-names></name><name><surname>Mortazavi</surname> <given-names>A</given-names></name><name><surname>Kwan</surname> <given-names>G</given-names></name><name><surname>van Baren</surname> <given-names>MJ</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name><name><surname>Wold</surname> <given-names>BJ</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1038/nbt.1621</pub-id><pub-id pub-id-type="pmid">20436464</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urakami</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment</article-title><source>Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy</source><volume>12</volume><fpage>1047</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.2147/DMSO.S179793</pub-id><pub-id pub-id-type="pmid">31360071</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Valk</surname> <given-names>RJ</given-names></name><name><surname>Kreiner-Møller</surname> <given-names>E</given-names></name><name><surname>Kooijman</surname> <given-names>MN</given-names></name><name><surname>Guxens</surname> <given-names>M</given-names></name><name><surname>Stergiakouli</surname> <given-names>E</given-names></name><name><surname>Sääf</surname> <given-names>A</given-names></name><name><surname>Bradfield</surname> <given-names>JP</given-names></name><name><surname>Geller</surname> <given-names>F</given-names></name><name><surname>Hayes</surname> <given-names>MG</given-names></name><name><surname>Cousminer</surname> <given-names>DL</given-names></name><name><surname>Körner</surname> <given-names>A</given-names></name><name><surname>Thiering</surname> <given-names>E</given-names></name><name><surname>Curtin</surname> <given-names>JA</given-names></name><name><surname>Myhre</surname> <given-names>R</given-names></name><name><surname>Huikari</surname> <given-names>V</given-names></name><name><surname>Joro</surname> <given-names>R</given-names></name><name><surname>Kerkhof</surname> <given-names>M</given-names></name><name><surname>Warrington</surname> <given-names>NM</given-names></name><name><surname>Pitkänen</surname> <given-names>N</given-names></name><name><surname>Ntalla</surname> <given-names>I</given-names></name><name><surname>Horikoshi</surname> <given-names>M</given-names></name><name><surname>Veijola</surname> <given-names>R</given-names></name><name><surname>Freathy</surname> <given-names>RM</given-names></name><name><surname>Teo</surname> <given-names>YY</given-names></name><name><surname>Barton</surname> <given-names>SJ</given-names></name><name><surname>Evans</surname> <given-names>DM</given-names></name><name><surname>Kemp</surname> <given-names>JP</given-names></name><name><surname>St Pourcain</surname> <given-names>B</given-names></name><name><surname>Ring</surname> <given-names>SM</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Bergström</surname> <given-names>A</given-names></name><name><surname>Kull</surname> <given-names>I</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Mentch</surname> <given-names>FD</given-names></name><name><surname>Bisgaard</surname> <given-names>H</given-names></name><name><surname>Chawes</surname> <given-names>B</given-names></name><name><surname>Stokholm</surname> <given-names>J</given-names></name><name><surname>Waage</surname> <given-names>J</given-names></name><name><surname>Eriksen</surname> <given-names>P</given-names></name><name><surname>Sevelsted</surname> <given-names>A</given-names></name><name><surname>Melbye</surname> <given-names>M</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Medina-Gomez</surname> <given-names>C</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>de Jongste</surname> <given-names>JC</given-names></name><name><surname>Taal</surname> <given-names>HR</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Armstrong</surname> <given-names>LL</given-names></name><name><surname>Eriksson</surname> <given-names>J</given-names></name><name><surname>Palotie</surname> <given-names>A</given-names></name><name><surname>Bustamante</surname> <given-names>M</given-names></name><name><surname>Estivill</surname> <given-names>X</given-names></name><name><surname>Gonzalez</surname> <given-names>JR</given-names></name><name><surname>Llop</surname> <given-names>S</given-names></name><name><surname>Kiess</surname> <given-names>W</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Flexeder</surname> <given-names>C</given-names></name><name><surname>Tiesler</surname> <given-names>CM</given-names></name><name><surname>Murray</surname> <given-names>CS</given-names></name><name><surname>Simpson</surname> <given-names>A</given-names></name><name><surname>Magnus</surname> <given-names>P</given-names></name><name><surname>Sengpiel</surname> <given-names>V</given-names></name><name><surname>Hartikainen</surname> <given-names>AL</given-names></name><name><surname>Keinanen-Kiukaanniemi</surname> <given-names>S</given-names></name><name><surname>Lewin</surname> <given-names>A</given-names></name><name><surname>Da Silva Couto Alves</surname> <given-names>A</given-names></name><name><surname>Blakemore</surname> <given-names>AI</given-names></name><name><surname>Buxton</surname> <given-names>JL</given-names></name><name><surname>Kaakinen</surname> <given-names>M</given-names></name><name><surname>Rodriguez</surname> <given-names>A</given-names></name><name><surname>Sebert</surname> <given-names>S</given-names></name><name><surname>Vaarasmaki</surname> <given-names>M</given-names></name><name><surname>Lakka</surname> <given-names>T</given-names></name><name><surname>Lindi</surname> <given-names>V</given-names></name><name><surname>Gehring</surname> <given-names>U</given-names></name><name><surname>Postma</surname> <given-names>DS</given-names></name><name><surname>Ang</surname> <given-names>W</given-names></name><name><surname>Newnham</surname> <given-names>JP</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Pahkala</surname> <given-names>K</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Panoutsopoulou</surname> <given-names>K</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Groen-Blokhuis</surname> <given-names>M</given-names></name><name><surname>Ilonen</surname> <given-names>J</given-names></name><name><surname>Franke</surname> <given-names>L</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Pers</surname> <given-names>TH</given-names></name><name><surname>Liang</surname> <given-names>L</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Hocher</surname> <given-names>B</given-names></name><name><surname>Knip</surname> <given-names>M</given-names></name><name><surname>Saw</surname> <given-names>SM</given-names></name><name><surname>Holloway</surname> <given-names>JW</given-names></name><name><surname>Melén</surname> <given-names>E</given-names></name><name><surname>Grant</surname> <given-names>SF</given-names></name><name><surname>Feenstra</surname> <given-names>B</given-names></name><name><surname>Lowe</surname> <given-names>WL</given-names></name><name><surname>Widén</surname> <given-names>E</given-names></name><name><surname>Sergeyev</surname> <given-names>E</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Custovic</surname> <given-names>A</given-names></name><name><surname>Jacobsson</surname> <given-names>B</given-names></name><name><surname>Jarvelin</surname> <given-names>MR</given-names></name><name><surname>Atalay</surname> <given-names>M</given-names></name><name><surname>Koppelman</surname> <given-names>GH</given-names></name><name><surname>Pennell</surname> <given-names>CE</given-names></name><name><surname>Niinikoski</surname> <given-names>H</given-names></name><name><surname>Dedoussis</surname> <given-names>GV</given-names></name><name><surname>Mccarthy</surname> <given-names>MI</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Sunyer</surname> <given-names>J</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Rivadeneira</surname> <given-names>F</given-names></name><name><surname>Bønnelykke</surname> <given-names>K</given-names></name><name><surname>Jaddoe</surname> <given-names>VW</given-names></name><collab>Early Genetics and Lifecourse Epidemiology (EAGLE) Consortium</collab><collab>Genetic Investigation of ANthropometric Traits (GIANT) Consortium</collab><collab>Early Growth Genetics (EGG) Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>A novel common variant in DCST2 is associated with length in early life and height in adulthood</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>1155</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu510</pub-id><pub-id pub-id-type="pmid">25281659</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varelas</surname> <given-names>X</given-names></name><name><surname>Samavarchi-Tehrani</surname> <given-names>P</given-names></name><name><surname>Narimatsu</surname> <given-names>M</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Cockburn</surname> <given-names>K</given-names></name><name><surname>Larsen</surname> <given-names>BG</given-names></name><name><surname>Rossant</surname> <given-names>J</given-names></name><name><surname>Wrana</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway</article-title><source>Developmental Cell</source><volume>19</volume><fpage>831</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2010.11.012</pub-id><pub-id pub-id-type="pmid">21145499</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varshney</surname> <given-names>A</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Welch</surname> <given-names>RP</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Albanus</surname> <given-names>RD</given-names></name><name><surname>Orchard</surname> <given-names>P</given-names></name><name><surname>Wolford</surname> <given-names>BN</given-names></name><name><surname>Kursawe</surname> <given-names>R</given-names></name><name><surname>Vadlamudi</surname> <given-names>S</given-names></name><name><surname>Cannon</surname> <given-names>ME</given-names></name><name><surname>Didion</surname> <given-names>JP</given-names></name><name><surname>Hensley</surname> <given-names>J</given-names></name><name><surname>Kirilusha</surname> <given-names>A</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Taylor</surname> <given-names>DL</given-names></name><name><surname>Watanabe</surname> <given-names>R</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Parker</surname> <given-names>SC</given-names></name><name><surname>Stitzel</surname> <given-names>ML</given-names></name><collab>NISC Comparative Sequencing Program</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic regulatory signatures underlying islet gene expression and type 2 diabetes</article-title><source>PNAS</source><volume>114</volume><fpage>2301</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1073/pnas.1621192114</pub-id><pub-id pub-id-type="pmid">28193859</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname> <given-names>D</given-names></name><name><surname>Berthelot</surname> <given-names>C</given-names></name><name><surname>Aldridge</surname> <given-names>S</given-names></name><name><surname>Rayner</surname> <given-names>TF</given-names></name><name><surname>Lukk</surname> <given-names>M</given-names></name><name><surname>Pignatelli</surname> <given-names>M</given-names></name><name><surname>Park</surname> <given-names>TJ</given-names></name><name><surname>Deaville</surname> <given-names>R</given-names></name><name><surname>Erichsen</surname> <given-names>JT</given-names></name><name><surname>Jasinska</surname> <given-names>AJ</given-names></name><name><surname>Turner</surname> <given-names>JM</given-names></name><name><surname>Bertelsen</surname> <given-names>MF</given-names></name><name><surname>Murchison</surname> <given-names>EP</given-names></name><name><surname>Flicek</surname> <given-names>P</given-names></name><name><surname>Odom</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Enhancer evolution across 20 mammalian species</article-title><source>Cell</source><volume>160</volume><fpage>554</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.01.006</pub-id><pub-id pub-id-type="pmid">25635462</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>A</given-names></name><name><surname>Yue</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Xie</surname> <given-names>R</given-names></name><name><surname>Harper</surname> <given-names>T</given-names></name><name><surname>Patel</surname> <given-names>NA</given-names></name><name><surname>Muth</surname> <given-names>K</given-names></name><name><surname>Palmer</surname> <given-names>J</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Lam</surname> <given-names>DK</given-names></name><name><surname>Raum</surname> <given-names>JC</given-names></name><name><surname>Stoffers</surname> <given-names>DA</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Sander</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epigenetic priming of enhancers predicts developmental competence of hESC-derived endodermal lineage intermediates</article-title><source>Cell Stem Cell</source><volume>16</volume><fpage>386</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.02.013</pub-id><pub-id pub-id-type="pmid">25842977</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname> <given-names>K</given-names></name><name><surname>Nishimura</surname> <given-names>Y</given-names></name><name><surname>Oka</surname> <given-names>T</given-names></name><name><surname>Nomoto</surname> <given-names>T</given-names></name><name><surname>Kon</surname> <given-names>T</given-names></name><name><surname>Shintou</surname> <given-names>T</given-names></name><name><surname>Hirano</surname> <given-names>M</given-names></name><name><surname>Shimada</surname> <given-names>Y</given-names></name><name><surname>Umemoto</surname> <given-names>N</given-names></name><name><surname>Kuroyanagi</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Nishimura</surname> <given-names>N</given-names></name><name><surname>Miyazaki</surname> <given-names>T</given-names></name><name><surname>Imamura</surname> <given-names>T</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>In vivo imaging of zebrafish retinal cells using fluorescent coumarin derivatives</article-title><source>BMC Neuroscience</source><volume>11</volume><elocation-id>116</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2202-11-116</pub-id><pub-id pub-id-type="pmid">20843315</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmoreland</surname> <given-names>JJ</given-names></name><name><surname>Kilic</surname> <given-names>G</given-names></name><name><surname>Sartain</surname> <given-names>C</given-names></name><name><surname>Sirma</surname> <given-names>S</given-names></name><name><surname>Blain</surname> <given-names>J</given-names></name><name><surname>Rehg</surname> <given-names>J</given-names></name><name><surname>Harvey</surname> <given-names>N</given-names></name><name><surname>Sosa-Pineda</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pancreas-specific deletion of Prox1 affects development and disrupts homeostasis of the exocrine pancreas</article-title><source>Gastroenterology</source><volume>142</volume><fpage>999</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.12.007</pub-id><pub-id pub-id-type="pmid">22178591</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whyte</surname> <given-names>WA</given-names></name><name><surname>Orlando</surname> <given-names>DA</given-names></name><name><surname>Hnisz</surname> <given-names>D</given-names></name><name><surname>Abraham</surname> <given-names>BJ</given-names></name><name><surname>Lin</surname> <given-names>CY</given-names></name><name><surname>Kagey</surname> <given-names>MH</given-names></name><name><surname>Rahl</surname> <given-names>PB</given-names></name><name><surname>Lee</surname> <given-names>TI</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Master transcription factors and mediator establish super-enhancers at key cell identity genes</article-title><source>Cell</source><volume>153</volume><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.035</pub-id><pub-id pub-id-type="pmid">23582322</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname> <given-names>AR</given-names></name><name><surname>Jonsson</surname> <given-names>A</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>van Leewen</surname> <given-names>N</given-names></name><name><surname>Palmer</surname> <given-names>ND</given-names></name><name><surname>Kobes</surname> <given-names>S</given-names></name><name><surname>Deelen</surname> <given-names>J</given-names></name><name><surname>Boquete-Vilarino</surname> <given-names>L</given-names></name><name><surname>Paananen</surname> <given-names>J</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>de Geus</surname> <given-names>EJC</given-names></name><name><surname>Eekhoff</surname> <given-names>EMW</given-names></name><name><surname>Fritsche</surname> <given-names>A</given-names></name><name><surname>Kramer</surname> <given-names>M</given-names></name><name><surname>Nijpels</surname> <given-names>G</given-names></name><name><surname>Simonis-Bik</surname> <given-names>A</given-names></name><name><surname>van Haeften</surname> <given-names>TW</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Banasik</surname> <given-names>K</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Pearson</surname> <given-names>ER</given-names></name><name><surname>Natali</surname> <given-names>A</given-names></name><name><surname>Mari</surname> <given-names>A</given-names></name><name><surname>Buchanan</surname> <given-names>TA</given-names></name><name><surname>Taylor</surname> <given-names>KD</given-names></name><name><surname>Xiang</surname> <given-names>AH</given-names></name><name><surname>Gjesing</surname> <given-names>AP</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Eiberg</surname> <given-names>H</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Chen</surname> <given-names>YD</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Norris</surname> <given-names>JM</given-names></name><name><surname>Smith</surname> <given-names>U</given-names></name><name><surname>Wagenknecht</surname> <given-names>LE</given-names></name><name><surname>Baier</surname> <given-names>L</given-names></name><name><surname>Bowden</surname> <given-names>DW</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Walker</surname> <given-names>M</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>'t Hart</surname> <given-names>LM</given-names></name><name><surname>Hanson</surname> <given-names>RL</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><collab>Diabetes Research on Patient Stratification (DIRECT)</collab></person-group><year iso-8601-date="2017">2017</year><article-title>A Genome-Wide association study of IVGTT-Based measures of First-Phase insulin secretion refines the underlying physiology of type 2 diabetes variants</article-title><source>Diabetes</source><volume>66</volume><fpage>2296</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.2337/db16-1452</pub-id><pub-id pub-id-type="pmid">28490609</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>R</given-names></name><name><surname>Everett</surname> <given-names>LJ</given-names></name><name><surname>Lim</surname> <given-names>HW</given-names></name><name><surname>Patel</surname> <given-names>NA</given-names></name><name><surname>Schug</surname> <given-names>J</given-names></name><name><surname>Kroon</surname> <given-names>E</given-names></name><name><surname>Kelly</surname> <given-names>OG</given-names></name><name><surname>Wang</surname> <given-names>A</given-names></name><name><surname>D'Amour</surname> <given-names>KA</given-names></name><name><surname>Robins</surname> <given-names>AJ</given-names></name><name><surname>Won</surname> <given-names>KJ</given-names></name><name><surname>Kaestner</surname> <given-names>KH</given-names></name><name><surname>Sander</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic chromatin remodeling mediated by polycomb proteins orchestrates pancreatic differentiation of human embryonic stem cells</article-title><source>Cell Stem Cell</source><volume>12</volume><fpage>224</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.11.023</pub-id><pub-id pub-id-type="pmid">23318056</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Meyer</surname> <given-names>CA</given-names></name><name><surname>Eeckhoute</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>DS</given-names></name><name><surname>Bernstein</surname> <given-names>BE</given-names></name><name><surname>Nusbaum</surname> <given-names>C</given-names></name><name><surname>Myers</surname> <given-names>RM</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biology</source><volume>9</volume><elocation-id>R137</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>B</given-names></name><name><surname>Pache</surname> <given-names>L</given-names></name><name><surname>Chang</surname> <given-names>M</given-names></name><name><surname>Khodabakhshi</surname> <given-names>AH</given-names></name><name><surname>Tanaseichuk</surname> <given-names>O</given-names></name><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Chanda</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1523</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmid">30944313</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59067.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The regard this as a well-designed study focused on developmental programs in pancreatic islet cells that underscore the risk of type 2 diabetes (T2D). Notably, it was found that progenitor-specific enhancers harboring T2D-associated variants regulate the cell polarity genes <italic>LAMA1</italic> and <italic>CRB2</italic>. Functionality was assessed by knocking down <italic>lama1</italic> or <italic>crb2</italic> in zebrafish embryos that led to defective pancreas morphogenesis and islet cell development. The studies unmask novel targets for therapeutic intervention for T2D.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Pancreatic progenitor epigenome maps prioritize type 2 diabetes risk genes with roles in development&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>The risk of developing Type 2 diabetes (T2D) is influenced by a combination of genetic and environmental factors. For most genetic loci implicated in T2D risk, the disease-relevant target genes remain to be defined. In addition, it is not clear in which tissues the underlying genes exert their function. This manuscript explores through genetic analysis, the long-standing hypothesis that prior defect in beta cell differentiation may predispose to higher risk of developing T2D later in life. The authors used chromatin mapping of different developmental stages during directed development of beta cells from human ESCs. They convincingly identify stretch enhancers that are open and active at progenitor stages, but not in fully (or nearly fully) developed islets that contain T2D risk variants. In addition, gene-editing experiments demonstrate that 2 of the stretch enhancers are necessary for complete expression of their eponymous genes within the TADs of these enhancers, without any obvious other in vitro phenotype. Furthermore, when the eponymous genes, LMAT and CRB2, were knocked down in zebra fish, they were found to be critical for normal pancreatic morphogenesis and beta cell development. Overall the paper is well written, the data are convincing, and the conclusions are reasonable. A number of issues need to be addressed that require new experiments.</p><p>Essential revisions:</p><p>1) Since important stretch enhancers define cellular phenotype, it is not clear that expression of only genes within the enhancers' TAD are influenced by their activities (see for instance, Jian and Felsenfeld paper, PNAS, 2018: DOI: 10.1073/pnas.1803146115). Thus, it is felt critical that the authors perform RNAseq at the PP2 stage comparing control and the CRISPR-deleted stretch enhancer lines, to determine if there is influence on any other transcription factor(s) in development or beta cell function (or to see changes in in vitro phenotype). Further, since enhancers were deleted in the hESC experiment, and the genes were deleted in the zebra fish experiment, it would be helpful to include deletion of the genes in the ES context (since it is clearly difficult to find a syntenic enhancer in the fish model).</p><p>2) The authors modelled deletion of PSSEs associated with <italic>LAMA1</italic> and <italic>CRB2</italic> in an in vitro hESC differentiation system. Unfortunately, the mutations had no effect on the endocrine differentiation program in the hESC model. This may be due to the in vitro environment, where morphogenesis of the pancreas is not adequately recapitulated. To circumvent this problem, the authors used morpholino knockdowns in zebrafish embryos and found a reduced number of beta cells forming in the islet of the developing pancreas. Thus, they conclude that <italic>LAMA1</italic> and <italic>CRB2</italic> specifically affect pancreatic developmental programs, and suggest that aberrant developmental processes can predispose to T2D. In its present form, the work has potential but it requires essential additional data to support the central claims of the paper. Importantly, there are well-known issues with the anti-sense reagents, including unspecific effects and toxicity. Therefore, the consensus in the zebrafish field is that morpholino knockdown alone is an unreliable approach to assign new gene function. In fact, the number of beta cells that form in the zebrafish embryo would be highly sensitive to morpholino-related side-effects and toxicity. Therefore, the findings that <italic>Lama1</italic> and <italic>Crb2b</italic> play a role in beta-cell development is at best unsubstantiated. To make this claim conclusive, the authors would need to show similar phenotypes using homozygous mutants in <italic>Lama1</italic> and <italic>Crb2b</italic> or deletions in the corresponding enhancers in zebrafish. Once a &quot;clean&quot; phenotype is demonstrated, it will be important to address several critical questions to strengthen the current analysis: (a) Is the reduction in beta-cell number due to a defect in beta-cell proliferation, differentiation or both? (b) Does <italic>Lama1</italic> or <italic>Crb2b</italic> deficiency affect the specification, expansion or morphogenesis of the progenitor domains in the extra-pancreatic and/or intra-pancreatic ducts? (c) do the genes play a role in the formation of the dorsal- or ventral-bud-derived beta-cells or both? (d) Do the genes play a role in endocrine-cell migration, coalescence or clustering of the islet?</p><p>and (e) Does the reduction in the number of beta cells have a functional consequence for glucose tolerance in the fish, either under homeostasis or upon metabolic challenges, such as high glucose incubation or egg-yolk feeding?</p><p>3) The mammalian antibodies used for IHC (anti-<italic>Lama1</italic>, anti-pan-Crb, and anti-pan-<italic>Crb2b</italic>) have not been validated in fish. The IHC should be repeated in <italic>Lama1</italic> and <italic>Crb2b</italic> mutants or morphants. There should be a loss of signal in the pancreas if everything is as expected.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59067.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Since important stretch enhancers define cellular phenotype, it is not clear that expression of only genes within the enhancers' TAD are influenced by their activities (see for instance, Jian and Felsenfeld paper, PNAS, 2018: DOI: 10.1073/pnas.1803146115). Thus, it is felt critical that the authors perform RNAseq at the PP2 stage comparing control and the CRISPR-deleted stretch enhancer lines, to determine if there is influence on any other transcription factor(s) in development or bet cell function (or to see changes in in vitro phenotype).</p></disp-quote><p>We apologize that we did not make it clear that we had already generated such datasets and performed the suggested analyses. RNA-seq data comparing control and CRISPR-deleted <italic>LAMA1</italic> stretch enhancer lines (Δ<italic>LAMA1</italic>Enh) at the PP2 stage are shown in Figure 4—figure supplement 1D, E. As shown in panel E we found minimal differences in the expression of transcription factors relevant to pancreas development between Δ<italic>LAMA1</italic>Enh and control PP2 cells, which led us to conclude that the enhancer deletion does not perturb pancreatic lineage induction. Similar RNA-seq analysis is shown comparing control and CRISPR-deleted <italic>CRB2</italic> stretch enhancer lines (Δ<italic>CRB2</italic>Enh) at the PP2 stage in Figure 5—figure supplement 2D, E. Combined, these analyses argue against a developmental phenotype resulting from the enhancer deletions, even when considering genes outside of each enhancer’s topologically associated domain. The list of all differentially expressed genes in <italic>LAMA1</italic> and <italic>CRB2</italic> enhancer-deleted PP2 cells is included as Figure 4—source data 1 and 2 and Figure 5—source data 1, respectively.</p><disp-quote content-type="editor-comment"><p>Further, since enhancers were deleted in the hESC experiment, and the genes were deleted in the zebra fish experiment, it would be helpful to include deletion of the genes in the ES context (since it is clearly difficult to find a syntenic enhancer in the fish model).</p></disp-quote><p>We agree that deletion of <italic>LAMA1</italic> and <italic>CRB2</italic> in hESCs would help better link the hESC system to the zebrafish results. Therefore, we generated and characterized clonal lines harboring deletions of the <italic>LAMA1</italic> (Δ<italic>LAMA1</italic>) and <italic>CRB2</italic> (Δ<italic>CRB2</italic>) genes, respectively.</p><p>In agreement with our observations in the Δ<italic>LAMA1</italic>Enh and Δ<italic>CRB2</italic>Enh lines, we found that deletion of <italic>LAMA1</italic> and <italic>CRB2</italic> does not perturb pancreatic lineage induction, as evidenced by the number of PDX1- and NKX6.1-positive cells and the expression of transcription factors relevant to pancreas development. The results are shown in revised Figure 4—figure supplement 2 and Figure 5—figure supplement 3, respectively. These new findings highlight the need for an in vivo model to fully characterize the role of <italic>LAMA1</italic> and <italic>CRB2</italic> in pancreatic development.</p><p>Regarding modeling of the enhancer deletion in zebrafish, results of a Basic Local Alignment Search Tool (BLAST) analysis (Altschul et al., 1990), as well as examination of each enhancer region using the Evolutionarily Conserved Regions (ECR) Browser (Ovcharenko et al., 2004) revealed that the <italic>LAMA1</italic> and <italic>CRB2</italic> stretch enhancers are indeed not conserved in this species.</p><disp-quote content-type="editor-comment"><p>2) The authors modelled deletion of PSSEs associated with LAMA1 and CRB2 in an in vitro hESC differentiation system. Unfortunately, the mutations had no effect on the endocrine differentiation program in the hESC model. This may be due to the in vitro environment, where morphogenesis of the pancreas is not adequately recapitulated. To circumvent this problem, the authors used morpholino knockdowns in zebrafish embryos and found a reduced number of beta cells forming in the islet of the developing pancreas. Thus, they conclude that LAMA1 and CRB2 specifically affect pancreatic developmental programs, and suggest that aberrant developmental processes can predispose to T2D. In its present form, the work has potential but it requires essential additional data to support the central claims of the paper. Importantly, there are well-known issues with the anti-sense reagents, including unspecific effects and toxicity. Therefore, the consensus in the zebrafish field is that morpholino knockdown alone is an unreliable approach to assign new gene function. In fact, the number of beta cells that form in the zebrafish embryo would be highly sensitive to morpholino-related side-effects and toxicity. Therefore, the findings that Lama1 and Crb2b play a role in beta-cell development is at best unsubstantiated. To make this claim conclusive, the authors would need to show similar phenotypes using homozygous mutants in Lama1 and Crb2b or deletions in the corresponding enhancers in zebrafish.</p><p>Once a &quot;clean&quot; phenotype is demonstrated, it will be important to address several critical questions to strengthen the current analysis:</p><p>a) Is the reduction in beta-cell number due to a defect in beta-cell proliferation, differentiation or both?</p><p>b) Does Lama1 or Crb2b deficiency affect the specification, expansion or morphogenesis of the progenitor domains in the extra-pancreatic and/or intra-pancreatic ducts?</p><p>c) do the genes play a role in the formation of the dorsal- or ventral-bud-derived beta-cells or both?</p><p>d) Do the genes play a role in endocrine-cell migration, coalescence or clustering of the islet? and</p><p>e) Does the reduction in the number of beta cells have a functional consequence for glucose tolerance in the fish, either under homeostasis or upon metabolic challenges, such as high glucose incubation or egg-yolk feeding?</p></disp-quote><p>While it is true that morpholino knockdowns can have non-specific effects and give rise to phenotypes that are inconsistent with genetic deletions, prior publications have extensively validated the morpholinos used in our study against <italic>lama1</italic> (Icha et al., 2016; Pollard et al., 2006; Randlett et al., 2011; Sidhaye and Norden, 2017; Yanakieva et al., 2019), <italic>crb2a</italic> (Omori and Malicki, 2006; Watanabe et al., 2010), and <italic>crb2b</italic> (Omori and Malicki, 2006). These studies validated efficacy for transcript and protein knockdown (Omori and Malicki, 2006; Randlett et al., 2011; Sidhaye and Norden, 2017) and demonstrated that the morphants phenocopy corresponding genetic mutants (Omori and Malicki, 2006). Of note, our controls for all morpholino experiments were embryos treated with non-targeting morpholinos rather than untreated embryos, therefore accounting for possible morpholino-based toxicity. We have provided additional information in the Materials and methods section of our manuscript to detail the extent to which these morpholinos have been previously validated.</p><p>While we agree that the suggestions for in-depth mechanistic studies in <italic>lama1</italic> and <italic>crb2b</italic> zebrafish mutants are interesting and important, we find them to be well beyond the scope of this manuscript and could themselves be the focus of an entirely separate project and publication. We maintain that the objective of our study is to define a progenitor-specific contribution to T2D risk by integrating genome-wide association data with chromatin maps from stem cell models of human pancreatic development. In this context, our analysis of <italic>lama1</italic> and <italic>crb2</italic> zebrafish morphants serves to illustrate that pancreatic endocrine cell development is sensitive to <italic>lama1</italic> and <italic>crb2</italic> transcript levels. Given that individually most type 2 diabetes-associated regulatory variants have subtle effects on transcript levels, a detailed understanding of phenotypes caused by complete <italic>lama1</italic> and <italic>crb2</italic> loss-of function through genetic deletion in zebrafish is likely of minor relevance to understanding variant effects and mechanisms of T2D risk. In fact, we are concerned about the likely possibility that a complete loss-of-function of these critical structural genes in animals would lead to more profound developmental defects that would mask the more subtle pancreatic phenotypes revealed by partial knockdown and therefore prove inconclusive. These considerations drove our decision to use morpholinos rather than genetic mutants for this study. The suggested experiments would require a significant time commitment to generate and analyze “clean” mutants (&gt;1 year) and substantial financial resources to address questions which we consider to be interesting, but ultimately would not alter the conclusions of our manuscript as a whole.</p><disp-quote content-type="editor-comment"><p>3) The mammalian antibodies used for IHC (anti-Lama1, anti-pan-Crb, and anti-pan-Crb2b) have not been validated in fish. The IHC should be repeated in Lama1 and Crb2b mutants or morphants. There should be a loss of signal in the pancreas if everything is as expected.</p></disp-quote><p>The anti-laminin antibody used in this study has been used in 105 zebrafish references. Relevant to our work, it has been validated, using the same morpholino for <italic>lama1</italic> as used in our study (Randlett et al., 2011; Sidhaye and Norden, 2017). Likewise, the antipan-Crb antibody has also been previously validated (Hsu and Jensen, 2010).</p><p>Nevertheless, we have stained respective morphants with anti-laminin, anti-<italic>Crb2a</italic>, and anti-pan-Crb antibodies. We observed an absence of signal for laminin (revised Figure 6—figure supplement 2) and <italic>Crb2a</italic> (Figure 6—figure supplement 3) throughout development in embryos treated with <italic>lama1-</italic> and <italic>crb2a</italic>-specific morpholinos, respectively.</p><p>When staining embryos treated with morpholinos targeting <italic>Crb2a</italic> and <italic>Crb2b</italic> with the anti-pan-Crb antibody, we find that signal is lost in the ventral pancreas, where Nkx6.1+ pancreatic progenitor cells reside (Figure 6—figure supplement 3). Although we find residual signal in the dorsal pancreas, we note that the anti-pan-Crb antibody not only detects <italic>Crb2</italic> proteins but also <italic>Crb1</italic> and <italic>Crb3</italic>. Therefore, it is possible that other Crb proteins are expressed in the dorsal pancreas, which would not be affected by morpholinos targeting <italic>Crb2a</italic> and <italic>Crb2b</italic>.</p><p>In sum, our findings serve to validate both the efficacy of the morpholinos used in our knockdown experiments as well as the specificity of our selected antibodies.</p></body></sub-article></article>